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SUMMARY 
Allogeneic haematopoietic stem cell transplantation (HSCT) is the 
standard therapy for many disorders of the haematological system. Its use 
is limited by the major complication acute graft-versus-host disease 
(GVHD). Development of acute GVHD predisposes to chronic GVHD 
whose autoimmune manifestations are integral components of disease. It 
remains uncertain, however, whether and how autoimmunity is linked to 
antecedent alloimmunity. A hallmark of murine acute GVHD is the de novo 
generation of autoreactive T cells that suggests breakdown of thymic 
tolerance induction. Central tolerance is dependent on the intrathymic 
expression of a full scope of tissue-restricted self-antigens (TRA), which is a 
distinct property of mature medullary thymic epithelial cells (mTEChigh). 
The ectopic expression of TRA in mTEChigh is partly controlled by the 
autoimmune regulator (Aire). Since the thymus epithelium is a target of 
donor T-cell alloimmunity, I hypothesised that thymic acute GVHD 
interfered with the mTEChigh capacity to sustain TRA diversity. I found 
that reductions in mTEChigh compartment sizes are universal manifestations 
of thymic acute GVHD in murine models of haploidentical, fully MHC-
disparate and MHC-identical allogeneic HSCT. Moreover, acute GVHD 
weakens the platform for central tolerance induction because individual 
TRA are purged from the total repertoire secondary to a decline in the 
Aire+mTEChigh subset. The most substantially reduced TRA are enriched 
for genes specific for known target tissues of chronic GVHD. I provide 
direct evidence in a transgenic mouse system using ovalbumin (OVA) as a 
model neo-TRA that the de novo production of TRA-specific CD4+ T cells 
during acute GVHD is a consequence of impaired ectopic TRA expression. 
OVA-specific CD4+ T cells are present in the periphery in mice with acute 
GVHD. Peritransplant administration of an epithelial cytoprotective agent, 
fibroblast growth factor-7, maintains a stable pool of Aire+mTEChigh, which 
is due to enhanced proliferation of cells within the total mTEC 
compartment. In parallel, Fgf7 improves the TRA transcriptome despite 
acute GVHD. Taken together, these data indicate the presence of an 
etiologic link between acute GVHD and autoimmunity during subsequent 
chronic GVHD. The present results also suggest that approaches for 
epithelial cytoprotection may prove to prevent the emergence of thymus-
dependent autoreactive T cells.    
	
  
	
  	
  	
   4 
TABLE OF CONTENTS 
1. INTRODUCTION .......................................................... 7 
1.1 Haematopoietic Stem Cell Transplantation ....................... 7 
1.1.1   Current Status ........................................................................... 7 
1.1.2 Principles of allogeneic HSCT ................................................... 8 
1.1.3 Successful Outcome of HSCT .................................................... 9 
1.2  T-cell Reconstitution post-HSCT .................................... 10 
1.2.1   Overview .................................................................................. 10 
1.2.2   Thymus-dependent T cell regeneration .................................... 11 
The Thymic Lymphoid Compartment ................................................... 13 
The Thymic Stromal Compartment ....................................................... 14 
Negative Selection in the Thymus Medulla ........................................... 15 
OVA – a tool to study thymic negative selection .................................. 17 
1.2.3 Thymus-independent T cell regeneration ................................... 17 
1.3 Graft-versus-host Disease ................................................. 19 
1.3.1 Clinical Features of Graft-versus-host Disease ........................ 19 
1.3.2 Pathophysiology of acute GVHD ............................................ 20 
1.3.3 Pathophysiology of chronic GVHD ......................................... 22 
1.3.4 Prophylaxis and Treatment of GVHD .................................... 24 
Prevention of GVHD ............................................................................. 24 
Treatment of GVHD .............................................................................. 24 
1.3.5 Post-transplant immune deficiency ......................................... 25 
1.3.6 Immune reconstitution in the presence of acute GVHD .......... 25 
1.3.7 Thymic GVHD ........................................................................ 26 
Pathomechanism of Thymic Injury – Preclinical Mouse Models ........... 26 
Thymic dysfunction during acute GVHD – a link to chronic GVHD? .. 28 
1.3.8 Strategies to Improve post-transplant Immune Deficiency ...... 29 
Fibroblast growth factor-7 ..................................................................... 29 
2. HYPOTHESES AND AIM OF THE THESIS ............. 31 
3.  MATERIALS AND METHODS ................................. 32 
3.1 Mice .................................................................................. 32 
3.2 BMT and GVHD induction .............................................. 32 
3.3 Fgf7 treatment ................................................................. 33 
3.4 Flow cytometry reagents .................................................. 33 
3.5 Analysis of the mTEChigh compartment by flow cytometry   
  ......................................................................................... 34 
3.6 Immunofluorescence confocal microscopy ......................... 35 
	
  	
  	
   5 
3.7 Quantitative PCR ............................................................ 36 
3.8 DNA microarray analysis ................................................. 37 
3.9 Bioinformatics .................................................................. 38 
3.10 Statistical analysis ........................................................... 39 
4. RESULTS ..................................................................... 40 
4.1  Impaired ectopic expression of tissue-restricted antigens 
in the thymus during murine acute GVHD ............................. 40 
4.1.1 Identification and characterisation of medullary thymic 
epithelial cell subsets by flow cytometry ............................................ 40 
4.1.2  Induction of thymic acute GVHD .......................................... 41 
4.1.3  Acute GVHD impairs mTEChigh compartment size ................ 44 
4.1.4  Acute GVHD impairs thymic Aire expression ........................ 47 
4.1.5  Acute GVHD impairs TRA expression ................................... 49 
4.2  Impaired thymic expression of tissue-restricted antigens 
licenses the de novo generation of autoreactive CD4+ T cells 
during murine acute GVHD ..................................................... 57 
4.2.1 A transgenic model to study generation of thymus-dependent 
autoreactive T cells during acute GVHD ............................................ 57 
4.2.2   Thymic GVHD induction in RIP-mOVA recipients ................ 58 
4.2.3 Acute GVHD reduces the thymic ectopic expression of the neo-
self-antigen ovalbumin ........................................................................ 63 
4.2.4 OVA-specific T cell clones escape negative selection during 
acute GVHD ....................................................................................... 64 
4.2.5 De novo generated OT-II T cells display a non-tolerant effector 
phenotype ........................................................................................... 67 
4.3  Epithelial cytoprotection with fibroblast growth factor-7 
(Fgf7) sustains ectopic expression of tissue-restricted antigens 
in the thymus during murine acute GVHD ............................. 70 
4.3.1 Fgf7 sustains the thymic mTEChigh compartment including Aire 
expression ........................................................................................... 70 
4.3.2 Fgf7 administration sustains a more diverse TRA transcriptome 
in mTEChigh during acute GVHD ..................................................... 76 
4.3.3 Fgf7 administration alters thymic expression of TRA 
independently of their tissue specificity and acute GVHD ................. 83 
5. DISCUSSION ............................................................... 85 
Loss of mTEC – a universal manifestation of acute GVHD .................. 86 
Acute GVHD weakens the platform for central tolerance ...................... 87 
	
  	
  	
   6 
Use of the RIP-mOVA system to study thymic negative selection in the 
presence of acute GVHD ........................................................................ 89 
Potential mechanism of autoreactive T-cell neogenesis following 
allogeneic HSCT ..................................................................................... 92 
Fgf7 restores the thymic mTEChigh compartment and sustains the 
diversity of TRA expression ................................................................... 96 
6. CONCLUSIONS .......................................................... 100 
7.  REFERENCES ............................................................ 101 
8.  ACKNOWLEDGEMENTS .......................................... 126 
9.  APPENDIX ................................................................. 127 
 
 
 
 
 
 
 
 
 
 
 
	
  	
  	
   7 
1. INTRODUCTION 
1.1 Haematopoietic Stem Cell Transplantation 
1.1.1  Current Status 
Haematopoietic stem cell transplantation (HSCT) has developed 
into the standard therapy for several disorders of the haematopoietic 
system.1-4 In 2011, more than 35,000 transplantations were performed 
annually in Europe, of which 42% were allogeneic and 58% autologous 
procedures.4,5 The main indications for allogeneic HSCT were malignancies 
of the haematopoietic system, in particular acute myeloid and 
lymphoblastic leukaemias (AML and ALL, respectively), myelodysplastic 
syndromes (MDS) and non Hodgkin lymphoma (Figure 1). Autologous 
HSCT was mainly performed to treat lymphoid neoplasias and non-Hodgkin 
and Hodgkin lymphomas.4-6 The success of allogeneic HSCT therapy 
depends on a multitude of parameters, including the type and stage of the 
underlying disease, patient age, genetic disparity between donor and host, 
type and intensity of the pretransplantation conditioning regimen, and the 
presence of transplant-related toxicities (TRTs).6,7 For instance, allogeneic 
HSCT is highly efficacious for patients with AML or ALL, since long term 
leukaemia-free survival can be achieved in 20-60% of these patients. 
Increased disease-free survival with allogeneic HSCT therapy can even be 
obtained in older patients (>65yrs): Here, the 5-year survival is <2% when 
treated with chemotherapy alone,8 whereas treatment with allogeneic HSCT 
increases the 5-year survival rate to 33%.9 For patients with MDS 
allogeneic HSCT is the only therapy with curative potential. 
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Figure 1. Indications for HSCT in Europe in 2011. (A) Proportions of disease 
indications for an allogeneic HSCT in Europe in 2011. (B) Proportions of disease indications 
for an autologous HSCT in Europe in 2011. AML = acute myeloid leukaemia; ALL = acute 
lymphoblastic leukaemia; MDS = myelodysplastic syndromes; NHL = non-Hodgkin 
lymphoma; HL = Hodgkin lymphoma.  
Adapted from Passweg et al., Bone Marrow Transplantation (2013)5 	
  
 
 
 	
  
1.1.2 Principles of allogeneic HSCT 
Patients that are chosen for HSCT therapy first undergo preparative 
cytoreductive conditioning with chemotherapy and/or total body 
irradiation (TBI). This treatment has several purposes as it serves, firstly, 
to reduce tumour burden in case of cancer treatment; secondly, to suppress 
the recipient’s immune system and thus prevent rejection of the donor 
graft; and lastly, to ablate the recipient’s haematopoietic system in order to 
create space in the stem cell niche and to enable proper engraftment of 
donor HSC. The preparative conditioning therapy can be applied in 
different intensities, resulting in either reduction or full ablation of the 
host’s haematopoietic system.10 The use of reduced intensity regimens 
(RIC) instead of myeloablative treatments was a major advance in 
allogeneic HSCT. The principle of RIC is to treat with an intensity that is 
high enough to prevent graft rejection, but that induces less tissue injury.11 
Conditioning is followed by allogeneic HSCT whose goal is two-fold: firstly, 
to replace the patient’s diseased haematopoietic system with new HSCs 
stemming from a genetically disparate healthy donor, and secondly, to 
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exploit the immunotherapeutic effect of the donor graft (i.e. graft-versus-
tumour effect, GVT; see below, section 1.2.3).  
HSCs can be harvested from different sources.  HSC mobilised by 
granulocyte colony-stimulating factor (G-CSF) into the peripheral blood 
(PB) are the preferred source for transplantation today (peripheral blood 
stem cells; PBSC; 99% of autologous and 71% of allogeneic HSCT).4,6 
Alternative sources for HSCs used clinically are bone marrow (BM) and 
umbilical cord blood (UCB). 
 	
  
1.1.3 Successful Outcome of HSCT 
The rates for 1-year and disease-free survival following allogeneic 
HSCT have significantly improved over the last few years.12,13 For allogeneic 
HSCT to be successful, three main objectives need to be fulfilled. Firstly, 
the underlying disease needs to be cured. The use of cytoreductive 
conditioning in combination with the capacity of donor T cells to mediate 
an anti-tumour effect is essential for tumour control. Secondly, the patient 
should not experience transplant-related toxicities (TRTs) that arise as a 
consequence of conditioning and donor T cell immunity that is directed 
against healthy host tissues. Unfortunately, TRTs are still major obstacles 
of allogeneic HSCT that hamper therapeutic success.14,15 TRTs include 
acute and chronic graft-versus-host disease (GVHD, see below chapter 1.3) 
and organ failure caused by the preparative conditioning regimen.16,17 When 
present, such adverse events put the patient at risk for transplant-related 
morbidity and mortality. Thirdly, immunity needs to be efficiently 
reconstituted in patients receiving HSCT. This is important, since the 
cytoreductive conditioning not only elicits an anti-tumour effect, but also 
compromises the patient’s innate and adaptive immune responses. This 
effect predisposes the HSCT recipient to opportunistic infections, increases 
the risk for malignancy relapse and the development of secondary 
malignancies, and hence, contributes to poor clinical outcome.18-22 Timing 
and quality of immune reconstitution following allogeneic HSCT have 
therefore a significant impact on the patient’s well-being. Acute GVHD 
increases the likelihood to be diagnosed with an opportunistic infection.23 
Hence, this particular TRT is a confounding factor for the re-establishment 
of immune competence. The following two chapters will first present 
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knowledge concerning (i) the immune regeneration after transplantation 
and (ii) the immunopathophysiology of GVHD, and then address (iii) the 
known mechanistic relationships between these two events.   
 
 
1.2  T-cell Reconstitution post-HSCT 
1.2.1  Overview 
Following cytoreductive treatment and allogeneic HSCT, there are 
two complementary pathways that restore immune competence. Firstly, 
residual host-derived haematopoietic cells and mature cells present in the 
donor graft undergo clonal expansion in peripheral host tissues secondary to 
homeostatic and alloantigenic stimuli; and secondly, myeloid and lymphoid 
cells are generated de novo from the donor HSCs. Whereas the innate 
immune system, including monocytes, granulocytes and natural killer (NK) 
cells, is restored within a few weeks, the regeneration of the adaptive 
immune system takes months (B cells) to years (T cells) to be completed.24-
29 Adequate T cell regeneration is pivotal for the patient’s survival. The 
absence of competent T cell immunity is associated with an increased risk 
for viral, bacterial and fungal infections.18,30-34 The speed of T-cell 
reconstitution depends on several in part interconnected factors, as diverse 
as recipient age and gender, underlying disease, type of conditioning, 
genetic disparity between donor and host, HSC source, acute and chronic 
GVHD, opportunistic infections and relapse of malignancy.35 Two pathways 
act in parallel to contribute to the regeneration of the T cell pool. First, 
donor graft- and residual host-derived mature T cells undergo peripheral 
clonal expansion in a thymus-independent manner. The second pathway 
comprises the de novo generation of T cells from the transplanted HSCs in 
a functionally intact thymus (Figure 2).  	
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Figure 2. T-cell reconstitution after allogeneic HSCT. T-cell regeneration post-HSCT 
is accomplished by two pathways. 1) Thymus-independent pathway. Residual host and 
mature donor T cells expand initially in response to homeostatic signals or cognate antigen. 
Alloreactive donor T cells can mediate both GVHD and GVT, but contribute also to the 
peripheral T cell compartment. Peripheral expansion of pre-existent T cells results in a 
conversion to memory phenotype, skewing of the TCR repertoire and contracted pool size. 
2) Thymus-dependent pathway. The de novo generation of naïve T cells from 
haematopoietic progenitors requires a functional thymus. The thymic microenvironment is a 
three-dimensional network that attracts T cell progenitors and supports their survival, 
expansion, differentiation and selection. Naïve, pathogen specific, non-self reactive T cells 
emerge from the thymus to the periphery.  
Adapted from Krenger et al., Blood (2011)36  	
  	
  
 
 	
  
1.2.2 Thymus-dependent T cell regeneration 
The primary site for T cell development during fetal and early 
postnatal life is the thymus.37-41 The cellular architecture of the thymus is 
highly conserved between vertebrate species and is organised in subcapsular 
region, cortex, cortico-medullary junction and medulla. Since the thymus 
does not contain numbers of HSC sufficient for permanent T-cell 
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regeneration, the thymus therefore needs to be continuously replenished 
with T cell progenitors from the BM via the blood circulation.42 Once these 
progenitors enter the thymus at the cortico-medullary junction, they pass 
through different maturation steps during which they develop into mature 
T cells (Figure 3).43 	
  	
  	
  
	
  
Figure 3. Thymic crosstalk – TEC-thymocyte interactions. The thymus is organised 
in discrete cortical and medullary areas. T cell progenitors enter the thymus at the cortico-
medullary junction and their development can be followed by different expression of cell 
surface markers. Interactions between thymoytes and the thymus stroma are important to 
drive T-cell maturation. 
Adapted from Anderson et al., Nature Reviews Immunology (2001)44    	
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The Thymic Lymphoid Compartment 
T cell progenitors that have entered the thymus bear a CD3-CD4-
CD8- triple negative (TN) phenotype and are commonly referred to as early 
thymic precursors (ETPs). Throughout their differentiation, ETPs interact 
with the thymic microenvironment (discussed in more detail below).45 The 
initial developmental stages of the TN ETPs are identified by the surface 
expression of CD25 and CD44 (double negative (DN) 1: CD25-CD44+; DN2: 
CD25+CD44+; DN3: CD25+CD44-; DN4: CD25-CD44-; Figure 3).46,47 DN 
thymocytes that are located in the thymic cortex and restricted to the α/β 
TCR lineage rearrange their Tcrb locus and then assemble the TCRβ and 
pre-TCRα (pTα) chains. This results in the expression of the pre-TCR 
complex on the cell surface, which is associated with CD3.48 The expression 
of the CD3:pre-TCR complex induces extensive proliferation, expression of 
the surface proteins CD4 and CD8 and hinders further β-chain 
rearrangement. These CD4+CD8+ double positive (DP) thymocytes then 
rearrange the α-chain locus, which results in expression of a complete, 
randomly chosen TCRαβ:CD3 complex with an antigen specificity. At the 
DP stage, thymocytes undergo a first selection process, termed positive 
selection, to assure TCR reactivity to self-peptide/self-major 
histocompatibility complex (MHC) complexes. The latter are presented by 
thymic stroma cells and thymocytes with sufficiently high affinity are 
selected and consequently receive further differentiation signals,49 whereas 
no interactions induce apoptosis (“death by neglect”) of DP. Positively 
selected thymocytes with a TCR restricted to MHC class II express CD4 on 
the surface, whereas CD8 is expressed on thymocytes with a TCR restricted 
to MHC class I (CD4+ single positive (SP) and CD8+ SP, respectively).50 
Only 3-5% of thymocytes receive a survival signal and migrate from the 
cortex to the medulla,51,52 where they are subject to thymic negative 
selection. In this process, SP thymocytes are checked for reactivity to self-
peptides, among them many antigens with tissue-specific expression of 
proteins (i.e. tissue-restricted antigens, TRA). These self-antigens are 
presented by medullary thymic epithelial cells (mTEC) and dendritic cells 
(DC) (discussed in more detail below). SP thymocytes with a TCR that 
binds with an inadequately high affinity to the self-peptide/MHC complexes 
are removed from the repertoire by apoptosis.53 Positive and negative 
selection processes together shape the T cell repertoire such that the 
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adaptive immune system is competent to react to a seemingly unlimited 
diversity of foreign antigens (“nonself”) whilst not being responsive to self-
antigens (“self”).54 This pivotal mechanism to assure self-tolerance is termed 
central (i.e. thymic) T cell tolerance induction. Before being exported to the 
periphery, thymocytes go through post-selection maturation in the 
medulla.43  	
  	
  
The Thymic Stromal Compartment     
The thymic stroma is a three-dimensional network composed of 
different cell types. Major components of this scaffold are thymic epithelial 
cells (TEC), but mesenchymal cells and cells of haematopoietic origin such 
as DCs and macrophages are also present. Together they build a unique 
structural and functional microenvironment that attracts T cell progenitors 
and supports their survival, expansion, differentiation and selection.38,55 The 
TEC compartment itself is composed of phenotypically, functionally and 
structurally different cortical and medullary subsets, which are completely 
replaced every 10 to 14 days.56,57 Several surface and intracellular markers 
characterise the TEC subsets of the murine thymus. The major markers are 
cytokeratins (CK) which include CK5, CK14, CK8 and CK18. Cortical 
TEC express CK8 and CK18 and can be further defined by flow cytometry 
by their expression of epithelial cell adhesion molecule (EpCam; CD326) 
and Ly51.38,58-60 In addition to the expression of both MHC class I and class 
II molecules, cTEC have the unique ability to support positive selection by 
antigen-processing and antigen-presentation capacities that are different 
from other cell types like mTEC and DCs present in the thymus.61 The 
mTEC subset is characterised by its expression of CK5 and CK14.58-60 
Recent progress further allowed a more precise identification of mTEC by 
flow cytometry. These cells express EpCam (CD326) and are reactive with 
Ulex europaeus agglutinin-1 (UEA-1), but do not express Ly51 and 
CD45.56,57,62-67 Similar to cTEC, mTEC express both MHC class I and class 
II.43 Since mTEC are major contributors to thymic negative selection they 
are of central importance to generate a self-tolerant T cell repertoire. 	
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Negative Selection in the Thymus Medulla 
The medullary TEC compartment contains cells at different 
maturational stages that can be classified according to the expression of 
costimulatory molecules, such as CD40, CD80, CD86, the intensity of MHC 
class II expression and the intracellular expression of the transcription 
factor Autoimmune Regulator (Aire).64,68 While immature mTEC express 
low levels of CD40, CD80, CD86 and MHC class II (referred to as 
mTEClow), mature mTEC express high levels of CD40, CD80, CD86 and 
MHC class II (mTEChigh) and express Aire at either low or high levels. A 
large array of TRA is produced by mTEC and presented to developing 
thymocytes either by mTEC themselves or by DCs via cross-presentation.69 
These TRA encode for antigens normally present in the periphery.64,70 
During mTEC maturation, TRA expression levels increase, as mTEChigh 
show the highest extent of TRA diversity.70 The process of TRA expression 
is called promiscuous gene expression (pGE). TRA expression by mTEC 
“mirrors the peripheral self” and is crucial for induction of central 
tolerance.71,72 Expression levels in mTEC are 50- to 170-fold lower when 
compared to the corresponding peripheral tissues.73-75 Given the fact that 
each TRA is only expressed by 1-3% of mTEC, which are dispersed in the 
medulla,75 the process of TRA presentation needs to be efficient. It is still 
poorly understood how mTEChigh transcribe and translate these 
promiscuous genes. One control mechanism that drives TRA expression is 
mediated via the transcription factor Aire (Figure 4). Within the thymus, 
Aire is expressed in mature mTEChigh,72,76,77 and lack of appropriate Aire 
expression predisposes to autoimmune disease. In humans, mutations in the 
Aire gene cause Autoimmune polyendocrinopathy-candidiasis ectodermal 
dystrophy (APECED; also known as autoimmune polyendocrine syndrome 
type 1, APS-1),78,79 a rare monogenic autoimmune disease that affects 
multiple organs.80,81 Aire+mTEChigh are typically post-mitotic and acquire 
features that are characteristic for professional APCs (e.g. high expression 
of MHC class II, CD40, CD80, CD86).56,77,82 Mice deficient for Aire (Aire-
knock out) show autoimmune manifestations that mimic the human 
APECED including the presence of autoantibodies against various tissues 
and mononuclear cell infiltrations of several organs.83,84 Gene expression 
analysis of mTEC isolated from Aire-knock out (Aire-/-) and Aire-wild type 
(Aire+/+) mice revealed that a fraction of ∼30% of TRA is controlled by 
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Aire.54,72 Among them are for example insulin, salivary protein 1, and fatty 
acid-binding protein.72 Importantly, inadequate Aire gene dosage or the 
absence of Aire expression and the loss of TRA diversity is associated with 
impaired negative selection.73 Consequently, T cells bearing a high-affinity 
TCR for a specific Aire-dependent TRA can emerge in the periphery.85,86 
The precise molecular mechanisms how Aire promotes TRA expression are 
still unsolved. Transcriptional regulation via epigenetic modifications is 
likely to be a candidate mechanism.64,70  
 
 
 
 
Figure 4. Aire promotes 
negative selection of self-reactive 
thymocytes. Aire induces the 
expression of a broad array of TRA, 
which are processed and presented by 
mTEC themselves or DCs via cross-
presentation. Inadequate binding of 
the TCR with a TRA/MHC complex 
results in clonal deletion of 
thymocytes.  
Adapted from Mathis et al., Annual 
Review of Immunology (2009)87  
 
Efficient tolerance induction is only achieved when thymocytes are 
exposed to the whole spectrum of self-antigens present in the thymic 
medulla. Hence, this process needs to be tightly regulated.88 Small 
interruptions such as a reduced number of mature mTEC and ensuing 
distraction of the three-dimensional network can obstruct this process.89,90 
Thymic negative selection is not 100% efficient. Additional mechanisms are 
in place that contribute to assure self-tolerance and prevent autoimmunity. 
For example, natural regulatory T cells (Treg) that are characterised by 
their CD4+CD25+ phenotype and the intracellular expression of the 
transcription factor Foxp3 are generated in the thymus.91-93 Recent data has 
demonstrated that the mTEC compartment provides a developmental niche 
for Treg cells and is therefore critically required for the proper generation of 
the latter.94-96  
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OVA – a tool to study thymic negative selection  
To study negative selection specially adapted mouse models are 
required that include the thymic expression of neo-self-antigen (model 
TRA). RIP-mOVA mice express membrane-bound ovalbumin (mOVA; 
OVA139-385) under the control of the rat insulin promoter (RIP).97 In these 
mice, mOVA is expressed in the pancreas but the transgene is also 
ectopically expressed in the thymus specifically in mTEC.98 Rag2-deficient 
OT-II mice have a transgenic Vα2Vβ5 TCR specific for OVA323-339 in the 
context of MHC class II (I-Ab).99,100 In bone marrow chimeras the developing 
OVA-specific thymocytes are deleted in a thymus of a RIP-mOVA mouse. 
This indicated that negative selection is mediated by thymic OVA 
expression.98 In contrast, OT-II thymocytes are not negatively selected in a 
wildtype thymus and emerge to the periphery. This experimental system 
allows the investigation of central tolerance to a known antigen and 
consequently the identification of autoreactive T cells that have escaped 
negative selection.   	
  	
  
1.2.3 Thymus-independent T cell regeneration 
Early T cell competence following allogeneic HSCT is provided both 
by residual host T cells that have survived conditioning and by mature 
donor T cells present in the non T cell depleted (non-TCD) graft (Figure 
2).27,101-106 Donor-derived T cells are the major contributors to T cell 
competence in cases of high-intensity conditioning.107,108 After use of RIC 
residual host T cells also play a prominent role in complementing early T 
cell immunity.10,109,110 Under physiological conditions T cells either expand in 
response to stimulation by cognate antigen or undergo homeostatic 
proliferation in case of lymphopenia.111,112 The diversity of the T cell pool 
generated through homeostatic peripheral expansion, largely depends on the 
diversity of the mature T cells that served as the source for expansion. 
Interactions with pathogens skew the repertoire because of oligoclonal 
expansion of pathogen-specific T cells, which may acquire a memory 
phenotype.113 Thymus-independent T cell immunity is largely transient and 
characterised by clonal exhaustion of cells caused by extensive replication 
and increased sensitivity to apoptosis.27,106,114-116 The transferred donor T 
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cells not only defend against post-HSCT infections, but also provide 
tumouricidal activity, which is termed graft-versus-tumour (GVT) effect,117 
and may cure malignancies in the context of allogeneic HSCT.118  In the 
case of leukaemia, this phenomenon is referred to as the graft-versus-
leukaemia (GVL) effect.119 Donor T cells and histocompatibility differences 
between donor and host are pivotal for the GVT effect.120 In MHC-
mismatched transplantation settings, alloreactive donor T cells react 
against both MHC molecules and antigens presented by the MHC molecule. 
However, in MHC-matched settings genetic differences between donor and 
recipient are restricted to minor histocompatibility antigens (miHAs).120 
The epitopes that promote the GVT effect are also mostly expressed on 
normal, non-malignant host cells and promote a GVH reaction (see chapter 
1.3).119 However, unique tumour associated antigens and miHA specifically 
expressed in haematopoietic cells, such as HA-1 and HA-2, can serve as 
preferential targets of GVT responses without developing GVHD.121-125 GVT 
and GVHD are thus tightly linked processes.  	
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1.3 Graft-versus-host Disease 
1.3.1 Clinical Features of Graft-versus-host Disease 
The development of novel transplantation strategies has contributed 
to the expansion of indications for allogeneic HSCT. However, GVHD 
remains a major complication and limits the use of transplantation 
therapy.126 GVHD manifests in an acute and/or chronic form. Acute GVHD 
is classified in a classic and a late-onset form according to the time when 
symptoms are visible.127 Acute GVHD predominantly affects the skin (81% 
of patients), gastrointestinal tract (GI; 54%), and liver (50%) (Figures 5 
and 6).126,128  
 
 
Figure 5. Acute GVHD of the skin (grade I).  
Taken from Ferrara et al., Lancet (2009)126 
 
The severity of acute GVHD depends on the extent of organ 
involvement and is graded as follows: grade I (mild); II (moderate); III 
(severe); and IV (very severe).129 Five-year survival for grade III acute 
GVHD is 25%. Grade IV disease diminishes long-term survival to 5%.130 
The development of acute GVHD depends on several factors, including 
genetic differences between donor and host, donor’s sex, and the stem cell 
source replete with donor T cells.131-134 While the incidence of acute GVHD 
in patients receiving fully-matched sibling donor grafts varies from 35 to 
45%,134 recipients of one-antigen HLA-mismatched unrelated donor grafts 
have an incidence of acute GVHD occurrence of up to 60-80%.135  
Chronic GVHD is the major cause for non-relapse death occurring 
late after allogeneic HSCT.136 Additionally, its presence prolongs the need 
for immune suppressive therapy.14,137,138 Two forms of chronic GVHD were 
defined; a classic type without features of acute GVHD and an overlap 
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syndrome with features of both, acute and chronic GVHD (Figure 6).127,139  
The overlap syndrome can arise in two different ways. Firstly, chronic 
GVHD occurs progressively, thus the acute form merges into chronic 
pathology. Secondly, chronic GVHD can appear quiescently, when fully 
resolved acute GVHD is followed by the chronic form. However, classic 
chronic GVHD is initiated de novo. The occurrence of chronic GVHD varies 
widely between 6-80%,136,140,141 with a mortality of 30%.126 Older recipient 
age and the presence of prior acute GVHD predispose to chronic 
GVHD.132,141,142 Chronic GVHD is a multiorgan pathology that affects the 
skin, eyes, mouth, gut, liver, lungs, joints and genitourinary system, which 
results in organ failure and decreased survival.139,143-147 According to the 
number and severity of organs involved, chronic GVHD is scored as mild, 
moderate or severe.139,148  
 
 
Figure 6. GVHD 
classification. Clinical 
manifestations determine 
whether the syndrome is 
considered as acute or chronic 
GVHD.  
Adapted from Pavletic et al., 
Hematology (2012)149  
 
 
1.3.2 Pathophysiology of acute GVHD 
The use of mouse models was crucial for the understanding of the 
pathophysiology of acute GVHD.150 The development of acute GVHD can 
be summarised to occur in three sequential steps: 1) activation of host 
APCs; 2) activation, expansion and differentiation, and trafficking of donor 
T cells; and 3) target tissue destruction by cellular and inflammatory 
effectors (Figure 7).126 
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Figure 7. Pathophysiology 
of acute GVHD. The 
development of acute GVHD 
consists of three different 
phases: 1) Host APC 
activation; 2) Donor T cell 
activation; 3) Cellular and 
inflammatory effectors.  
Taken from Ferrara et al., 
Lancet (2009)126 
 
Prior to transplantation, the underlying disease and cytoreductive 
conditioning cause damage to patient’s tissues. The latter respond to this 
damage with the secretion of “danger signals”, including proinflammatory 
cytokines, such as tumour necrosis factor-α (TNF-α) and interleukins 1 and 
6 (IL-1 and -6, respectively), and chemokines. Furthermore, expression of 
adhesion molecules, costimulatory molecules, and MHC antigens on host 
APCs is increased. Together, these danger signals result in the activation of 
host APCs.151-154  
The central step of the GVH reaction is the second phase, in which 
donor T cells proliferate and differentiate upon recognition of signals from 
host APC.155,156 Donor/host disparities in MHC class I initiate a CD8-driven 
GVHD response, while differences in MHC class II result in stimulation of 
CD4+ T cells.157 However, recipients of HLA-identical grafts can still 
develop acute GVHD mediated by both CD4+ and CD8+ T cells because of 
genetic disparities outside of the MHC loci referred to as minor 
histocompatibility antigens (miHA).158,159 The combination of signals 
mediated by antigen-specific receptors and costimulatory molecules results 
in the activation of donor T cells and consequently their expression of 
cytokines. T-helper 1 (TH1) cytokines, which include interferon-γ (IFN-γ), 
IL-2 and TNF-α, but also TH2 cytokines (IL-4, -5, -10, and -13), are 
extensively released during acute GVHD. A unique combination of 
chemokines expressed by host tissues that target receptors expressed on 
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donor T cells regulates the migration of alloreactive T cells from lymphoid 
tissues to specific target tissues. Once migrated to target tissues, 
alloreactive effector T cells can mediate tissue damage through both direct 
cytotoxicity and the recruitment of additional leukocytes, such as NK 
cells.152  
The third phase of acute GVHD is a complex cascade of cellular 
mediators, such as cytotoxic T cells and NK cells, and soluble inflammatory 
agents, such as TNF-α, IFN-γ, IL-1 and nitric oxide.126 These molecules 
work synergetically to amplify local tissue injury and further promote 
inflammation and target tissue destruction. IFN-γ has an ambivalent role in 
acute GVHD and can either enhance or reduce the disease.160,161 But my lab 
has demonstrated a central role for IFN-γ in thymic injury (see 1.3.7).162  
 
 
1.3.3 Pathophysiology of chronic GVHD 
In comparison to acute GVHD, the pathophysiology of chronic 
GVHD is less well understood. This restriction is due to a limited 
availability of suitable mouse models.147,150 Four mechanisms may likely 
contribute to the development of chronic GVHD. Firstly, cytokines such as 
transforming growth factor-β (TGF-β) may play a crucial role in chronic 
GVHD, since neutralisation of TGF-β in experimental models ameliorated 
the manifestations of chronic GVHD.163 Secondly, the role of B cells in the 
pathophysiology of chronic GVHD is supported by both experimental and 
clinical data. For example, experimental models showed that the 
development of a chronic GVHD syndrome with cutaneous sclerosis and 
glomerulonephritis phenotype is dependent on the presence of both, donor 
CD4 T and B cells.164 Patients treated with a anti-CD20 antibody showed 
improvement of clinical symptoms of chronic GVHD, indicating a role for B 
cells.165 Thirdly, a defect in the Treg population was associated with the 
development of chronic GVHD. Acute GVHD affects the development of 
Treg cells, which might be capable of preventing chronic GVHD.166 
Experimental data from different GVHD models showed that donor and 
host Treg cells were able to prevent or even reverse already existing 
GVHD.164,167,168 Clinical data from chronic GVHD in humans are not 
consistent, but an association between low Treg levels and increased GVHD 
risk is likely.169-175 Lastly, defective thymic negative selection has been 
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implicated in the development of chronic GVHD. Thymic damage caused 
by prior acute GVHD (discussed in more detail below) has been reported to 
impair negative selection of developing thymocytes in mice.176 Evidence that 
the disruption in the thymic microenvironment plays a role for the typical 
autoimmune syndrome observed in chronic GVHD has been gained from 
experimental transplantation models. The de novo generation of 
autoreactive T cells from donor HSC is a hallmark of murine acute 
GVHD.177,178 These autoreactive T cell clones can mediate the evolution 
from the acute to the chronic GVHD form.179-181 Moreover, thymic damage 
in the course of acute GVHD has been connected to a severely altered TCR 
repertoire selection.180 Taken together, the impairment of the Treg 
development and thymic negative selection provide two possibilities how 
acute GVHD can predispose to chronic GVHD. Since some studies182,183 
showed that chronic GVHD recipients do not necessarily have a defect in 
thymic negative selection, and that transplantation of healthy thymic tissue 
did not ameliorate chronic GVHD, thymus-independent pathways can also 
give rise to autoreactive T cells breaking the tolerance and mediating 
chronic GVHD. Supporting this notion, Zhao et al.183 showed that 
autoimmune-like chronic GVHD can be induced in euthymic, T cell-
deficient athymic, and thymectomised MHC-matched recipients by donor 
CD4+ T cells. As a possible mechanism, mature donor CD4+ T cells that 
are transferred in the donor stem cell graft show both, host and donor 
reactivity, and are activated and expanded by alloimmune response. This 
results in a skewed TCR repertoire that is able to mediate autoimmune 
manifestations in the absence of effective T-cell regulation.146 After being 
activated, these donor T cells contribute to the development of 
autoimmune-like manifestations characteristic of chronic GVHD.183,184 A 
crucial role for donor APCs in the evolution from alloreactivity to 
autoreactivity was suggested in this context.185 In a first phase of GVHD, 
donor T cells recognise alloantigen presented on host APCs. However, these 
APCs are replaced by donor APCs, which present host alloantigen via the 
indirect pathway of allorecognition to donor T cells. During this transition, 
breaking of self-tolerance occurs and donor T cells acquire the ability to 
recognise both host and donor.  
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1.3.4 Prophylaxis and Treatment of GVHD   
Prevention of GVHD 
The primary strategy to prevent GVHD is to suppress the patient’s 
immune competence.186 Since T cells play a central role in initiating GVHD 
many clinical studies used T-cell depletion (TCD) in order to effectively 
prevent GVHD. TCD can be done either by negative selection of T cells ex 
vivo; by positive selection of CD34+ stem cells ex vivo; and/or by antibodies 
targeting T cells in vivo.126 Unfortunately, TCD is associated with high 
rates of graft failure, malignancy relapse, and opportunistic infections.8,187-189 
At present, no therapy or combination of therapies exist to effectively 
prevent clinical acute GVHD. The current standard prophylaxis of acute 
GVHD is a combination of immunophilin ligands, such as cyclosporine and 
tacrolimus, and/or antimetabolites, such as methotrexate.128 Since both 
beneficial anti-tumour effects and deleterious anti-host effects responses are 
based on T-cell immunity, a generalised immunosuppression will inhibit 
both effects equally. The separation of GVT and GVH responses is hence a 
major challenge to transplant immunologists. The use of RIC results in 
diminished conditioning-caused tissue damage and consequently the 
secretion of inflammatory cytokines is decreased. This could explain the 
reduced frequency of severe acute GVHD after RIC compared to full 
myeloablative conditioning.190-193 Current approaches to prevent chronic 
GVHD are strategies to deplete donor T cells before HSCT. The efficacy of 
this approach is low and the overall survival is not increased, however, 
clinical studies suggest the use of in vivo T-cell depletion to prevent chronic 
GVHD.194,195 	
  	
  
Treatment of GVHD 
Despite preventive efforts, GVHD develops in a large number of 
patients and treatment is required. The gold standard for acute GVHD 
treatment are steroids, which have potent anti-lymphocyte and anti-
inflammatory activity.126,128,186 However, to treat steroid-refractory acute 
GVHD other therapy options need to be available, including 
antilymphocyte antibody, infusion of mesenchymal stromal cells, 
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extracorporeal photopheresis or the blockade of the inflammatory cytokine 
TNF-α.126,128 To control acute GVHD, often multiple agents are used in 
combination. Still, treatment responses remain incomplete and 
complications occur frequently, which puts the patient at risk of morbidity 
and mortality. Chronic GVHD is treated with a variety of 
immunosuppressive drugs. The treatment response varies dramatically not 
only among patients, but also among the patient’s different organs, which 
makes chronic GVHD difficult to treat. Prolonged treatment with steroids 
is highly toxic and predisposes the patient to higher risk for infections.126,196  
 	
  
1.3.5 Post-transplant immune deficiency 
Post-transplant immune reconstitution is affected by several factors 
including advanced age of the patient, type of preparative conditioning 
regimen, use of TCD stem cell grafts, genetic differences between donor and 
host, presence of GVHD, and immunosuppressive drugs in order to prevent 
or treat GVHD. GVHD impacts on the restoration of the patient’s immune 
competence in two separate ways; firstly, GVHD directly affects the 
thymus,197,198 and secondly, treatment of GVHD with immunosuppressive 
drugs impairs immune reconstitution.199-204 	
  	
  
1.3.6 Immune reconstitution in the presence of acute 
GVHD  
The presence of acute GVHD has been inversely associated with the 
capacity to reconstitute immune competence. In both patients with and 
without acute GVHD immune competence drops post-transplantation. At 
one year post-transplantation total T cell counts are only slightly higher in 
patients without acute GVHD compared to patients suffering from acute 
GVHD. However, the reconstitution of naïve CD4+ T cells 
(CD45RA+CD62L+) is significantly delayed in patients suffering from acute 
GVHD (Figure 8).197,205-207  
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Figure 8. Acute GVHD delays 
reconstitution of naïve CD4+ T 
cells. Without complications, 
normal numbers of naïve CD4+ T 
cells are reached between 12 and 24 
months post-transplantation. In the 
presence of acute GVHD, this 
reconstitution process is slowed 
down. (blue shading indicates the 
normal range for naïve peripheral 
CD4+ T cells) 
Adapted from Clave et al., Blood 
(2009)197 
 
In addition to the total cellularity, the quality of the TCR repertoire 
is also affected. The generation of a polyclonal repertoire is restricted in the 
presence of acute GVHD and takes longer than the usual 1-2 years in 
patients without complications.197 Since the thymus is essential for the 
generation of a naïve polyclonal T cell pool, these data argue for a defect in 
thymus-dependent T cell development.  	
  	
  
1.3.7 Thymic GVHD 
Morphological changes in the lymphoid and epithelial components of 
the thymus have been observed in transplanted patients more than 30 years 
ago, which led to the identification of the thymus as a target of GVHD.208-
211 The histological features of thymic dysplasia caused by acute GVHD 
include the depletion of cortical and medullary thymocytes, changes in 
number and composition of the different TEC subpopulations, 
disappearance of the corticomedullary demarcation, phagocytosis of cellular 
debris, and the elimination of Hassall’s bodies.212 In parallel to the 
destruction of the thymic architecture, deficits in thymopoiesis are 
observed. This results in a distorted TCR repertoire and lower thymic 
output in comparison to healthy controls.197,205,206,213-215  	
  	
  
Pathomechanism of Thymic Injury – Preclinical Mouse Models    
Preclinical mouse models of allogeneic HSCT can provide insight 
into the pathophysiology of thymic GVHD. Thymic dysplasia induced in 
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experimental mouse models resembles the typical features observed in 
human thymic GVHD (see above).162,178,216,217 The impact of radiation and 
chemotherapy on thymic structure and function are well described.218 
However, the mechanisms by which an alloreaction causes thymic injury are 
still incompletely understood. To investigate the effect of acute GVHD on 
thymic structure and function independently of conditioning, experimental 
transplantation model that do not necessitate radiation are required. In a 
haploidentical transplantation model, parental T cells (for example: 
C57BL/6; H-2b) are infused into a F1 strain (for example: BDF1; H-2bd). 
Since host immune cells recognise the donor T cells as “self” (in the example 
given they share the b haplotype), there is no risk of graft rejection and 
pre-conditioning can be omitted. Donor T cells react in turn against the 
other parental alloantigens presented on host cells (in the example provided 
H-2d), which leads to the destruction of thymic tissue in addition to tissue 
injury of typical GVHD target organs.162 In this system, the reduced thymic 
cellularity in the context of acute GVHD is primarily a consequence of the 
depletion of the most abundant DP thymocyte population. There are two 
independent mechanisms that contribute to this defect. Under physiological 
conditions, cell numbers of the most immature thymocytes increase 20- to 
50-fold during progression of TN to DP thymocytes.219,220 However, in the 
presence of acute GVHD the proliferation of TN thymocytes is impaired, 
resulting in an elevated frequency of stage I TN thymocytes compared to 
stage III TN thymocytes.221 Hence, acute GVHD causes a failure of survival 
and further maturation of thymocytes to the DP stage. The second 
mechanism that accounts for the profound loss of the DP population is the 
increased apoptosis of DP thymocytes themselves.222 As an underlying 
mechanism, alloreactive donor T cells target the host thymic 
microenvironment, thereby indirectly causing impairments in thymopoiesis 
and thymic output.162,212 Donor T cells infiltrate the recipient’s thymus in 
the absence of pre-conditioning and their number corresponds to the degree 
of the defect in thymopoiesis.221 Recent detailed analysis of the thymic 
stromal network in the course of acute GVHD revealed that TEC undergo 
apoptosis in response to IFN-γ secreted by donor T cells (Figure 9).162,223-225 
IFN-γ activates STAT1 and consequently initiates apoptosis in TEC.162 
These data suggest that TEC are competent to directly prime naïve 
allogeneic donor T cells.162 The approach of depletion of host APCs would 
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therefore not be sufficient to protect the recipient from TEC injury caused 
by alloreactive T cells. 	
  
	
  
Figure 9. Alloreactive T cells cause 
TEC injury in acute GVHD. 
Alloreactive T cells present in the donor 
graft infiltrate the host’s thymus (1) 
where they recognise alloantigens 
presented by TEC. This results in their 
activation and secretion of IFN-γ (2), 
which in turn upregulates STAT1 in 
TEC. Upregulation of STAT1 in TEC 
leads to an apoptotic programme and 
consequently TEC death (3). The loss of 
TEC results in a defective support of T 
cell development and therefore decreased 
thymopoiesis (4). Consequently, less 
mature T cells emerge to the periphery 
and post-HSCT immune deficiency arises 
(5).  
Adapted from Weinberg KI., Blood 
(2007)226   
 
 
Thymic dysfunction during acute GVHD – a link to chronic 
GVHD? 
A hypothesis can be formulated that impairment of TEC function in 
early acute GVHD, and consequently the impaired TCR selection, provide 
an etiological link between alloreactivity of acute GVHD and the 
autoimmunity features observed in chronic GVHD. Hence, measures that 
protect, repair, and enhance TEC function may become the focus of future 
treatment strategies to prevent thymic acute GVHD and consequently post-
transplantation immune deficiency and autoimmunity.  
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1.3.8 Strategies to Improve post-transplant Immune 
Deficiency   
Since thymic injury in the course of acute GVHD contributes to 
deficits in post-transplantation T-cell regeneration, strategies that seek to 
boost thymic function hold promise for ameliorating immune deficiency 
following allogeneic HSCT. Interventions may include therapies that act 
directly on TEC in order to increase their numbers, and consequently, to 
enlarge the availability of developmental niches within the thymic stromal 
network.227 Various concepts to stimulate thymus function have been 
proposed that include for example growth hormone or androgen blockage, 
interference with signalling pathways as for example p53 inhibition and 
stimulation of Flt3 signalling, and exogenous administration of cytokines 
and growth factors such as IL-7, IL-22, and fibroblast growth factor-7 
(Fgf7).227 Since my studies dealt with Fgf7, I focus here on this epithelial 
growth factor.    
 
  
Fibroblast growth factor-7 
Fibroblast growth factor-7 (Fgf7; also known as keratinocyte growth 
factor, KGF; Palifermin, Kepivance®) is an epithelial growth factor that 
belongs to the family of fibroblast growth factors.228 Palifermin, which is a 
recombinant human Fgf7, is currently an approved drug for the prevention 
of oral mucositis in patients undergoing HSCT.229-231 Fgf7 induces 
differentiation and proliferation in a variety of epithelial cell tissues via 
binding and activation of its receptor FgfR2IIIb, which is a splice variant of 
the Fgf receptor 2.232 This receptor is expressed on several epithelial tissues 
in the intestine, skin, lung, liver, and thymus.233 Within the thymus, 
FgfR2IIIb is expressed on TEC,216 but not on haematopoietic cells.234 In the 
thymus, Fgf7 is endogenously produced by mesenchymal cells and by 
mature thymocytes of the αβ-lineage.235,236 Experimental studies with mice 
deficient for FgfR2IIIb revealed an important role for Fgf7 during thymus 
organogenesis.236-238 The fact that thymic Fgf7 production is sustained 
throughout life and FgfR2IIIb is expressed on both immature and mature 
TEC argues for a continued requirement of Fgf7 by the postnatal thymic 
stromal compartment.239,240 Fgf7 has the capacity to correct thymus 
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senescence241 and to repair thymus injury caused by irradiation.240 
Exogenous postnatal administration of Fgf7 results in enhanced 
proliferation of the TEC compartment and consequently in increased 
thymopoiesis (Figure 10).239  
 
 
 
Figure 10. Fgf7 increases thymic 
size and cellularity. Fgf7 
administration directly acts on TEC and 
increases the number of both cortical 
and medullary TEC. As a consequence, 
enlarged TEC compartment boosts 
thymopoiesis, which results in an 
increase in CD4+CD8+ DP and mature 
CD4+ and CD8+ SP T cells. 
Adapted from Chu et al., Blood 
(2007)242  
 
 
Moreover, the increased thymopoiesis correlates with enhanced 
thymic export. Applied in experimental mouse models of acute GVHD, Fgf7 
preserved normal function and architecture of the TEC subpopulations.216 
Importantly, regular T cell development is supported despite the presence 
of alloreactive donor T cells. Moreover, thymus protection by Fgf7 prevents 
the emergence of self-reactive T cells from the thymus to the periphery,180 
and promotes faster immune recovery following transplantation.243 These 
data indicate that early Fgf7 administration corrects thymic injury caused 
by acute GVHD, and therefore supports and boosts normal thymic T cell 
development and output. Nevertheless, Fgf7’s impact on the immune 
reconstitution in humans following allogeneic HSCT has not been 
established yet and further studies are needed.    
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2. HYPOTHESES AND AIM OF THE 
THESIS 
The overall hypothesis underlying this thesis postulates that GVHD-
mediated injury to the thymus, in particular to the thymic epithelial cell 
compartment, is a major limitation responsible for defective T-cell immune 
reconstitution after allogeneic HSCT. This defect results in adverse effects 
as diverse as post-transplantation immune deficiency and autoimmunity.  
 
The aim of the present study was to address whether altered TEC 
function as a consequence of acute GVHD is causative for the autoimmune 
syndrome typically seen in chronic GVHD. To address this question, I have 
tested several specific hypotheses: 1) acute GVHD causes a loss of mTEC 
number and integrity, 2) impairment of the mTEC compartment alters 
intrathymic ectopic self-antigen expression which is required for normal 
central tolerance induction, 3) lack of appropriate thymic negative selection 
causes autoreactive T cells to emerge during acute GVHD, and 4) TEC 
cytoprotection consequently allows normal mTEC function. 
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3.  MATERIALS AND METHODS 
3.1 Mice 
Female C57BL/6 (B6; H-2b), (C57BL/6xDBA/2)F1 (BDF1; H-2bd), 
Balb/c (H-2d), CBy.PL(B6)-Thy1a/ScrJ (Balb/c-Thy1.1; H-2d), 129/Sv (H-
2b), B6.SJL-PtprcaPep3b/BoyJ (B6.CD45.1; H-2b) and C57BL/6-Tg(Ins2-
TFRC/OVA)296Wehi/WehiJ (RIP-mOVA; H-2b) mice were kept in 
accordance with federal regulations. B6.OT-II-Rag2-/-CD45.1 mice (OT-
II.CD45.1; H-2b) were bred at Benaroya Research Institute at Virginia 
Mason, Seattle, USA.  
 
 
3.2 BMT and GVHD induction 
Thymic acute GVHD was induced in unirradiated or total body 
irradiated (TBI) recipients. In an unconditioned haploidentical allo-HSCT 
model, acute GVHD was induced in 8-week old non-irradiated BDF1 (H-2bd) 
mice by i.v. injection of 15x106 B6.CD45.1 (CD45.1+; H-2b) splenic T-cells 
as described.162,225 As controls, 15x106 syngeneic BDF1 splenic T-cells were 
infused into syngeneic recipients which were age-matched with recipients of 
allogeneic donor cells. The same haploidentical transplantation model was 
studied following myeloablative conditioning. Acute GVHD (b→bd) was 
induced in 8-week old lethally irradiated BDF1 mice (1000 cGy) by i.v. co-
injection of 2.5x106 B6.CD45.2 splenic T-cells and 5x106 B6.CD45.1 T-cell 
depleted (TCD) bone marrow cells. As controls without disease, recipients 
of 5x106 B6.CD45.1 TCD bone marrow cells alone were used. In a fully 
MHC-disparate transplantation model, acute GVHD (d→b) was induced in 
9-week old lethally irradiated B6 mice (975 cGy) by i.v. co-injection of 
3x106 Balb/c-Thy1a (H-2d) splenic T-cells and 5x106 Balb/c TCD bone 
marrow cells. As controls without disease, recipients of 5x106 Balb/c TCD 
bone marrow cells were used. In a MHC-matched, minor histocompatibility 
antigen-mismatched transplantation model, acute GVHD (b→b) was 
induced in 8-week old lethally irradiated B6 mice (1000 cGy) by i.v. co-
injection of 4x106 splenic T-cells and 7x106 TCD bone marrow cells from 
129/Sv (H-2b) donors. As controls without disease, recipients of 7x106 TCD 
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bone marrow cells were used. To induce thymic acute GVHD into RIP-
mOVA mice, Balb/c T cells (3x106) isolated from the spleen were 
transplanted into total body irradiated (TBI)-fully MHC-mismatched RIP-
mOVA recipients (H-2d → H-2b). Control mice (no GVHD) received T-cell 
depleted Balb/c-Thy1.1 bone marrow (10x106) only. Four weeks after 
generation of [Balb/c → RIP-mOVA] chimeras (GVHD- or GVHD+), 
recipients were reirradiated and transplanted with T-cell depleted OT-II 
bone marrow (5x106 TCDBM; CD45.1) mixed with B6 TCDBM (15x106; 
CD45.2). OVA-specific T cells stemming from the OT-II BM were analysed 
4-6 weeks after the 2nd HSCT in the thymus and periphery (spleen and 
lymph nodes). These OVA-specific T cells were defined as CD4+, CD45.1+, 
Vα2+, Vβ5+. 
 
 
3.3 Fgf7 treatment 
Recombinant human Fgf7 (palifermin, Kepivance®, Biovitrum, 
Sweden) was injected i.p. from day -3 to day +3 after allogeneic HSCT at a 
dose of 5 mg/kg/day.216,225,239  
 	
  
3.4 Flow cytometry reagents 
For six- and seven colour flow cytometric analyses, the moAbs 
directed against the following murine proteins were used: CD4 (clone RM4-
5 and GK1.5), CD8 (53-6.7), CD45.1 (A20), CD45 (30-F11), CD90.1 
(19E12), I-Ab (AF6-120.1), I-A/I-E pan MHCII (clone M5/114.15.2), Ly51 
(6C3/BP-1, clone 6C3), H-2Kb (AF6-88.5), H-2Kd (SF1-1.1), Va2 (B20.1), 
TCRb (H57-597), H-2Kb (25-D1.16), CD44 (IM7), CD73 (TY/11.8), FR4 
(eBio12A5), Foxp3 (FJK-16s) and 5’-bromo-2’-deoxyuridine (BrdU, clone 
3D4; Mouse Anti-BrdU Set). These reagents were obtained from BD 
Biosciences Pharmingen (San Diego, CA) or eBioscience (San Diego, CA). 
The moAbs against EpCam (CD326; clone G8.8),62 and Aire (clone 5H12) 
were obtained from The Developmental Studies Hybridoma Bank 
(University of Iowa, IA) and Dr. H. Scott (Melbourne, Australia),77 
respectively. UEA1 lectin was purchased from Vector Laboratories 
(Burlingame, CA, USA) and 7-amino-actinomycin D (7-AAD) was obtained 
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from BD Biosciences. Primary moAbs were conjugated to either biotin, 
fluorescein isothyocyanate (FITC), phycoerythrin (PE), cyanin 5 (Cy5), 
allophycocyanin (APC), Alexa Fluor®700 or the tandem dyes PECy5, 
PECy7, PerCPCy5.5, APCCy7 (BD Biosciences, eBioscience, BioLegend, 
San Diego, CA). Biotin-conjugated primary moAbs were detected using 
secondary anti-rat polyclonal antibodies conjugated to 
streptavidin/APCCy7 or streptavidin/PerCPCy5.5 (BioLegend, San Diego, 
CA). 
 
 
3.5 Analysis of the mTEChigh compartment by flow 
cytometry 
Thymi were isolated at the indicated time points after 
transplantation and enzymatically digested with 
collagenase/dispase/DNAse I (Roche Diagnostics, Switzerland). For RNA 
isolation and detection of Aire expression in mTEC, the enzymatic digests 
were incubated with biotin-conjugated EpCam (G8.8) followed by anti-
biotin magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
and enrichment of EpCam+ stromal cells by positive selection on an 
AutoMACS Pro (Miltenyi). For analysis of BrdU incorporation, mice were 
either injected intraperitoneally (i.p.) twice with 1mg BrdU 16 and 8 hours 
prior to analysis, or were fed from day -3 to 3 after HSCT with drinking 
water supplemented with 0.8mg/ml BrdU. The first method aims to analyse 
cell cycle during a short time window, whereas the latter provides 
information about the kinetics of cell proliferation.244 For both BrdU 
analysis methods the enzymatic digests were incubated with anti-CD45 
magnetic microbeads (Miltenyi) followed by depletion via negative selection 
of CD45+ cells. Depending on the experimental goal, enriched cell 
preparations were stained with different combinations of primary moAbs 
against surface and intracellular proteins and the lectin UEA1. Prior to 
intracellular staining, cells were fixed and permeabilised using the BD 
Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Bioscience) 
according to the manufacture’s guidelines. For intracellular Foxp3 staining, 
cells were fixed and permeabilised using the Foxp3/Transcription Factor 
Staining Buffer Set (eBioscience) according to the manufacture’s 
instructions. Non-fixed labelled cells were stained with DAPI; (4',6-
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Diamidine-2'-phenylindole dihydrochloride; Roche Diagnostics, Switzerland) 
and were analysed or sort purified using a FACSAria® flow cytometer 
(Becton Dickinson, Mountain View, CA) and FACSDiva (Becton 
Dickinson) and FlowJo software (Tree Star Inc, Ashland, OR). MHC class 
IIlow and class IIhigh mTEC were defined as DAPI-CD45-EpCam+Ly51-
UEA1+MHCIIlow/int and MHCIIhigh cells, respectively (Table 1). For the 
purpose of RNA isolation, non-fixed viable (DAPI-) cells were sorted on ice 
to a purity of >99% and immediately processed. To analyse cell 
proliferation, cells were also treated with DNAse I (Sigma, St. Louis, USA) 
followed by BrdU staining and re-staining of tandem dyes. 
 	
  
3.6 Immunofluorescence confocal microscopy 
For analysis of Aire expression in TEC, thymi were isolated at 2, 4 
and 7 weeks after transplantation (which corresponded to recipient ages of 
10, 12 and 15 weeks) and frozen in OCT. Sections (8 µm) were cut on a 
cryostat, dried and fixed with acetone (-20°C). Primary antibodies were 
biotin-conjugated cytokeratin (CK)-18 (Ks18.04, Progene GmbH, 
Heidelberg, Germany), CK14 (rabbit) (Covance, Princeton, NJ, USA), and 
Aire/Cy5 (5H12, provided by H. Scott, Adelaide, Australia). Secondary 
reagents were streptavidin/Cy3 (BioLegend) and goat anti-rabbit IgG A488 
(Invitrogen). Sections were stained with DAPI and mounted with 
hydromount. All images were captured on a Zeiss LSM 510 Meta Laser 
Scanning Confocal Microscope system (Carl-Zeiss AG, Feldbach, 
Switzerland). Isotype controls were used in all experiments. Images were 
acquired with a 20x Plan-Neofluar air objective with NA 0.5 at room 
temperature. The microscope used photomultiplier tubes (PMT) for 
detection. Overlays of blue (Cy5), red (Cy3), and green (Alexa488) 
stainings were coloured by computer-assisted management of confocal 
microscopy data generated with Zeiss LSM 510 software version 3.2. Image 
analysis was done using the software ImageJ (http://imagej.nih.gov/ij). 
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3.7  Quantitative PCR 
RNA was isolated from sorted mTEChigh using the RNeasy Micro 
Kit (Qiagen, Switzerland) according to the manufacturer’s protocol. RNA 
was transcribed into cDNA with the SuperScript III Reverse Transcriptase 
(Invitrogen) according to the manufacturer’s instructions. Real-time PCR 
was performed on a Rotor-Gene 3000A (Qiagen) using SensiMix SYBR Kit 
(Bioline, London, United Kingdom) for quantitative expression analyses. 
Primer sequences were:  
EpCam:  
forward, 5’-TGAGGACCTACTGGATCATC;  
reverse, 5’-TATCGAGATGTGAACGCCTC;  
Foxn1:  
forward, 5’-TCTACAATTTCATGACGGAGCACT;  
reverse, 5’-TCCACCTTCTCAAAGCACTTGTT;  
GAPDH:  
forward, 5’-GGTGAAGGTCGGTGTGAACG;  
reverse, 5’-ACCATGTAGTTGAGGTCAATGAAGG;  
salivary protein 1 (Spt1):  
forward, 5’-GGCTCTGAAACTCAGGCAGA;  
reverse, 5’-TGCAAACTCATCCACGTTGT;  
major urinary protein 1 (Mup1):  
forward, 5’-CTATCCAATGCCAATCGCTG;  
reverse, 5’-GATAGGAAGGGATGATGGTGG;  
casein γ (Csn1s2a):  
forward, 5’-ATTACACCTTCCCAAATGCT;  
reverse, 5’-CAGTTAATACGGCTCCACAG;  
Ovalbumin (OVA):  
forward, 5’-TGCCTTTCAGAGTGACTGAG;  
reverse, 5’-GAAGCCATTGATGCCACTC;  
autoimmune regulator (Aire):  
forward, 5’-TGTGCCACGACGGAGGTGAG;  
reverse, 5’-GGTTCTGTTGGACTCTGCCCTG   
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3.8 DNA microarray analysis 
To determine gene expression profiles in mTEChigh cells, biotin-
labelled and fragmented cRNA from sorted cells was hybridized to DNA 
microarrays (Affymetrix Mouse Expression Set MOE430A). MIAME 
compliant microarray data was generated by analysis of triplicates for each 
of the experimental conditions which included syngeneic (bd→bd) and 
allogeneic (b→bd) transplantation with or without Fgf7 treatment. RNA 
from sorted mTEChigh (approximately 1000-3000 cells per sample) was 
isolated on 2, 4 and 7 weeks after transplantation using the RNeasy Micro 
Kit (Qiagen, Switzerland) according to the manufacturer’s protocol. High 
quality RNA was confirmed with the Experion RNA HighSens Analysis Kit 
(Bio-Rad, Reinach, Switzerland). cRNA target synthesis was done starting 
from a minimum of 1.16 ng total RNA using the Ovation Pico WTA 
System (NuGEN Technologies, The Netherlands) following standard 
recommendations. Following second reverse transcription, fragmentation 
and labelling of amplified cDNA were performed using the WT Terminal 
Labelling Kit (Affymetrix, Santa Clara, CA). Synthesis reactions were 
carried out using a PCR machine (TProfessional, Biometra, Goettingen, 
Germany). DNA was loaded on Mouse Gene 1.0 ST Array (Affymetrix), 
hybridised for 17 hours, washed and stained using Affymetrix protocol 
FS450_0007. The GeneChips were processed with an Affymetrix GeneChip 
Scanner 3000 7G. DAT images and CEL files of the microarrays were 
generated using Affymetrix GeneChip Command Control 3.0.0.1214. Data 
quality controls were led using Expression console 1.1 (Affymetrix). 
Affymetrix CEL files were normalised245 and data were log2-transformed 
using Partek® Genomics Suite v.6 software (Partek Inc, St. Louis, MO). To 
select differently expressed genes a one-way ANOVA model was applied. 
Genes were filtered on the basis of an adjusted p-value lower than 0.01. 
Microarray data of triplicate samples of pure mTEChigh preparations are 
available under accession number E-MEXP-3745 at 
http://www.ebi.ac.uk/arrayexpress.  
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3.9 Bioinformatics 
Bioinformatics was done using R software (R Foundation for 
Statistical Computing, Vienna, Austria, http://www-r-project.org). Gene 
expression data from the public databases Mouse GNF1M and MOE430 
Gene Atlases (http://biogps.org) were taken as a starting point for the 
identification of TRA among the total number of transcripts expressed in 
mTEChigh cells. Using data from the GEO platform 
(www.ncbi.nlm.nih.gov/geo, GEO series accession number GSE85) and the 
literature,64,70,72 genes were annotated as ubiquitously expressed genes (Ub) 
and TRA, respectively. We initially used the same algorithm for Aire-
dependent and independent TRA as previously described.64,70 Briefly, 
transcripts with expression in <5 different tissues in combination with a 
lower threshold of 5-fold signal intensity of the average of all tissues were 
designated as tissue restricted. The annotated gene lists were further 
curated by incorporating recent sequencing data generated from thymic 
epithelial subpopulations (data not shown). Transcripts whose expression 
levels increased or decreased greater than three-fold in relation to the 
control group (corresponding to relative expression values of <0.33 and 
>3.0, respectively) were considered to be altered in consequence of acute 
GVHD. To test hypothesis of transcript distribution, O/E analyses were 
performed. In this ratio, O is the observed number of events, and E is the 
expected number of events.246 Using hypergeometric statistical analysis, the 
accuracy of the O/E ratio was tested. Pearson’s correlation coefficient 
(Pearson’s r) was calculated including only 50% of the genes that had a 
inter quartile range (IQR) higher than the median of the IQR values of all 
genes. IQR is a measure of statistical dispersion. Tissue representation of 
TRA was analysed using the public databases Mouse GNF1M and MOE430 
Gene Atlases (http://biogps.org). For display of heatmaps, signal intensities 
(log2) were colour coded and plotted for selected genes. 
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3.10 Statistical analysis 
All values are depicted as mean ± SD. The nonparametric unpaired 
Mann-Whitney U test was used for two-group comparisons, whereas for 
multiple group comparisons Kruskal-Wallis one-way ANOVA with Dunn’s 
post test was performed using GraphPad Prism version 6 for Mac OS X 
(GraphPad Software, San Diego California USA, www.graphpad.com). 
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4. RESULTS        
4.1  Impaired ectopic expression of tissue-
restricted antigens in the thymus during 
murine acute GVHD 
4.1.1 Identification and characterisation of medullary 
thymic epithelial cell subsets by flow cytometry  
Advances in the understanding of thymic epithelial cell (TEC) 
biology have allowed for a more precise identification of the terminally 
differentiated, postcycling medullary TEC (mTEC) that are responsible for 
central tolerance induction. This EpCam+UEA1+ cell subset is distinguished 
from other immature or mature epithelial subsets in the thymic cortex and 
medulla by its expression of Aire, lack of Ly51 surface protein and its high 
surface density of MHC class II (mTEChigh cells) (Figure 11, Table 1).56,57,62-66  
 
 
 
 
Table 1. Surface markers to 
identify TEC subsets. Depending on 
the experimental goal, thymic cell 
preparations were stained with different 
combinations of primary moAbs against 
surface and intracellular proteins and 
the lectin UEA-1 
 
 
 
 
 
 
 
 
 
 
Marker Phenotype mTEClow mTEChigh 
DAPI - - 
CD45 - - 
EpCam + + 
UEA-1 + + 
Ly51 - - 
MHCII +/++ +++ 
Aire - -/+ 
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Figure 11. Identification and characterisation of medullary thymic epithelial cell 
subsets by flow cytometry. I used a modified isolation method for thymic stromal cells 
which preferentially enriched for medullary thymic epithelial cells (mTEC).67 (A) Gating 
strategy for mTEChigh cells. The flow cytometry plot on the far right shows the mature MHC 
class IIhigh and the immature MHC class IIlow mTEC subpopulations as cells with CD45-
EpCam+Ly51-UEA-1+MHCIIhigh and MHCIIlow/int phenotypes, respectively. (B) Gating 
strategy for identification of postcycling mTEC that are responsible for central tolerance 
induction and express Aire. The flow cytometry plot on the far right shows intracellular Aire 
staining of CD45-EpCam+Ly51-UEA-1+ mTEC. Doublet discrimination was applied in all 
flow cytometry analyses.  
 
 
 
 
4.1.2  Induction of thymic acute GVHD  
To study the effect of acute GVHD on mTEC number and function, 
I used four different murine models of lethal acute GVHD with or without 
pre-transplantation conditioning. Firstly, to investigate thymic acute 
GVHD independently of total body irradiation or other preconditioning 
regimens, I employed a haploidentical transplantation model (Figure 12A). 
In this model, acute GVHD was induced in 8-week old non-irradiated BDF1 
(H-2bd) mice by i.v. injection of 15x106 B6.CD45.1 (CD45.1+; H-2b) splenic 
T cells (designated as B6→BDF1 group, b→bd) as described.225 BDF1 
recipients injected with 15x106 BDF1 splenic T cells served as syngeneic 
controls (BDF1→BDF1 group, bd→bd).  
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Figure 12. Induction of thymic acute GVHD in two haploidentical HSCT 
models. (A) In an unconditioned haploidentical allogeneic HSCT model, acute GVHD was 
induced in 8-week old non-irradiated BDF1 (H-2bd) mice using B6.CD45.1 (CD45.1+; H-2b) as 
donors (B6→BDF1 group; b→bd, ). As controls, BDF1 mice were transplanted with 
syngeneic donor cells (BDF1→BDF1 group; b→bd, ). The flow cytometry dot plots depict 
surface expression of CD4 and CD8 on host thymocytes. Cell analysis was restricted to live 
thymocytes as defined by forward/side scatter and exclusion of cells staining positive for 
propidium iodide. The numbers shown in each quadrant represent frequencies (% of the 
respective populations, mean ± SD). The figure represents combined data from four separate 
experiments; with an aggregate of 11 mice analysed for each group. Infiltration of donor-
derived CD45.1+ T cells into host thymi is given as frequency (% among total thymic cells) 
and absolute cell numbers (x 10-6, mean ± SD). *p<0.05, Mann-Whitney U-test, acute 
GVHD versus syngeneically transplanted mice without disease. (B) Acute GVHD (b→bd) 
was induced in 8-week old lethally irradiated BDF1 mice by co-injection of T cells and T-cell 
depleted (TCD) bone marrow from B6.CD45.2 and B6.CD45.1 donors, respectively (TCD+T 
group, ). Control recipients without disease received TCD bone marrow only (TCD group, 
). The flow cytometry dot plots depict surface expression of CD4 and CD8 on donor bone 
marrow derived thymocytes and analysis was done as above. Donor T cell infiltration is 
given as fraction (%) of CD45.2+H-Kb+Kd- T cells among thymocytes (mean ± SD).  
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The development of thymic acute GVHD was assessed by flow cytometric 
analysis of host thymocyte development and donor T-cell infiltration into 
the host thymus as a function of age. Here, 10, 12 and 15 week old 
recipients corresponded to 2, 4 and 7 weeks post-transplantation, 
respectively. In allogeneically transplanted recipients, the frequency of the 
CD4/CD8 double positive (DP) population was decreased from ∼88% in 
syngeneic controls to ∼50% at all time points (Figure 12A, middle panel). In 
contrast, an increase in the portion of single positive (SP) thymocytes was 
observed when compared to syngeneic controls (∼1% to ∼8% and ∼6% to 
∼18% for CD8+ SP and CD4+ SP, respectively). This aberrant thymopoiesis 
was characteristic for the presence of thymic acute GVHD and reflected 
enhanced apoptosis of CD4+CD8+ DP thymocytes.221 Since GVHD-
dependent changes in thymocyte maturation correlates directly with the 
number of infiltrating donor T cells,221 I next investigated frequencies and 
absolute numbers of donor T cells present in recipients’ at 10, 12 and 15 
weeks of age. Donor T cells were detected as early as 2 weeks after 
transplantation (Figure 12A, right panel) and remained present in thymi for 
the whole observation period. Next, the same haploidentical transplantation 
model was studied following myeloablative conditioning: Eight-week old 
BDF1 mice were lethally irradiated (1000 cGy) prior to i.v. co-injection of 
2.5x106 B6.CD45.1 splenic T cells (H-2b) and 5x106 B6.CD45.2 T-cell 
depleted (TCD) bone marrow cells (TCD+T group) (Figure 12B). Similar 
to the non-irradiated haploidentical model, I observed defective 
thymopoiesis (Figure 12B, middle panel) and the presence of donor T cells 
(Figure 12B, right panel) in thymi of mice with acute GVHD. To confirm 
these data in other clinically relevant transplantation models, I further 
investigated a fully MHC-disparate transplantation model. To this end, 
acute GVHD (d→b) was induced in 9-week old lethally irradiated B6 mice 
(975 cGy) by i.v. co-injection of 3x106 Balb/c (H-2d) splenic T cells and 
10x106 Balb/c-Thy1a TCD bone marrow cells (TCD+T group) (Figure 
13A). Consistent with the observations before, intrathymic T-cell 
development was aberrant and donor T cells infiltrated the thymus in the 
presence of acute GVHD. Lastly, a MHC-matched, minor histocompatibility 
antigen (miHA)-mismatched transplantation model was analysed (Figure 
13B). Here, defective thymopoiesis (higher frequencies of CD4 and CD8 SP 
thymocytes in the presence of acute GVHD) was also a hallmark of acute 
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GVHD but defects were not as pronounced as in the MHC-mismatched 
allo-HSCT models described above.  
 
 
Figure 13. Induction of thymic acute GVHD in a MHC- and a miHA-
mismatched HSCT model. (A) Acute GVHD (d→b) was induced in 9-week old lethally 
irradiated B6 recipients by co-injection of T cells and TCD bone marrow from MHC-
mismatched Balb/c and Balb/c-Thy1a donors, respectively (TCD+T group, ). Control 
recipients without disease received TCD bone marrow only (TCD group, ). The same 
analysis was performed as in panels A and B. Donor T cell infiltration is given as 
percentages of Thy1a-H-2Kd+ T cells among total thymic cells ( mean ± SD). (B) Acute 
GVHD (b→b) was induced in 8-week old lethally irradiated B6 mice by co-injection of T 
cells and TCD bone marrow from MHC-matched, minor histocompatibility antigen-
mismatched 129/Sv (H-2b) donors (TCD+T group, ). Control recipients without disease 
received TCD bone marrow only (TCD group, ). Flow cytometry analysis of total 
populations was performed as above.  
 
 
4.1.3  Acute GVHD impairs mTEChigh compartment size  
Based on the aforementioned identification and characterisation scheme for 
TEC subsets and the fact that the thymic epithelium is a target of donor 
T-cell alloimmunity,36,162,223 I next aimed to investigate whether frequencies 
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and absolute numbers of the different TEC subsets were affected by thymic 
acute GVHD (Figures 14 and 15). Total numbers of mTEChigh declined 
indeed over time in untransplanted adult BDF1 and B6 mice, confirming 
age-dependent changes of the thymic stroma in normal mice (Figure 15).57  
 
 
Figure 14. Flow cytometric analysis of medullary thymic epithelial cell subsets 
in presence of acute GVHD. mTEChigh and mTEClow were analysed by flow cytometry as 
a function of age using the strategy described in Figure 11. (A) mTEChigh and mTEClow 
analysis in the haploidentical transplantation model described in Figure 12A. The numbers 
shown in each flow cytometry dot plot represent frequency (% mean ± SD) of the respective 
population among total mTEC. The figure represents combined data of individual mice from 
6 separate experiments. bd→bd; syngeneic controls, no acute GVHD. b→bd; allogeneic 
HSCT, acute GVHD. The same analysis was performed for three other allogeneic HSCT 
models (described in Figures 12 and 13). (B) Haploidentical HSCT model (b→bd) with lethal 
irradiation (1000 cGy). TCD; no acute GVHD, TCD + T; acute GVHD. (C) MHC-
mismatched HSCT model (d→b) with lethal irradiation (975 cGy). TCD; no acute GVHD, 
TCD + T; acute GVHD. (D) MHC-matched, miHA-mismatched HSCT model (b→b) with 
lethal irradiation (1000 cGy). TCD; no acute GVHD, TCD + T; acute GVHD 
 
 
I then investigated the four mouse models of age-matched allo-HSCT 
described in section 4.1.2. Flow cytometric analysis revealed that relative 
frequencies of both mTEClow and mTEChigh subsets were altered in the 
presence of acute GVHD as early as 2 weeks post-transplantation in 
	
  	
  	
   46 
unconditioned recipients of haploidentical HSCT (H-2b→H-2bd; b→bd) 
(Figure 14). The induction of thymic acute GVHD progressively reduced 
total mTEClow and mTEChigh numbers from ∼104 cells/mouse in 
syngeneically transplanted animals to ≤103 cells/mouse in animals surviving 
acute GVHD (Figure 15A). This observation was mirrored in allo-HSCT 
that included total body-irradiation (TBI) before MHC-identical, MHC-
disparate, or haploidentical transplantation (Figure 15B-D). In these 
models, the conditioning initially reduced mTEChigh numbers independently 
of acute GVHD, but cell loss was either more pronounced (b→bd) or more 
protracted (d→b; b→b) in the presence of disease. Hence, reduction in 
mTEChigh compartment size is a universal manifestation of thymic acute 
GVHD, and radiation injury is not mandatory, as suggested before.223 
 
 
Figure 15. Absolute cell numbers of mTEChigh and mTEClow are decreased in the 
presence of acute GVHD. Absolute numbers of the mTEC compartment were analysed 
as a function of recipient age in 4 different murine models of allogeneic HSCT. (A) Acute 
GVHD was induced in 8-week old unconditioned BDF1 recipients (b→bd, black circles). 
Untransplanted BDF1 mice (grey squares) or syngenically transplanted mice (bd→bd, open 
circles) served as controls. A total of 6 experiments were performed, with 3 to 5 mice per 
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group and experiment. (B) Acute GVHD (TCD + T group, black circles) was induced in 
irradiated 8-week old BDF1 recipients (b→bd). Untransplanted BDF1 mice (grey squares) 
and recipients of TCD bone marrow only (TCD group, open circles) were used as controls 
without disease. (C) Acute GVHD (TCD + T group, black circles) was induced into 9-week 
old B6 recipients (d→b). Untransplanted age-matched B6 mice (grey squares) and B6 mice 
that received TCD bone marrow only (TCD group, open circles) were used as controls. (D) 
Acute GVHD (TCD + T group, black circles) was induced into 8-week old B6 recipients 
(b→b). Untransplanted age-matched B6 mice (grey squares) and B6 mice that received TCD 
bone marrow only (TCD group, open circles) were used as controls. A total of 3 experiments 
were performed. The line graphs show total cell numbers (mean ± SD) of mTEChigh (left) 
and mTEClow (right) cells as a function of recipient age post-transplantation. *p<0.05, 
analysis of variance (ANOVA), acute GVHD versus transplanted mice without acute 
GVHD. TCD, T-cell depleted; n.d., not done.  
 
 
 
4.1.4  Acute GVHD impairs thymic Aire expression  
Crucial for negative selection of self-reactive T cells is the exposure 
of thymocytes to self-antigens including those with highly restricted tissue 
expression. Within the thymus, the ectopic expression of many tissue-
restricted peripheral self-antigens (TRA) is a particular property of cells of 
the mTEChigh compartment.71,72,247,248 Expression of TRA is partly under the 
control of the transcription factor autoimmune regulator (Aire).72 Therefore, 
I next investigated whether acute GVHD affected qualitatively and 
quantitatively the postcycling medullary TEC subset (Aire+mTEChigh) that 
expresses Aire and is responsible for central tolerance induction. Confocal 
microscope analysis of thymic sections stained with cytokeratin 18 (CK18), 
CK14 and Aire confirmed Aire+ cells to localise in the thymus medulla 
(Figure 16A). Syngeneically transplanted mice (bd→bd) were not different 
from age-matched untransplanted control mice (data not shown73). 
However, in the presence of acute GVHD in unconditioned recipients 
(b→bd) thymic cortical and medullary organisation was lost and Aire+ cells 
became virtually undetectable with time. Hence, contraction of the total 
mTEChigh pool in b→bd recipients corresponded to a progressive decrease in 
the subset that expresses Aire.73,77 This observation was confirmed by FACS 
analysis of Aire+ cells among the mTEChigh population (Figure 16B, C). In 
12-week-old recipients, residual Aire+mTEChigh were low in numbers (<300 
cells/thymus compared to ∼5x103 cells/thymus in animals without acute 
GVHD) and were not detectable anymore during progressive disease, owing 
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to the smaller than normal frequencies of Aire-expressing cells among 
declining mTEChigh numbers. Taken together, these data demonstrated that 
mature medullary thymic epithelial cells were targets of acute GVHD and 
that the cells most affected belonged to the subset of Aire-expressing 
mTEChigh.  
 
 
Figure 16. Acute GVHD causes loss of Aire+mTEChigh cells. (A-C) Qualitative and 
quantitative analysis of thymic Aire expression. Immunohistochemistry and confocal 
microscope analysis (A) was performed on thymic frozen sections taken from unconditioned 
transplant recipients at ages 10, 12, and 15 weeks (i.e. 2, 4, and 7 weeks after 
transplantation; [i-iii] bd→bd, [iv-vi] b→bd). Cytokeratin-18 (CK18, blue) and CK14-positive 
cells (red) denote cTEC and mTEC, respectively.67,162 The flow cytometry plots in (B) depict 
Aire and MHC class II expression of DAPI-CD45-EpCam+Ly51-UEA-1+ mTEC. Numbers 
represent frequencies (%) of cells (mean ± SD). Total numbers of Aire+mTEChigh in thymi 
from individual recipient mice (C) was calculated from flow cytometry data (mean ± SD). 
(syngeneic HSCT, bd→bd, open circles; allogeneic HSCT, b→bd, black circles). A total of 5 
experiments were performed with 3 to 5 mice per group. *p<0.05, ANOVA, acute GVHD vs. 
transplanted mice without acute GVHD.   
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4.1.5  Acute GVHD impairs TRA expression  
Given the intimate associations between Aire-deficiency, TRA 
repression, and autoimmunity,248 I next determined whether acute GVHD 
interfered with TRA transcription. To this end, I isolated total remaining 
mTEChigh cells at HSCT recipient ages of 10, 12 and 15 weeks in the 
presence or absence of acute GVHD in unconditioned allo-HSCT recipients. 
Gene expression analysis of these cells was performed using DNA 
microarray technology. Development of thymic acute GVHD (b→bd) 
altered global gene expression profiles in total residual mTEChigh cell pools 
isolated at 2 to 4 weeks after transplantation (Figure 17A, Table 2). An 
increase or decrease in expression level greater than three-fold in relation to 
the control group (corresponding to relative expression values of <0.33 and 
>3.0, respectively) was considered as altered gene expression in consequence 
of acute GVHD. To discriminate between TRA and ubiquitously expressed 
transcripts (Ub) in mTEChigh, I used a special algorithm which had 
previously been described.64,70,72(Personal communication by Bruno Kyewski, 
Heidelberg, Germany) Here, transcripts with expression in <5 different 
tissues in combination with a lower threshold of 5-fold signal intensity of 
the average of all tissues were designated as tissue restricted. Recent next 
generation RNA sequencing data generated from thymic epithelial 
subpopulations (G. A. Holländer) were incorporated to adjust the 
annotated gene lists. Using this method, I classified 10017 transcripts as 
TRA among a total of 17336 transcripts analysed (Figure 17A). It should 
be noted that due to absence of tissue expression data, not all of the 21759 
transcripts present on the microarray chips could be categorised as TRA or 
Ub. Several hundred transcripts were expressed at reduced levels (>3-fold 
change; relative expression <0.33) in mice with acute GVHD. For 
transcripts whose expression was either enhanced or depressed as a 
consequence of acute GVHD, I expected that TRA and Ub sequestered 
according to the relative frequencies of TRA and Ub in normal adult mice. 
To test the accuracy of this hypothesis, O/E analysis was performed, an 
easy to interpret and widely used statistic for measuring performance 
(Figure 17B).246 In this ratio, O is the observed number of events, and E is 
the expected number of events. An O/E ratio = 1 represents an expected 
observation, which in my case would be a distribution among TRA and Ub 
according to the relative frequencies of TRA and Ub in normal adult mice. 
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Using hypergeometric statistical analysis I could demonstrate, however, 
that among the transcripts with lowered expression levels (relative 
expression <0.33) the O/E ratios were >1.0 for TRA and <1.0 for Ub 
(Figure 17B). These data indicated that TRA were significantly enriched 
among the downregulated transcripts at both time points (i.e. 2 and 4 
weeks post-transplantation). To quantify the observed changes between the 
two experimental groups, a correlation matrix was generated (Figure 17C).  
 
 
Figure 17. Acute GVHD alters gene expression. Global gene expression was analysed 
in entire residual mTEChigh cell pools isolated from individual recipients at 10, 12, and 15 
weeks of age (i.e. 2, 4, and 7 weeks after transplantation). The figure reflects data from 5 
independent experiments, with 2 to 4 mice per group and experiment. (A) Gene expression 
profiling of mTEChigh in transplant recipients using Mouse Gene 1.0 ST arrays (Affymetrix). 
The x- and y-axes represent relative expression of individual genes (given as log2 values of 
signal intensity ratios, S.I.) in mice with acute GVHD (b→bd) vs. syngeneically transplanted 
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recipients without disease (bd→bd). Data is plotted as a function of recipient age (10 vs. 12 
weeks). Genes whose expression levels are enhanced or decreased more than 3-fold relative to 
the control group (corresponding to relative expression values given by the S.I. ratios of 
<0.33 and >3.0, respectively, or <-1.6 and >+1.6 on the log2 scale) are considered to be 
significantly altered in consequence of acute GVHD (threshold is indicated by dashed lines). 
Q2 is the lower left quadrant, denoting genes whose expression levels are depressed at both 2 
and 4 weeks after allogeneic HSCT (10- and 12-week old recipients). Q1 denotes transcripts 
whose expression levels are depressed at 2 but not at 4 weeks after allogeneic HSCT and Q3 
denotes genes that are decreased only at 4 weeks. The inserted numbers denote the absolute 
numbers of genes in the respective quadrants. Transcripts from a total of 21759 genes are 
analysed. Ub (ubiquitously expressed genes, grey segment) and TRA (dark blue segment). 
(B) O/E performance analysis (O, observed number of events; E, expected number of 
events) of the presence of TRA vs. Ub among the genes with relative expression <0.33 and 
>3.0. O/E ratio >1.0 for TRA and <1.0 for Ub; *p<0.001 using hypergeometric statistical 
analysis. (C) Analysis of linear relationship of global gene expression between no GVHD 
(bd→bd) and GVHD (b→bd) experimental groups for TRA (upper panel) and ubiquitously 
expressed transcripts, Ub (lower panel). In a correlation matrix analysis, signal intensities 
(log2) of individual transcripts are plotted and the Pearson’s correlation coefficient r between 
two variables is individually calculated as a function of recipient age.  Numbers in each 
quadrant indicate Pearson’s r values between the two groups tested. The asterisk (*) symbol 
indicates a p<0.001 value for the quality of any measured Pearson’s r at the given time 
point for TRA or Ub. Right panel: Pearson’s correlation coefficient r is shown as a function 
of age and time after transplantation for Ub (grey squares) and TRA (blue squares). 
*p<0.001 of Pearson’s r. 
 
 
Here, the variation of each gene was calculated using the inter quartile 
range (IQR), a measure of statistical dispersion. Only 50% of the genes that 
had an IQR higher than the median of the IQR values of all genes were 
included for calculation of the Pearson’s correlation coefficient (Pearson’s 
r). A low strength of association of TRA expression between mice with 
acute GVHD (b→bd) and syngeneically transplanted mice without acute 
GVHD (bd→bd) was indicated by a Pearson’s r = 0.7004 and r = 0.6255 in 
10 and 12 week old recipients, respectively (Figure 17C). These low r values 
showed that many TRA differed in the presence of acute GVHD in their 
expression level from a physiological level. In contrast, a higher r value 
indicated that expression levels were closer to normal. This analysis was 
done for TRA and Ub according to their definition and demonstrated that r 
values for TRA were lower than for Ub at all time points and experimental 
conditions employed. Hence, the GVHD-induced alterations were not as 
pronounced for Ub as for TRA. I interpreted these data such that a 
contraction in TRA diversity during acute GVHD was caused by cellular 
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loss of mTEChigh, in particular Aire-positive mTEC. This explanation was 
based on the fact that ectopic TRA expression is a stochastic process in 
which only a limited number of mTEChigh express a given TRA.66,75,249 A 
comprehensive coverage of TRA expression is therefore only achieved by a 
sufficiently large mTEChigh pool, which is, however, missing under 
conditions of acute GVHD. Next, I was interested whether TRA with 
lowered expression levels in mTEChigh during acute GVHD in 10- and 12-
week-old recipients were Aire-dependent. I compared my gene expression 
profile with published data from gene expression in mTEC from Aire-/--
deficient mice.72 A fraction of the downregulated TRA belonged to the 
subset of Aire-dependent TRA (Figure 18A). Impaired Aire-dependent 
TRA included for example Scgb1a (secretoglobin), Csn1s2a (casein g), 
Mup1 (major urinary protein 1) and Spt1 (salivary protein 1). Expression 
profile data of selected genes obtained by microarray analysis was verified 
by quantitative PCR (qPCR) (Figure 18B). This analysis confirmed the 
acute GVHD-induced reduction in expression of the Aire-dependent TRA 
Spt1, Mup1 and Csn1s2a. Among TRA that remained unchanged in the 
presence of acute GVHD, around one third was specific for a chronic 
GVHD target tissue (Figure 18C, left pie chart). However, the most 
substantially reduced TRA were found to be enriched for genes that are 
characteristically expressed in tissues known to be targets of chronic GVHD 
(i.e. skin, liver, salivary gland, lung, eye and G.I. tract) (Figure 18C, right 
pie charts).147 These data led me to propose that a defect in the ectopic 
expression of a particular TRA during acute GVHD may result in the 
failure to negatively select TCR specific for this TRA and hence to the 
emergence of autoreactive T cells, a feature typical for GVHD. This 
hypothesis was tested in the work described in chapter 4.2. 
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Figure 18. Altered TRA are dependent on Aire and specific for chronic GVHD 
target tissues. (A) Aire dependency of TRA with lowered expression levels in mTEChigh 
during acute GVHD in 10- and/or 12-week old recipients (the axes are the same as in Figure 
17A). Examples shown are the following: Scgb1a1, secretoglobin; Csn1s2a, casein g; Mup1, 
major urinary protein 1; Spt1, salivary protein 1. Aire-dependent TRA (yellow circles), Aire-
independent TRA (dark blue circles), and Ub (grey circles). (B) Microarray data of selected 
genes is verified by quantitative PCR (qPCR). Expression in syngeneically transplanted 
recipients is set as 1 (thick, dashed line) and used as a control. Expression in allogeneically 
transplanted recipients is shown as x-fold change over controls as a function of recipient’s 
age. Foxn1, forkhead box N1; EpCam, epithelial cell adhesion molecule; Spt1, salivary 
protein 1; Mup1, major urinary protein 1; Csn1s2a, casein alpha s2-like A (casein g). n.d., 
not done. (C) Tissue representation of TRA reduced during acute GVHD (<0.1 and <0.33 
relative expression, respectively, vs. mice without acute GVHD at 10 and 12 weeks of age). 
As control, a random set of 200 TRA is used that remained unchanged in the course of acute 
GVHD (relative expression ∼1).  
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Table 2. 
(A) Genes downregulated during acute GVHD (relative expression <0.125) 
Gene Accession
# 
Name Rel. 
Expression 
b→bd vs. 
bd→bd 
 
TRA are 
shaded  
in grey   
 
 
10 wk 12 wk 
Scgb1a1 NM_011681 secretoglobin, family 1A, member 1, lung 0.037 0.030 
Rgs13 NM_153171 
regulator of G-protein signaling 13, tonsil, 
intestine 0.055 0.022 
Olfr461 NM_146382 olfactory receptor 461, sensory system 0.058 0.193 
Fabp2 NM_007980 fatty acid binding protein 2, intestine 0.058 0.041 
Fabp1 NM_017399 fatty acid binding protein 1, liver, intestine 0.060 0.081 
Spt1 NM_009267 salivary protein 1, salivary gland 0.062 0.041 
Defb3 NM_013756 defensin beta 3, intestine, lung, other 0.066 0.180 
Retnla NM_020509 
resistin like alpha, mammary, adipose tissue, 
other 0.067 0.107 
Gnat3 
NM_001081
143 
guanine nucleotide binding protein, gustatory 
system 0.076 0.032 
Tm4sf20 NM_025453 
transmembrane 4 L six family member 20, 
intestine 0.077 0.118 
1700026D08Ri
k NM_029335 RIKEN cDNA 1700026D08 gene, testis, other 0.078 0.192 
Saa1 NM_009117 serum amyloid A 1, intestine, liver, intestine 0.078 0.161 
Ttr NM_013697 transthyretin, liver, lung, placenta, eye 0.080 0.159 
Lgals2 NM_025622 
lectin, galactose-binding, soluble 2, intestine, 
stomach 0.080 0.111 
Reg3b NM_011036 
regenerating islet-derived 3 beta, pancreas, 
intestine 0.081 0.404 
Ctrb1 NM_025583 chymotrypsinogen B1, pancreas, other 0.084 0.252 
Mup2 NM_008647 major urinary protein 2, liver, lung 0.089 0.069 
Bmx NM_009759 BMX non-receptor tyrosine kinase 0.090 0.107 
Gpr50 NM_010340 G-protein-coupled receptor 50, placenta, other 0.090 0.480 
Lipn NM_027340 lipase, family member N, adipocytes, other 0.091 0.115 
Calb1 NM_009788 calbindin 1, brain, kidney, other 0.091 0.182 
Svs4 NM_009300 seminal vesicle secretory protein 4, prostate 0.091 0.234 
Dynlrb2 NM_029297 
dynein light chain roadblock-type 2, lung, 
testis, adipose 0.091 0.154 
Mup7 
NM_001134
675 major urinary protein 7, lung, mammary gland 0.094 0.062 
Pf4 NM_019932 platelet factor 4, platelets, other 0.094 0.172 
Mup11 
NM_001164
526 major urinary protein 11, genital tract, other 0.095 0.076 
Vnn3 NM_011979 vanin 3, liver 0.096 0.126 
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Abp1 NM_029638 amiloride binding protein 1, intestine 0.097 0.078 
Chi3l4 NM_145126 chitinase 3-like 4, intestine 0.100 0.172 
Tcfap2b NM_009334 
transcription factor AP-2 beta, skin, salivary, 
eye 0.100 0.088 
Hsd17b6 NM_013786 
hydroxysteroid (17-beta) dehydrogenase 6, 
liver, intest. 0.102 0.037 
Reg1 NM_009042 regenerating islet-derived 1, intestine 0.105 0.129 
Anxa13 NM_027211 annexin A13, intestine 0.105 0.134 
Apoa4 NM_007468 apolipoprotein A-IV, intestine 0.106 0.050 
2210415F13Rik 
NM_001083
884 RIKEN cDNA 2210415F13 gene, intestine 0.107 0.055 
Mup19 
NM_001135
127 major urinary protein 19, liver, lung 0.107 0.087 
Cst10 NM_021405 cystatin 10, eye 0.108 0.154 
Klk1b11 NM_010640 
kallikrein 1-related peptidase b11, salivary 
gland 0.109 0.080 
Serpina7 NM_177920 serine (or cysteine) peptidase inhibitor, liver 0.115 0.056 
Nts NM_024435 neurotensin, intestine 0.118 0.168 
Sis 
NM_001081
137 sucrase isomaltase, intestine 0.119 0.220 
Mup1 
NM_001163
011 major urinary protein 1, liver, lung 0.119 0.094 
Mctp1 NM_030174 multiple C2 domains, transmembrane 1, brain 0.121 0.069 
Ear11 NM_053113 
eosinophil-associated, ribonuclease A family, 
11 0.121 0.196 
Prap1 NM_009475 proline-rich acidic protein 1, intestine 0.123 0.256 
Gpr128 NM_172825 G protein-coupled receptor 128 0.124 0.082 
 
 
(B) Genes upregulated during acute GVHD (relative expression >4.0) 
Gene Accession
# 
Name Rel. 
Expression 
b→bd vs. 
bd→bd 
 
TRA are 
shaded  
in grey   10 wk 12 wk 
Gbp5 NM_153564 guanylate binding protein 5, IFN-regulated 9.36 3.62 
Myl9 NM_172118 myosin, light polypeptide 9, regulatory 8.54 10.36 
Gbp2 NM_010260 guanylate binding protein 2, IFN-regulated 8.10 3.35 
C1s NM_144938 complement component 1, IFN-regulated 7.76 2.49 
Casp12 NM_009808 caspase 12, inflammation, apoptosis 7.50 4.74 
Mpeg1 NM_010821 macrophage expressed gene 1 7.26 2.84 
Gm12250 
NM_001135
115 predicted gene 12250 6.88 4.33 
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Nfib 
NM_001113
209 nuclear factor I/B 6.73 9.56 
Gbp3 NM_018734 guanylate binding protein 3 6.60 4.05 
Gbp6 NM_145545 guanylate binding protein 6 6.52 2.07 
Apol10b NM_177820 apolipoprotein L 10b 6.42 1.18 
Lifr NM_013584 leukemia inhibitory factor receptor 5.87 4.20 
Art2b NM_019915 ADP-ribosyltransferase 2b 5.70 2.79 
Mpzl2 NM_007962 myelin protein zero-like 2 5.29 1.92 
Kitl NM_013598 kit ligand 5.26 3.95 
Snord16a NR_028548 small nucleolar RNA, C/D box 16A 5.25 1.46 
Cxcl12 
NM_001012
477 chemokine (C-X-C motif) ligand 12 5.23 2.69 
Sulf1 
NM_001198
565 sulfatase 1 5.20 4.94 
Rad51 NM_011234 RAD51 homolog 5.15 4.74 
Dcn NM_007833 decorin 5.09 4.84 
Pros1 NM_011173 protein S (alpha) 5.04 5.08 
Myadm 
NM_001093
765 myeloid-associated differentiation marker 4.92 1.70 
Clca5 NM_178697 chloride channel calcium activated 5 4.89 1.61 
Ptn NM_008973 pleiotrophin 4.87 1.86 
Prss16 NM_019429 protease, serine, 16 (thymus) 4.84 1.95 
Flna NM_010227 filamin, alpha 4.78 3.73 
Irgm1 NM_008326 immunity-related GTPase family M member 1 4.72 3.92 
Pgm5 NM_175013 phosphoglucomutase 5 4.56 4.15 
Hey1 NM_010423 
hairy/enhancer-of-split related with YRPW 
motif 1 4.56 3.18 
P4ha3 NM_177161 
procollagen-proline, 2-oxoglutarate 4-
dioxygenase 4.49 2.90 
Olfml1 NM_172907 olfactomedin-like 1 4.38 1.61 
Tnfsf10 NM_009425 
tumor necrosis factor (ligand) superfamily, 
member 10 4.37 0.36 
Hmmr NM_013552 hyaluronan mediated motility receptor 4.30 1.55 
Lrrc17 NM_028977 leucine rich repeat containing 17 4.26 1.36 
Fgfr2 NM_010207 fibroblast growth factor receptor 2 4.16 2.28 
Osmr NM_011019 oncostatin M receptor 4.15 5.12 
Ccnb1 NM_172301 cyclin B1 4.13 1.38 
Mtss1l NM_198625 metastasis suppressor 1-like 4.08 1.86 
Prc1 NM_145150 protein regulator of cytokinesis 1 4.03 1.43 
Scn1a NM_018733 sodium channel, voltage-gated, type I, alpha 4.02 4.05 
Acta2 NM_007392 actin, alpha 2, smooth muscle, aorta 4.02 1.76 
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Slfn5 NM_183201 schlafen 5 4.00 4.07 
Il15 NM_008357 interleukin 15 4.00 2.66 
 
 
 
4.2  Impaired thymic expression of tissue-restricted 
antigens licenses the de novo generation of 
autoreactive CD4+ T cells during murine acute 
GVHD 
4.2.1 A transgenic model to study generation of 
thymus-dependent autoreactive T cells during 
acute GVHD  
Because thymic negative selection is sensitive to small changes in 
TRA expression,73 a reduction in mTEC compartment size and hence TRA 
expression may lead to the emergence of thymus-dependent autoreactive T 
cells in the context of acute GVHD.180 The de novo generation of 
autoreactive T cells from donor HSC is a hallmark of murine acute 
GVHD.177,178 These autoreactive clones can mediate the transition from 
acute to chronic GVHD in different mouse models of alloHSCT.179-181,224 
There is now much experimental evidence that the thymic epithelium is a 
target of donor alloimmunity,162,223,224 and that thymic acute GVHD 
interferes with the capacity of Aire-expressing mTEChigh to sustain TRA 
diversity in the course of disease.225 However, a direct link between the 
weakened platform for central tolerance and the emergence of autoreactive 
T cells during acute GVHD, and ultimately the development of an 
autoimmune syndrome during chronic GVHD, has not yet been proven. I 
decided to study the de novo production of TRA-specific T cells in the 
thymus during acute GVHD by using a transgenic mouse allogeneic HSCT 
model (Figure 19). Here, membrane-bound ovalbumin (mOVA) is expressed 
in transgenic mice under the rat insulin promoter (RIP) as a model neo-self-
antigen not only in the pancreas but also in the thymus by both mature 
and immature mTEC. This model provided the tool to investigate tolerance 
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induction to a known antigen during acute GVHD, thus overcoming the 
lack of knowledge with regard to the specificities of the autoreactive effector 
T cells in chronic GVHD.146,184 I chose the OT-II→RIP-mOVA system 
because (1) thymic mOVA expression is restricted to mTEC, (2) TCR 
selection against mOVA recapitulates physiological tolerance induction to 
TRA in the thymus medulla,71,72,76,98,250,251 and (3) a reduction in mOVA 
mRNA in mTEC by as little as 30% suffices for the lack of deletion of OT-
II cells in RIP-mOVA mice.252  
 
 
Figure 19. A model to study generation of thymus-dependent autoreactive T 
cells during acute GVHD. Balb/c-Thy1.1+ TCD bone marrow replete with Balb/c 
splenic T cells was grafted into lethally irradiated RIP-mOVA recipients generating 
[Balb/c→RIP-mOVA] chimeric mice with thymic acute GVHD. Non-GVHD control mice 
received Balb/c-Thy1.1+ TCD bone marrow only. Four to five weeks after first allogeneic 
HSCT (=GVHD induction), recipients were lethally re-irradiated and transplanted in a 
second syngeneic HSCT with TCD bone marrow from CD45.1+ OT-II (H-2b) and wildtype 
B6 mice (H-2b). Four to five weeks after OT-II TCD bone marrow transfer, thymi, spleen 
and lymph nodes were isolated from RIP-mOVA recipients and OVA-reactive T cell clones 
analysed (congenically marked CD45.1+; Vα2+ Vβ5+). 
 
 
4.2.2  Thymic GVHD induction in RIP-mOVA 
recipients  
I first investigated whether impaired thymic function was a 
hallmark of acute GVHD in lethally irradiated RIP-mOVA recipients of 
fully MHC-mismatched HSCT (H-2d→H-2b). To this end, 8-week old 
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lethally irradiated RIP-mOVA mice (H-2b; 1000 cGy) were transplanted 
with 3x106 Balb/c (H-2d) splenic T cells and 10x106 Balb/c-Thy1a TCD 
bone marrow cells (Balb/c→RIP-mOVA; H-2d→H-2b; TCD+T group). 
Control mice without disease received TCD bone marrow alone (TCD 
group). Two weeks after transplantation, total thymic cellularity was 
severely diminished in both B6 and RIP-mOVA recipients from ≥6x107 to 
<5x106 cells in the presence of acute GVHD (Figure 20A, C). This reduced 
cellularity was reflected by aberrant thymopoiesis in mice suffering from 
acute GVHD. Frequencies of CD4+CD8+ DP thymocytes were decreased 
from ∼90% to ∼30% in both, non-transgenic and transgenic mice, whereas 
increased frequencies of SP populations were detected (Figure 20B, D, left 
panel). This defect was related to alloreactive donor T cells (H-2d+ Thy1.1-) 
infiltrating the thymus. Four weeks after allogeneic HSCT, RIP-mOVA 
recipients with or without acute GVHD showed >80% donor chimerism in 
thymi (Figure 20B, D, middle panel). Donor bone marrow derived cells 
were defined as H-2b- H-2d+ Thy1.1+. Due to the persistent presence of 
alloreactive donor T cells (splenic T cells; H-2b- H-2d+ Thy1.1-), donor bone 
marrow-derived T-cell development (H-2b- H-2d+ Thy1.1+; Figure 20B, D, 
right panel) remained impaired. In total, the experiments demonstrated 
that the induction of thymic acute GVHD in transgenic RIP-mOVA mice 
did not differ from a non-transgenic fully MHC-mismatched transplantation 
model. 
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Figure 20. Induction of thymic acute GVHD in RIP-mOVA mice. In a fully MHC-
mismatched transgenic and non-transgenic transplantation model, thymic acute GVHD was 
induced in 8-9 week old lethally irradiated RIP-mOVA and B6 mice (H-2b), respectively, by 
i.v. co-injection of Balb/c-Thy1.1+ TCD bone marrow and Balb/c splenic T cells. Control 
animals without disease received Balb/c-Thy1.1+ TCD bone marrow only. (A) Thymic 
cellularity in B6 recipients is analysed as a function of time post-HSCT (total cells per 
thymus) in mice without (TCD group, ) and with acute GVHD (TCD+T group, ). 
Donor T cell infiltration is given as percentages of H-2Kd+Thy1.1- T cells among total 
thymic cells (mean ± SD). (B) Donor bone marrow engraftment and the development of 
thymic acute GVHD was assessed by flow cytometric analysis. Left column: The flow 
cytometry dot plots depict surface expression of CD4 and CD8 on total thymocytes at 2 
weeks post-transplantation. Middle and right columns: The flow cytometry dot plots depict 
surface expression of H-2Kb and Thy1.1 on total thymocytes and CD4 and CD8 expression 
on donor bone marrow derived thymocytes at 4 weeks post-transplantation. Cell analysis 
was restricted to live thymocytes as defined by Dapi- staining. The numbers shown in each 
quadrant represent frequencies (% of the respective populations, mean ± SD). (C-D) 
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Transgenic RIP-mOVA mice were used as recipients of a fully MHC-disparate 
transplantation model. Acute GVHD was induced as in panel A and the same analysis was 
performed as in panels A and B. The figure represents combined data from three separate 
experiments with ≥3 mice analysed per group. *p<0.05, Mann-Whitney U-test.       
 
 
Next, I intended to corroborate that reduction in mTEC compartment size 
- proved to be a universal manifestation of thymic acute GVHD (Figures 14 
and 15 of this thesis, and Dertschnig et al.225) - was also a hallmark of acute 
GVHD when transgenic HSCT recipients were used. The transfer of 
allogeneic T cells into RIP-mOVA mice indeed reduced total mTEChigh 
numbers from ∼5000 (no GVHD) to <1000 (GVHD) cells/mouse after 2 
and from ∼2000 (no GVHD) to <200 (GVHD) cells/mouse after 4 weeks 
(Figure 21). Two weeks after allo-HSCT total mTEClow numbers were 
reduced by approximately 50% when compared to mice without acute 
GVHD. This reduction was more pronounced at four weeks after allo-
HSCT. Here, the presence of acute GVHD reduced total mTEClow numbers 
in RIP-mOVA mice from ∼5000 to <500 cells/mouse in a manner similar to 
non-transgenic recipients. In the haploidentical acute GVHD model (b→bd) 
described in chapter 4.1, the loss of mTEChigh cells was associated with a 
reduction among mTEChigh expressing Aire (Aire+mTEChigh). In the absence 
of Aire expression, clonal deletion of OVA-specific CD4 T cells (OT-II) in 
RIP-mOVA mice is compromised,76,252,253 hence I compared Aire expression 
in thymi isolated from RIP-mOVA mice with and without acute GVHD. In 
thymi of recipients of TCD bone marrow Aire+ cells were as expected 
localised exclusively in the thymic medulla (Figure 22). Transgenic RIP-
mOVA recipients did not differ from age-matched non-transgenic B6 
recipients (Figure 22; panel i). However, in the presence of acute GVHD 
(TCD+T), Aire-expressing mTEC were neither detectable in non-transgenic 
(B6) nor in transgenic (RIP-mOVA) recipients (Figure 22; panels ii and iv). 
Taken together, the data presented in this chapter confirmed that acute 
thymic GVHD could be elicited in RIP-mOVA recipients as expected. With 
respect to impaired thymopoiesis and the defect in the Aire+mTEChigh cell 
compartment these GVHD-induced changes were not different from non-
transgenic HSCT systems.  
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Figure 21. Acute GVHD causes mTEC defects in RIP-mOVA mice. mTEChigh and 
mTEClow were analysed by flow cytometry as described in Figure 11. (A) Flow cytometry 
analysis identifying mTEClow and mTEChigh in B6 (top panel) and RIP-mOVA (bottom 
panel) recipients in the presence and absence of acute GVHD 2 weeks post-transplantation. 
The numbers shown in each flow cytometry dot plot represent frequency (% mean ± SD) of 
the respective population among total mTEC. (B) Absolute cell numbers of mTEClow and 
mTEChigh were calculated at 2 weeks post-HSCT for B6 and RIP-mOVA recipients. (C-D) 
The same analysis as in panels A and B was performed 4 weeks post-transplantation. The 
figure represents combined data from 3 independent experiments with ≥3 mice per group 
analysed. *p<0.05, 2-way ANOVA, Sidak’s multiple comparison test.  
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Figure 22. Aire expression is lost in 
RIP-mOVA mice with acute GVHD. 
Immunohistochemistry and confocal 
microscope analysis was performed on thymic 
frozen section taken from B6 and RIP-mOVA 
transplant recipients 2 weeks after HSCT. i) 
TCD Balb/c→B6; no GVHD, ii) TCD + T 
Balb/c→B6; acute GVHD, iii) TCD 
Balb/c→RIP-mOVA; no GVHD, iv) TCD + 
T Balb/c→RIP-mOVA; acute GVHD. 
Cytokeratin-18 (CK18, blue) and CK14-
positive cells (red) define cTEC and mTEC, 
respectively. Aire+ cells are shown in yellow 
and localise to the thymus medulla.  
 	
  
4.2.3 Acute GVHD reduces the thymic ectopic 
expression of the neo-self-antigen ovalbumin  
Given the importance of OVA expression in mTEC for the efficacy 
of thymic negative selection of OVA-specific TCR,71,72,98,250,252 I next 
determined whether acute GVHD interfered with global thymic OVA gene 
expression in mTEClow and mTEChigh. As expected, there was no OVA 
expression detected in non-transgenic B6 mice, neither in mTEClow, nor in 
mTEChigh. In allogeneically transplanted RIP-mOVA mice without disease 
(TCD) OVA expression was detected to the same extent in mTEClow and 
mTEChigh (Figure 23A). These data argued for an Aire-independent 
regulation of OVA, since Aire expression was as expected only present in 
mTEChigh (Figure 23B). In allogeneically transplanted RIP-mOVA mice 
with acute GVHD (TCD+T) the quantitative PCR data indicated that 
OVA mRNA levels were reduced in both mTEClow and mTEChigh compared 
to the TCD group (Figure 23A). Aire expression was reduced at 2, but not 
at 4, weeks post-transplantation in mice with acute GVHD. Taken together, 
the data presented in this and the previous chapter demonstrated that 
reduced OVA expression was due to loss of OVA-expressing mTEC during 
acute GVHD.  
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Figure 23. OVA mRNA is decreased in acute GVHD. Expression of OVA and Aire 
mRNA was determined by quantitative PCR in sorted mTEClow and mTEChigh in B6 and 
RIP-mOVA recipients with (black bars) and without (white bars) acute GVHD. (A) OVA 
expression in RIP-mOVA recipients without acute GVHD is set as 1 and used as a control. 
Expression in RIP-mOVA recipients with acute GVHD and in B6 recipients is depicted as 
fold change over control. (B) Aire expression is shown as relative expression normalised to 
GAPDH. Analysis was done at 2 and 4 weeks post-transplantation.  
 
 
4.2.4 OVA-specific T cell clones escape negative 
selection during acute GVHD  
Since efficient central tolerance induction requires adequate 
intrathymic OVA expression levels, the above results suggested that acute 
GVHD may affect negative selection of OVA-specific T cells. To directly 
test this hypothesis, RIP-mOVA recipients with acute GVHD were lethally 
re-irradiated 4-5 weeks after allogeneic HSCT (Balb/c→RIP-mOVA; H-
2d→H-2b) and transplanted in a second syngeneic HSCT with TCD bone 
marrow mixture from CD45.1+ OT-II (H-2b) and CD45.2+ B6 mice (H-2b) 
(Figure 19). As controls, RIP-mOVA recipients without acute GVHD and 
non-transgenic B6 mice were used. In these OT-II→[Balb/c→RIP-mOVA] 
mice (H-2b→[H-2d→H-2b]) the hematopoietic system was fully replaced with 
cells stemming from OT-II and wt B6 donor HSC. Except in lymph nodes 
of RIP-mOVA mice with acute GVHD, donor chimerism in all cell lineages 
was >80% in thymus, spleen and lymph nodes of all experimental groups 
(Figure 24). 
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Figure 24. Haematopoietic system is 
replaced by donor bone marrow. 
Donor chimerism was analysed after 
second syngeneic HSCT (OT-II + 
B6→[Balb/c→RIP-mOVA]) as 
percentages of H-2Kb+ H-2Kd- Thy1.1- cells 
among total cells in thymus, lymph node 
and spleen. n.d., not done. N ≥ 2  
 
 
 
As expected, OVA-specific T cells expressing the TCR Vα2 Vβ5 chains and 
the congenic marker CD45.1 were not deleted in thymi of B6 mice without 
OVA expression. In these mice, CD45.1+ CD4 T cells were detected at 
significantly higher frequencies than in RIP-mOVA mice without disease 
(Figure 25; 14 vs. 2%, 8 vs. 1%, and 8 vs. 3% in thymus, lymph nodes and 
spleen, respectively). In the latter group, adequate clonal deletion of OVA-
reactive T cells resulted from normal levels of thymic OVA expression. In 
the absence of thymic OVA expression (OT-II→[Balb/c→B6]), CD45.1+ 
CD4 OVA-specific T cells were not deleted in the thymus (10%) however 
and emerged in the periphery where they were detected in lymph nodes and 
spleen (Figure 25; 7 and 14%, respectively). Hence, the acute GVHD-
dependent loss of OVA expression in OT-II→[Balb/c→RIP-mOVA] mice 
was sufficient to prevent effective negative selection of OT-II TCR and 
allowed the de novo generation of TCR Vα2+ Vβ5+ CD4 SP thymocytes 
(CD45.1+). 
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Figure 25. OVA-specific T cells are not negatively selected during acute GVHD. 
(A) Flow cytometric analysis of thymocytes of B6, RIP-mOVA without acute GVHD and 
RIP-mOVA with acute GVHD transplanted with OT-II TCD bone marrow. Flow cytometry 
plots depict surface expression of CD4, CD45.1, Vα2 and Vβ5. The numbers shown in each 
quadrant represent frequency (mean ± SD) of CD4+ CD45.1+ T cells among total CD4+ SP 
thymocytes (left column). The numbers in the flow cytometry plots on the right represent 
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frequencies (mean ± SD) of Vα2Vβ5 double positive thymocytes among CD45.1- CD4+ and 
CD45.1+ CD4+ thymocytes, respectively. Cell analysis is restricted to live thymocytes as 
defined by Dapi- staining. The frequencies of CD4+ CD45.1+ thymocytes in all three groups 
are summarised in a dot plot (right). The same analysis was performed in (B) lymph nodes 
and (C) spleen. The figure represents combined data of two independent experiments with 
≥3 mice analysed per group. *p<0.05, ANOVA.  
 
 
4.2.5 De novo generated OT-II T cells display a non-
tolerant effector phenotype  
To test whether OVA-specific T cells that were not negatively 
selected were functional and non-tolerant, expression of folate receptor 4 
(FR4) and CD73 was measured on peripheral T cells. I chose to study these 
cell surface proteins since their expression is known to be low on non-
anergic CD4+ T cells.254 Non-OVA-specific CD4+ T cells expressed FR4 and 
CD73 at low levels, indicating a non-anergic phenotype in RIP-mOVA mice 
either with or without acute GVHD.  Because expression of FR4 and CD73 
was previously reported on CD4+ regulatory T cells (Treg),255,256 I also 
included Foxp3 as a marker for Treg in the analysis. The ratio Teff:Treg was 
increased from ∼2.5 to ∼17 in RIP-mOVA mice suffering from acute GVHD 
and then re-transplanted with TCD OT-II bone marrow when compared to 
RIP-mOVA mice without disease (Figure 26A). Thus, the frequency of Treg 
was diminished among the whole CD4+ T cell pool in the spleen in the 
presence of disease (Figure 26A). OT-II T cells detected in the periphery of 
RIP-mOVA mice suffering from acute GVHD did not convert into Treg and 
displayed a FR4- CD73- non-tolerant effector phenotype (Figure 26B). 
These data strongly suggested - but did not finally prove - that 
responsiveness to self-antigen may have been sustained. The OT-II T cells 
had increased CD44 expression (Ag-experienced phenotype) and are larger 
in size, suggesting that they were capable of responding to self-
peptide/MHC complexes (Figure 27).254 These data suggested that OVA-
specific T cells that were not negatively selected were non-anergic.   
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Figure 26. OT-II T cells are non-anergic and represent non-Treg cells. (A) 
Intracellular Foxp3 expression was analysed in total splenocytes in recipients without (left) 
and with (right) acute GVHD 4 weeks after the second syngeneic HSCT (OT-
II→[Balb/c→RIP-mOVA]). Flow cytometry plots depict surface expression of CD4 versus 
intracellular expression of Foxp3. The numbers shown are frequencies of CD4+ Foxp3- and 
CD4+ Foxp3+ cells, respectively. Bar graph shows ratio of Foxp3- versus Foxp3+ CD4 T cells 
in RIP-mOVA mice in the presence (black) and absence (white) of acute GVHD. *p<0.05, 
Mann-Whitney U-Test. Surface expression of folate receptor 4 (FR4) and CD73 was 
analysed in (B) OVA-specific and non specific splenic CD4+ Foxp3- T cells, and (C) in OVA-
specific and non specific splenic CD4+ Foxp3+ Treg cells. The numbers shown represent 
frequencies of respective population (mean ± SD). The figure represents data from one 
experiment with ≥2 mice analysed per group. 
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Figure 27. OT-II cells show activated 
phenotype. OVA-specific (bottom) and non-
specific (top) CD4+ splenic T cells were analysed 
for their CD44 expression. Splenocytes were 
isolated four 4 weeks after second syngeneic 
HSCT (OT-II→[Balb/c→RIP-mOVA]) from RIP-
mOVA recipients with (right) and without (left) 
acute GVHD. The flow cytometry plots depict 
surface CD44 expression versus forward scatter 
profile. Numbers in the plots indicate frequencies 
(mean ± SD) of CD44low and CD44high 
populations among the indicated T cell 
population. The figure represents data from one 
experiment with ≥2 mice analysed per group.  
 
 
In summary, the data shown in part two of the results provided a 
mechanism for how autoimmunity may develop in the context of acute 
GVHD. In the presence of disease, a reduction in mTEC pool size causes 
loss of an individual TRA that results in a failure to establish central 
tolerance to this TRA. In consequence TRA-reactive T cells can be 
exported to the periphery of allo-HSCT recipients.  
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4.3  Epithelial cytoprotection with fibroblast 
growth factor-7 (Fgf7) sustains ectopic 
expression of tissue-restricted antigens in the 
thymus during murine acute GVHD 
4.3.1 Fgf7 sustains the thymic mTEChigh compartment 
including Aire expression  
Given my observations above, approaches for mTEC cytoprotection 
may increase thymus-dependent T-cell production and may also prevent the 
emergence of thymus-dependent autoreactive T cells180 and thus alter 
autoimmune outcome. Since previous studies by Rossi et al. 216,239 described 
that administration of the epithelial growth factor Fgf7 acts directly on 
TEC and results in increased thympoiesis, I chose to study the role of Fgf7 
on mTEChigh in the course of acute GVHD. Because efficient central 
tolerance requires the full scope of TRA, which is only ensured by a 
sufficient large enough mTEChigh cell pool, I asked whether the mTEChigh 
compartment size and heterogeneity were sustained by using Fgf7 as a 
strategy for epithelial cytoprotection. First, Fgf7’s effect on thymus size and 
structure and T cell development was assessed to confirm the previous 
findings.216 Fgf7 was administered in a peritransplant manner (i.p. 5 
mg/kg/day from day -3 to 3 after allogeneic HSCT) in recipients of 
allogeneic HSCT (b→bd +Fgf7) as described.216,239 Confirming previous 
data, thymus size was increased in Fgf7 treated mice with acute GVHD 
compared to untreated animals (Figure 28A).216 Furthermore, structural 
organisation and thymic T-cell development was normal in those mice, 
despite the continued presence of acute GVHD in other target organs. The 
protective effect of Fgf7 was independent of the presence of donor T cells, 
as suggested previously,216 since the absolute numbers of thymus-infiltrating 
donor T cells were comparable to untreated recipient with acute GVHD 
(Figure 28B).  
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Figure 28. Fgf7 boosts thymopoiesis and restores thymic architecture. Acute 
GVHD was induced by the transfer of B6.CD45.1 splenic T cells to unirradiated BDF1 
recipients (b→bd; ). Syngeneically transplanted BDF1 mice serve as controls without 
disease (bd→bd; ). Fgf7 was i.p. injected into one group of BDF1 recipients that underwent 
allogeneic transplantation (b→bd +Fgf7; r). (A) Photographic pictures of thymi without 
acute GVHD (i; bd→bd), with acute GVHD (ii; b→bd) and with acute GVHD but after Fgf7 
treatment (iii; b→bd +Fgf7) (top row). Histopathology of thymic section was analysed by 
H&E staining at 2 weeks after transplantation (iv; bd→bd, v; b→bd, vi; b→bd +Fgf7). M, 
medulla; C, cortex. (B) The flow cytometry dot plots depict surface expression of CD4 and 
CD8 on host thymocytes. Cell analysis is restricted to live thymocytes as defined by 
forward/side scatter and exclusion of cells staining positive for propidium iodide. The 
numbers shown in each quadrant represent frequencies (% of the respective populations, 
mean ± SD). The figure represents combined data from four separate experiments; with an 
aggregate of 11 mice analysed for each group. Infiltration of donor-derived CD45.1+ T cells 
into host thymi is given as frequency (% among total thymic cells) and absolute cell 
numbers (x 10-6, mean ± SD). *p<0.05, Mann-Whitney U-test.  
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The TEC compartment was analysed in 8, 10, 12 and 15 week old 
recipients (4 days, 2, 4 and 7 weeks post-transplantation). Fgf7 failed to 
prevent initial mTEChigh cell loss in b→bd recipients (Figure 29). However, 
Fgf7 maintained stable numbers of mTEChigh (≥4x103 cells/mouse) which 
were significantly higher compared to b→bd recipients not treated with 
Fgf7 (≤103 cells/mouse) for the whole observation time (Figure 29). 
 
 
Figure 29. Fgf7 sustains mTEC compartment size. The mTEC compartment was 
analysed after Fgf7 administration (i.p. 5 mg/kg/day; day -3 to day +3 after allogeneic 
HSCT). (A) mTEChigh and mTEClow were analysed by flow cytometry as a function of age 
using the strategy described in Figure 11. Bottom row depicts flow cytometry plot of 
allogeneically transplanted BDF1 recipients that underwent Fgf7 treatment (b→bd +Fgf7). 
The numbers shown in each flow cytometry dot plot represent frequency (% mean ± SD) of 
the respective population among total mTEC. The figure represents combined data of 
individual mice from 6 separate experiments. bd→bd; syngeneic controls, no acute GVHD. 
b→bd; allogeneic HSCT, acute GVHD. (B) Absolute numbers of mTEChigh (left) and 
mTEClow are analysed as a function of recipient age in three groups of a haploidentical 
transplantation model. Acute GVHD was induced in 8-week old unconditioned BDF1 
recipients (b→bd, black circles). Cell numbers in allogeneic recipients that were injected with 
Fgf7 are depicted as white triangles. Untransplanted BDF1 mice (grey squares) or 
syngenically transplanted mice (bd→bd, open circles) serve as controls. A total of 6 
experiments were performed, with 3 to 5 mice per group and experiment. *p<0.05, analysis 
of variance (ANOVA). 
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Cell numbers were comparable to syngeneically transplanted control 
animals and to untransplanted, age-matched naïve mice. Furthermore, 
normal cell numbers of mTEClow were present in mice with acute GVHD 
but treated with Fgf7 (≥104 cells/mouse and ≤103 cells mouse with and 
without treatment, respectively). Upon Fgf7 treatment the mTEChigh subset 
expressing Aire was preserved at ∼3000 cells/mouse during acute GVHD, 
which contrasted the depletion of these cells to numbers as low as 300 
cells/mouse in untreated animals with acute GVHD (Figure 30).  
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Figure 30. Fgf7 rescues Aire expressing mTEC. Aire expression was qualitatively and 
quantitatively analysed in recipients’ thymi. (A) OCT embedded thymi from unconditioned 
transplant recipients at ages 10, 12, and 15 weeks (i.e. 2, 4, and 7 weeks after 
transplantation) were cut in sections and analysed by confocal microscope. Sections were 
stained for Cytokeratin-18 (CK18, blue; cortex), CK14 (red; medulla) and Aire (yellow). 
Analyses of allogeneically transplanted mice with Fgf7 treatment are shown in the bottom 
row. [i-iii] bd→bd, [iv-vi] b→bd, [vii-ix] b→bd +Fgf7. (B) The flow cytometry plots display 
intracellular Aire and surface MHC class II expression of DAPI-CD45-EpCam+Ly51-UEA-1+ 
mTEC. Numbers represent frequencies (%) of cells (mean ± SD). Bottom row shows data of 
b→bd +Fgf7 recipients. (C) Based on flow cytometry data absolute numbers of 
Aire+mTEChigh were calculated per individual recipient mouse (mean ± SD). Syngeneic 
HSCT, bd→bd, open circles; allogeneic HSCT, b→bd, black circles; allogeneic HSCT +Fgf7 
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treatment, b→bd +Fgf7, open triangles. A total of 5 experiments were performed with 3 to 5 
mice per group. *p<0.05, ANOVA.  
 
 
To investigate if increased cell numbers upon Fgf7 treatment were due to 
enhanced proliferation within the mTEC compartment, I analysed BrdU 
incorporation. I first analysed BrdU incorporation and cell cycle during a 
short time window 2 weeks after transplantation. To this end, recipient 
mice were intraperitoneally (i.p.) injected with BrdU and analysed 16 hours 
afterwards. 11% of mTEChigh cells were proliferating (in S phase) in 
syngeneically transplanted mice, whereas frequency for mTEClow cells was 
slightly lower (9%) (Figure 31A, left panel). This observation was 
consistent with published data from normal mice.57 Treatment with the 
mitogenic agent Fgf7 did not result in increased proliferation rates of 
mTEChigh. In mice suffering from acute GVHD without Fgf7 treatment, 
26% of mTEChigh were in S phase, whereas prior Fgf7 administration 
resulted in only 16% proliferating mTEChigh (Figure 31A, middle and right 
panel). The same observation was made for mTEClow cells. The frequency of 
proliferating mTEClow in untreated mice with acute GVHD was twice as 
high as in GVHD-positive animals that underwent Fgf7 treatment (Figure 
31A, middle and right panel; 11 vs. 5%). This snapshot analysis revealed 
that 2 weeks after transplantation, the mitogenic effect of earlier Fgf7 
treatment was not existent. To analyse kinetics of cell proliferation and to 
test whether higher turnover within the mTEC compartment was present 
earlier, a pulse chase experiment was performed. Here, mice were fed from 
day -3 to 3 after HSCT with drinking water supplemented with BrdU (0.8 
mg/ml). The time period of BrdU feeding corresponded to the time frame of 
Fgf7 therapy. BrdU incorporation into mTEC was analysed at 8.5, 10 and 
12 weeks of age (4 days, 2, 4 weeks post-transplantation, respectively). 
Consistent with reports that mTEC are continuously replaced in 
adulthood,57,66 ∼5% of mTEC underwent cell division within 1 week in the 
b→bd and bd→bd transplant groups (Figure 31B). This frequency increased 
to ∼15% in mice with acute GVHD but that were treated with Fgf7. Label 
retention analyses indicated high turnover of mTEC in response to Fgf7 in 
b→bd recipients as BrdU concentration declined to <10% in 12 week old 
recipients. This analysis of proliferation history showed that rescue of 
mTEChigh numbers was therefore the consequence of enhanced proliferation 
within the entire mTEC compartment.  
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Figure 31. Fgf7 enhances proliferation of the mTEC compartment. Analysis of 
BrdU incorporation. (A) Cell cycle analysis of mTEClow and mTEChigh 2 weeks after GVHD 
induction. BrdU was i.p. injected 16 hours prior to analysis in syngeneically recipients and 
untreated or Fgf7-treated allogeneically recipients. Flow cytometry plots depict intracellular 
expression of BrdU and 7-AAD (7-Aminoactinomycin D), which marks the DNA. The 
numbers represent frequencies of cells in G0/G1 (BrdU- 7-AAD-), S (BrdU+ 7-AAD-/+) and 
G2/M phase (BrdU- 7-AAD+). (B) Analysis of mTEC proliferation in response to Fgf7. 
Eight-week-old BDF1 mice were left untreated or were treated with Fgf7 from days -3 to +3 
after allogeneic HSCT. All mice simultaneously received 0.8 mg/ml BrdU in their drinking 
water. mTEC were analysed for BrdU incorporation at the indicated ages after 
transplantation. Left: flow cytometry histogram. Right: BrdU+ cells (%) ±SD, *p<0.001, 
ANOVA, acute GVHD vs. mice without acute GVHD. 
 
 
4.3.2 Fgf7 administration sustains a more diverse TRA 
transcriptome in mTEChigh during acute GVHD  
Because treatment of mice suffering from acute GVHD with Fgf7 
restored the mTEChigh compartment including Aire-expression, I next asked 
whether Fgf7 also sustained the heterogeneity of TRA expression by 
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mTEChigh (Table 3). To quantify changes of global gene expression patterns 
in response to Fgf7, a correlation matrix analysis was performed (see 
section 4.1.5). During early acute GVHD, the TRA spectrum was not 
preserved by Fgf7 indicated by a Pearson’s r = 0.635 versus bd→bd mice. 
However, a broader array of TRA was expressed by 4 and 7 weeks after 
allogeneic HSCT as indicated by an expression profile that was closer to 
that of age-matched bd→bd controls (Pearson’s r = 0.722 and 0.807, 
respectively) (Figure 32A, C). Hence, peritransplant administration of Fgf7 
sustained a more diverse TRA transcriptome during acute GVHD. 
Furthermore, the Ub expression spectrum was maintained by Fgf7 shown 
by higher Pearson’s r values than without treatment (Pearson’s r = 0.8242 
for bd→bd versus b→bd +Fgf7; Pearson’s r = 0.7526 for bd→bd versus 
b→bd +Fgf7) (Figure 32B, C). Expression levels of a selection of genes that 
were altered by acute GVHD were plotted as a heatmap to illustrate the 
effect of Fgf7 (Figure 33). Individual TRA expression patterns were 
differentially affected by acute GVHD and Fgf7 as some but not all Aire-
dependent TRA returned to nearly normal expression in the observation 
period. An increase in gene expression of three Aire-dependent TRA (Spt1, 
Mup1 and Csn1s2a) was detected in b→bd +Fgf7 mice by qPCR (Figure 
34). Epithelial cell adhesion molecule (EpCam), which is specifically 
expressed in epithelial tissues257, and forkhead box N1 (Foxn1), whose 
expression characterises the thymic epithelial lineage,258 served as controls. 
EpCam and Foxn1 expression was neither downregulated by acute GVHD, 
nor increased due to Fgf7 treatment.   
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Table 3. 
(A) Genes upregulated in response to Fgf7 during acute GVHD (>5-fold) 
Gene Accession# Name Fold change 
b→bd +Fgf7, 15 wk  
vs. b→bd, 12 wk 
(rel. expression) 
TRA are 
shaded  
in grey   
rel. 
expr. 
b→bd vs. 
bd→bd 
10wk   12 wk 
Gsta1 NM_008181 glutathione S-transferase, alpha 1 24.07 0.302 0.028 
Mzt1 NM_175245 testis-specific serine kinase 3 17.39 0.972 0.421 
Tac1 NM_009311 tachykinin 1 16.24 0.509 0.045 
Gsta2 NM_008182 glutathione S-transferase, alpha 2 16.06 0.301 0.041 
Gmnn AF068780 serine (or cysteine) peptidase inhibitor 14.63 1.459 0.252 
Gm10639 
NM_001122
660 predicted gene 10639 13.84 0.291 0.047 
Cyb5d1 
NM_001045
525 cytochrome b5 domain containing 1 13.04 0.897 0.404 
4930420K17R
ik BC147127 ribosomal protein L34 12.76 1.024 0.052 
Spink5 
NM_001081
180 SRY-box containing gene 8 11.60 0.893 0.018 
Apool NM_026565 apolipoprotein L 7e 11.59 0.991 0.118 
Fam175b NM_198017 gap junction protein, delta 3 11.26 1.114 0.106 
Taf1d AK161656 
TATA box binding protein (Tbp)-
assoc. factor 10.96 0.455 0.322 
Ddah1 NM_026993 
dimethylarginine 
dimethylaminohydrolase 1 10.53 0.765 0.341 
LOC672291 BC128281 
similar to Ig kappa chain V-V region 
MOPC  9.85 0.507 0.915 
Ccdc58 NM_198645 transmembrane protein 167B 9.69 1.055 0.139 
Calml4 NM_138304 calmodulin-like 4 9.65 0.198 0.052 
Defb5 NM_030734 defensin beta 5 9.51 0.145 0.749 
1110032A03R
ik NM_023483 RIKEN cDNA 1110032A03 gene 8.94 0.411 0.123 
D230041D01
Rik AK141161 RIKEN cDNA D230041D01 gene 8.94 0.563 0.404 
Ccnc NM_016746 
zinc finger, DHHC domain containing 
11 8.40 1.033 0.120 
Mir677 NR_030442 predicted gene 9890 8.39 0.888 0.479 
Igf1 NM_010512 insulin-like growth factor 1 8.26 0.311 0.070 
Tslp NM_021367 thymic stromal lymphopoietin 8.25 0.297 0.151 
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Rock2 
ENSMUST116
446 scavenger receptor class A, member 3 7.64 1.391 0.403 
Gca NM_145523 grancalcin 7.64 0.596 0.120 
Spink3 NM_009258 serine peptidase inhibitor 7.32 0.152 0.040 
Ear1 NM_007894 
eosinophil-associated, ribonuclease A 
family,1 7.07 0.300 0.031 
Apoa4 NM_007468 apolipoprotein A-IV 6.99 0.106 0.050 
Fam19a1 NM_182808 
family with sequence similarity 19, 
member A1 6.93 0.403 0.153 
Hnf4g NM_013920 hepatocyte nuclear factor 4, gamma 6.89 0.333 0.067 
Retnla NM_020509 resistin like alpha 6.76 0.067 0.107 
Ucma 
NM_001113
558 
upper zone of growth plate and 
cartilage matrix  6.75 0.384 0.094 
Fabp7 NM_021272 fatty acid binding protein 7 6.64 0.399 0.044 
5730455O13R
ik 
NM_001081
075 RIKEN cDNA 2700078E11 gene 6.52 1.082 0.207 
A630095E13
Rik 
NM_001033
325 RIKEN cDNA A630095E13 gene 6.25 0.314 0.175 
Il1rl2 NM_133193 interleukin 1 receptor-like 2 6.20 0.472 0.093 
Scgb1a1 NM_011681 secretoglobin, family 1A, member 1 6.19 0.037 0.030 
Fabp2 NM_007980 fatty acid binding protein 2 6.03 0.058 0.041 
Ifi205 NM_172648 interferon activated gene 205 6.01 2.099 0.380 
Fam126b NM_172513 family with sequence similarity 126 5.91 0.759 0.154 
Rnf113a2 NM_025525 integrin alpha M 5.86 0.843 0.158 
Polr2j NM_011293 
mediator of RNA polymerase II 
transcription,18 5.63 1.361 0.093 
Clec12b NM_027709 
C-type lectin domain family 12, 
member B 5.53 2.078 0.796 
Olfr98 NM_146510 dual adaptor for phosphotyrosine 5.52 1.396 0.463 
Thap6 NR_028429 THAP domain containing 6 5.27 0.600 0.372 
Mir680-2 NR_030448 
SH3 domain binding glutamic acid-rich 
p-like 3 5.23 0.713 0.237 
Igj NM_152839 cryptochrome 2 5.22 1.196 0.760 
Fabp9 NM_011598 fatty acid binding protein 9 5.14 0.268 0.085 
Uevld 
NM_001040
695 Ngg1 interacting factor 3-like 1 5.13 1.449 1.090 
C130021I20R
ik AK147796 RIKEN cDNA 4930430A15 gene 5.13 0.970 1.123 
Styx NM_019637 
smu-1 suppressor of mec-8 and unc-52 
homol. 5.05 1.099 0.319 
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Figure 32. Peritransplant administration of Fgf7 sustains a more diverse TRA 
transcriptome in mTEChigh during acute GVHD. The linear relationship of global 
gene expression between two experimental groups is tested independently for (A) TRA and 
(B) ubiquitously expressed transcripts, Ub. In a correlation matrix analysis, signal intensities 
(log2) of individual transcripts are plotted and the Pearson’s correlation coefficient r between 
two variables is individually calculated as a function of recipient age. Numbers in each 
quadrant (Fgf7 treatment is shaded in grey) indicate Pearson’s r values between the two 
variables tested. The asterisk (*) symbol indicates a p<0.001 value for the quality of any 
measured Pearson’s r at the given time point for TRA or Ub. (C) Pearson’s correlation 
coefficient r is shown as a function of age and time after transplantation for Ub (grey 
squares) and TRA (blue squares). *p<0.001 of Pearson’s r.  
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Figure 34. Quantitative PCR confirms microarray data. Microarray data of selected 
genes is verified by quantitative PCR (qPCR). Expression in syngeneically transplanted 
recipients was set as 1 (thick, dashed line) and used as a control. Expression in allogeneically 
transplanted recipients that were left untreated or treated with Fgf7 is shown as x-fold 
 
Figure 33. Individual TRA expression patterns are differentially affected by 
acute GVHD and Fgf7. Expression levels of individual genes expressed in mTEChigh are 
given in a heatmap as colour coded log2 value of signal intensities. (A) The map is sorted 
according to relative expression of genes in mTEChigh (b→bd vs. bd→bd mice; 12 week old) 
and contains all TRA with a relative expression of <0.08 (which equals a 12.5-fold decrease 
in signal intensities of all genes) during acute GVHD in age-matched mice. (B) Left panel: 
The map is sorted according to relative expression of genes in mTEChigh (b→bd vs. bd→bd 
mice; 12 week old) and contains all TRA with a relative expression of <0.3 (∼3-fold 
decrease) during acute GVHD in age-matched mice. Enhancement of TRA expression in 
response to Fgf7 was detectable by higher signal intensities of individual genes. Right panel: 
Aire-dependent TRA were sorted as before.   
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change over controls as a function of recipient’s age. Foxn1, forkhead box N1; EpCam, 
epithelial cell adhesion molecule; Spt1, salivary protein 1; Mup1, major urinary protein 1; 
Csn1s2a, casein alpha s2-like A (casein g). n.d., not done.  
 
 
 
I hypothesised that Fgf7 restored TRA expression independently of their 
signal intensity and that treatment did not preferentially affect Aire-
dependent TRA. To test this assumption, multidensity histogram analysis 
was performed (Figure 35). In this analysis signal intensities of individual 
transcripts of Ub, Aire-independent and Aire-dependent TRA were plotted 
against transcript frequencies. Only transcripts whose expression levels were 
decreased during acute GVHD by greater than 3-fold at 2 and 4 weeks after 
allogeneic HSCT (corresponding to genes in lower left quadrant Q2 of 
Figure 17A), were included in the analysis. The data demonstrated that 
signal intensity distribution was similar for all three gene pools in 
syngeneically transplanted mice (bd→bd; Figure 35, top panels). Since 
signal intensities did not differ between Ub, Aire-independent and Aire-
dependent TRA, the finding of an enrichment of TRA among 
downregulated genes during acute GVHD was independent of signal 
intensities, but rather caused by a loss of mTEChigh (Figure 35, middle 
panels). Fgf7 treatment of b→bd mice partially restored both Aire-
dependent and Aire-independent TRA (b→bd +Fgf7; Figure 35 lower 
panels). Thus, no preference for restoration of Aire-dependent TRA by Fgf7 
was observed. I interpreted this data as such that Fgf7 restored the whole 
mTEChigh compartment, and not only Aire+mTEChigh. This resulted in Fgf7 
being efficient to restore both, Aire-independent and Aire-dependent TRA.  
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Figure 35. Fgf7 administration alters thymic expression of TRA independently 
of their signal intensity. Multidensity histogram analyses of TRA and Ub whose 
expression levels are decreased during acute GVHD by greater than 3-fold at 2 and 4 weeks 
after allogeneic HSCT (10 and 12-week old recipients, respectively). Data shown corresponds 
to quadrant Q2 of Figure 17 with a total of 280 tested transcripts. Signal intensities of 
individual transcripts in three different gene pools are plotted against transcript frequencies 
(density). Ub (grey), Aire-independent TRA (dark blue) and Aire-dependent TRA (yellow).  
 
 
4.3.3 Fgf7 administration alters thymic expression of 
TRA independently of their tissue specificity and 
acute GVHD  
Finally, based on the aforementioned results regarding the tissue 
specificity of downregulated TRA, I asked whether Fgf7 specifically affected 
TRA that were expressed mainly in chronic GVHD target tissues. Both the 
effects of Fgf7 on TRA in mice without disease (bd→bd) (Figure 36A) and 
with acute GVHD (b→bd) (Figure 36B) were analysed. The data clearly 
demonstrated that neither in the absence nor in the presence of disease an 
enrichment of genes that are typically expressed in tissues known to be 
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targets of chronic GVHD was present. Notably, analysis of tissue 
representation of TRA whose expression levels were lower during acute 
GVHD but normal in response to Fgf7 revealed that genes segregated at 
similar high frequencies for their tissue expression profiles as shown on page 
52 (Figure 36C). These data demonstrated that the Fgf7 effect was not 
specific for genes that are expressed mainly in chronic GVHD target tissues.  
 
 
Figure 36. Fgf7 administration alters thymic expression of TRA independently 
of their tissue specificity and acute GVHD. (A) Effect of Fgf7 on TRA in mice 
without disease (syngeneic transplantation, bd→bd). The pie chart shows tissue 
representation of the 220 and 60 TRA whose expression levels are enhanced by >3-fold in 
response to Fgf7 at 10 and 12 weeks of age, respectively (2 and 4 weeks after syngeneic 
transplantation). (B) Effect of Fgf7 on TRA in mice with acute GVHD (b→bd). The pie 
chart shows tissue representation of the 39 and 110 TRA whose expression levels were 
enhanced by >3-fold in response to Fgf7 at 10 and 12 weeks of age, respectively (2 and 4 
weeks after acute GVHD induction). (C) Effect of Fgf7 on TRA reduced during acute 
GVHD (b→bd). The pie chart shows tissue representation of the 190 and 291 TRA, 
respectively, whose expression levels are lower during acute GVHD but normal in response 
to Fgf7.   
 
 
Taken together, the data demonstrated that mTEC cytoprotection by Fgf7 
sustained the mTEC compartment in the course of acute GVHD and hence 
a more diverse TRA transcriptome could be achieved despite ongoing 
alloimmunity. 
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5. DISCUSSION  
Despite advances in experimental and clinical HSCT, acute and 
chronic GVHD continue to be major causes of posttransplant mortality and 
morbidity.126 Several clinical studies proved acute GVHD to be a risk factor 
for chronic GVHD; the latter of which is characterised by autoimmune 
manifestations.132,141,143 In contrast to acute GVHD, the pathomechanism of 
chronic GVHD is less well understood. Moreover, clinical data for the 
mechanism of the transition from acute to chronic GVHD do not exist at 
present. From studies of animal models, four different mechanisms have 
been proposed that may alone or in combination contribute to the 
pathogenesis of chronic GVHD.147 These propositions include 1) a deficiency 
in the Treg compartment; 2) a role for B cells and autoantibodies; 3) 
activation of the TGF-β pathway; and 4) thymic dysfunction resulting from 
prior acute GVHD. Since thymic dysfunction is a characteristic feature of 
both clinical and experimental acute GVHD,162,177-181 understanding of the 
precise mechanism of thymic injury may prove to be crucial for the 
understanding of the transition from acute to chronic GVHD. Here, 
alterations in the mTEC compartment may serve as a possible explanation 
for the emergence of autoreactive T cells in the periphery following 
allogeneic HSCT.  
The existence of a link between mTEC injury and the emergence of 
autoreactive T cells generated in the course of acute GVHD remained 
unknown at the start of this thesis project. My study was based on data 
that had established TEC as direct targets of allorecognition and, in 
response, their apoptosis during acute GVHD.162 Moreover, acute GVHD-
caused TEC injury was shown to impair intrathymic T-cell development 
and T-cell export to the periphery.213 I therefore hypothesised that defects 
in mTEC function during acute GVHD result in impaired thymic negative 
selection and consequently in a peripheral T-cell repertoire that harbours 
autoreactive clones at higher levels than normal. 
Within my thesis work, I demonstrated that mTEC injury is a 
universal event in different murine models of acute GVHD. Mature 
mTEChigh were deleted in the course of disease which resulted in a reduced 
size of the entire mTEC compartment (Figure 15). The mTEChigh 
compartment is essential for thymic negative selection, since it has the 
unique capacity to express a large array of peripheral self-antigens, which 
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are to a great extent controlled by the transcription factor Aire.87 I found 
that within the mTEC compartment, the Aire+mTEChigh cells were 
particularly affected by acute GVHD (Figure 16). In consequence, the 
diversity of TRA expression was significantly impaired (Figure 17). Using a 
transgenic transplantation model, I was able to demonstrate that loss of 
TRA had a biological effect. In this model, purging of an individual self-
antigen (OVA) from the TRA pool failed to induce central tolerance 
induction against this specific TRA. OVA-specific CD4+ T cells were 
present in the spleen and lymph nodes of mice with acute GVHD as a 
consequence of diminished OVA expression in mTEC (Figure 25). I also 
investigated the cytoprotective agent Fgf7 as a potent treatment to protect, 
repair, and enhance TEC function, resulting in improved thymic negative 
selection. Peritransplant administration of Fgf7 restored the mTEC 
compartment, including cells that expressed Aire. In consequence, TRA 
expression in mTEChigh was sustained despite the presence of allogeneic 
donor T cells in the thymus (Figure 32).  
 
 
Loss of mTEC – a universal manifestation of acute GVHD 
The use of the non-ablative B6→BDF1 transplantation model 
allowed me to distinguish pathogenic influences on TEC caused by acute 
GVHD from those that resulted from cytoreductive therapy. I confirmed 
previous data from this haploidentical model that the TEC compartment is 
affected by alloreactive T cells.162 In this previous study, mostly cTEC were 
lost during acute GVHD. However, recent progress in the identification of 
TEC subsets provided the tool to investigate the thymic stroma in more 
detail.56,57,63-66 I identified the mTEC compartment as the major target of 
allorecognition by donor T cells. Since I distinguished immature and mature 
mTEC by using detection of MHC class II, my data provides further details 
into thymic injury in the course of acute GVHD. The mature mTEChigh 
cells were preferentially affected by acute GVHD as cell numbers were 
reduced to almost undetectable levels during the observation period. I could 
confirm these data in other models, including haploidentical, MHC-
mismatched and MHC-matched transplantation systems that used TBI as 
cytoreductive conditioning. In these models, radiation therapy initially 
reduced mTEChigh numbers independently of acute GVHD, but the presence 
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of acute GVHD pronounced this injury further. My data argue for a 
reduction of mTEChigh compartment size as a universal manifestation, and 
radiation injury is not mandatory as suggested before.223 None of the 
experimental models fully reflected the complexity of the clinical situation 
as individual experimental models are specifically designed to address only 
desired subsets of all the clinical parameters. Seeking to identify specific 
autoimmune mechanisms in a multifactorial pathology such as acute 
GVHD, a reductionist approach was, however, advantageous, which was 
then further strengthened by a comparison of data sets gained from distinct 
experimental models.   
 Both mTEClow and mTEChigh numbers regenerated to normal values 
upon acute GVHD induction in the haploidentical transplantation model 
with TBI (Figure 15B). The reason for this observation was not addressed 
but a recent study suggests a role for cytokine-mediated thymic 
regeneration after TBI.259 Here, radio-resistant DCs were shown to 
upregulate IL-23 following irradiation and subsequently induce IL-22 
expression in thymic lymphoid tissue inducer cells. This mechanism resulted 
in IL-22-mediated regeneration of the thymic microenvironment. Hence, 
such a regenerative mechanism might apply for the haploidentical b→bd 
+TBI model. Such a contention remains to be tested.  
My conclusion that loss of mTEC is a universal manifestation of 
acute GVHD was consistent with a recent study where TBI treated Balb/c 
recipient were transplanted with B6 TCD bone marrow replete either with 
donor CD4+ or CD8+ T cells.224 In this transplantation model CD8+ T cells 
were more potent in mediating mTEC injury than CD4+ T cells but both 
donor T cells caused a significant loss in mTEC numbers. In other 
experimental systems, mTEC were shown to be highly susceptible to 
chemotherapy.260 Among all TEC subsets, mTEChigh were ablated foremost 
as a consequence of chemotherapy, which mirrored my observation that 
acute GVHD mostly affects these tolerance inducing cells.  
 
 
Acute GVHD weakens the platform for central tolerance  
The above data suggested that negative selection is affected by 
acute GVHD, since mTEC provide the platform for central tolerance. I 
approached this issue by investigating in more detail the effect of acute 
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GVHD on mTEChigh function. Contraction of the total mTEChigh pool in 
unconditioned b→bd recipients indeed corresponded to progressive decreases 
in the subset that expresses Aire. In other systems, e.g. systems that used 
ablation of Aire, the absence of Aire is associated with decreased TRA 
expression, which leads in turn to impaired negative selection.72,73,85,86 
Similar to these systems, gene expression analysis of isolated mTEChigh 
indeed revealed that the development of thymic acute GVHD was 
associated with an overall decrease in TRA expression levels (Figure 17). 
Since signal intensities of TRA and ubiquitously expressed genes (Ub) did 
not differ from each other, the enrichment of TRA among the 
downregulated genes was independent of signal intensity but rather caused 
by a loss of mTEChigh. Not all TRA were reduced to the same extent, 
however, and some were not affected at all. I also observed differences in 
the profiles of reduced TRA at 2 and 4 weeks post-transplantation but 
many TRA were affected by acute GVHD at both time points. This 
observation may have been due to the fact that ectopic TRA expression is a 
stochastic process.75,249 Only a limited number of mTEChigh (1-3%) express a 
particular TRA,66,75 and a comprehensive coverage of TRA expression is 
hence only achieved by a sufficiently large mTEChigh pool. The latter is, 
however, missing under conditions of acute GVHD. 
Promiscuous gene expression by mTEC is independent of any 
spatial or temporal pattern control observed during regular tissue 
development and is typically representative of all organs. The size and 
complexity of this profile is highly conserved between mouse and man70 
thus underscoring the suitability of using experimental models to emulate 
the situation in clinical HSCT. Analysis of published data of TRA tissue 
representation in C57BL/6 mice from Kyewski et al.70 revealed that 
approximately one third of TRA represent genes specifically expressed in 
the major targets of chronic GVHD such as the skin, liver, salivary glands, 
lung, eye, and gastrointestinal tract (Figure 37). This tissue distribution 
remained unchanged in age-matched recipients of syngeneic transplants. 
However, the most substantially downregulated TRA during acute GVHD 
were specific for these tissues that are target organs of human chronic 
GVHD. These data suggested the generation of autoreactive T cells specific 
for these chronic GVHD target tissues.  
 
 
	
  	
  	
   89 
 
Figure 37. TRA tissue distribution. (A) Left pie chart: Data from Kyewski et al. 
(2006)70 showing tissue distribution of TRA in mTEChigh from naïve mice. Right pie chart: 
Dataset from naïve mice displaying only the TRA that are specifically expressed in the 
major target tissues of chronic GVHD. (B) Altered representation of panel A which 
combines these TRA in one area (left pie chart). TRA tissue representation in naïve mice 
was then compared to syngeneically transplanted mice (pie chart on the right).  
 
 
 
Use of the RIP-mOVA system to study thymic negative selection 
in the presence of acute GVHD 
Having established that acute GVHD was associated with a defect 
in TRA expression, I intended to demonstrate whether there was a 
mechanistic link to the emergence of autoreactive T cells. Since the 
specificities of the autoreactive T cells in chronic GVHD remain 
unidentified, and since even the identification of such would not definitely 
prove a causal relationship with impaired thymic TRA expression, I decided 
to study ovalbumin (OVA), which can be introduced into the thymus as a 
neo-self-antigen. I took advantage of the well established OT-II→RIP-
mOVA transplantation system.98 This system is suitable to study thymic 
negative selection mediated by mTEC since firstly, thymic membrane-
bound OVA (mOVA) expression under the RIP-promoter is restricted to 
mTEC; secondly, TCR selection against mOVA recapitulates physiological 
tolerance induction to TRA in the thymus medulla;71,72,76,98,250,251 and thirdly, 
a reduction in the expression of mOVA mRNA by as little as 30% suffices 
for the failure deletion of OT-II T cells in RIP-mOVA mice.252 Thymic 
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OVA expression was detected in the mTEC compartment in transgenic 
recipients without disease as expected. Unexpected was, however, that 
OVA was present in both mTEClow and mTEChigh, which argued for OVA 
being regulated independently of Aire, since only mTEChigh express 
Aire.72,76,77  These data were not consistent with studies showing OVA 
expression to be Aire-dependent,252,261 but they agreed with another study.76 
The first two studies determined OVA expression in total thymic stromal 
preparations, however, and not specifically in mTEC. 
The induction of acute GVHD in RIP-mOVA mice led to mTEC 
injury. Both mTEClow and mTEChigh were decreased in absolute cell 
numbers similar to the non-transgenic haploidentical transplantation model 
used above (Figure 21). In addition, Aire-expressing mTEChigh were deleted 
in the presence of acute GVHD (Figure 22). However, Aire mRNA 
expression was not significantly affected by disease. The reason why acute 
GVHD only interferes with Aire protein expression, but not with Aire 
mRNA expression, remains to be elucidated. Possible mechanisms may 
include defects in mRNA translation, stability of protein, or degradation of 
the Aire protein. In summary, my data demonstrated that OVA-expressing 
mTEC were deleted during acute GVHD, and consequently thymic OVA 
expression was reduced. Under physiological conditions, i.e. mice without 
acute GVHD, OT-II T cells were efficiently deleted in a RIP-mOVA 
thymus and they accounted for frequencies of only 1-3% among all CD4+ T 
cells in the periphery (Figure 25). However, acute GVHD allowed the 
emergence of OT-II T cells to the periphery due to diminished thymic OVA 
expression, which resembled the situation in non-transgenic wildtype mice 
(no thymic OVA expression). These data indicated that the loss of a single 
TRA licenses the de novo generation of autoreactive CD4+ T cells during 
acute GVHD. Characterisation of OT-II T cells in the periphery with acute 
GVHD revealed that they were fully functional and did not acquire an 
anergic phenotype. Moreover, an activated phenotype was suggested based 
on larger cell size and higher CD44 expression (Figure 27). It is noteworthy 
that OT-II T cells detected in the periphery represented Teffector cells, i.e. 
non-Treg cells, which was another indication that they were capable of 
responding to their antigen. It was, however, not surprising that Treg cells 
were found to be diminished in hosts in the presence of acute GVHD, since 
Treg development relies on a functional thymus.92 Their absence was 
consistent with observations from clinical studies where peripheral blood 
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Treg numbers are reduced in patients suffering from acute GVHD.262 This 
relationship thus provides a further explanation for the presence of an 
autoimmune syndrome following acute GVHD.  
I did not test directly if OT-II T cells that escaped negative 
selection were capable of responding to OVA, a feature that would be 
required for effector function that leads to autoimmune disease. To test 
this, CD4+ OT-II T cells will have to be isolated directly from the thymus 
or periphery and cultured in vitro together with host-derived APCs pulsed 
with OVA peptide or protein. Proliferation of OT-II T cells will indicate 
their ability to respond to OVA. To test the OT-II response directly in 
vivo, the transfer of isolated CD4+ OT-II SP thymocytes in a secondary 
Rag-deficient recipient immunised with recombinant Listeria 
monocytogenes bacteria engineered to secrete chicken OVA might also be 
helpful.98 Another in vivo system that might be useful to answer this 
question is the immunisation of the RIP-mOVA host itself.263 RIP-mOVA 
mice allow the activation of OVA-reactive T cells in the pancreatic lymph 
node, which is the principal site for activation of diabetogenic T cells.97,263,264 
Primed OT-II T cells are able to infiltrate the pancreas and to attack the 
neo-self-antigen OVA, which results in the development of diabetes in these 
RIP-mOVA mice. The development of diabetes can be followed by blood 
glucose measurements. OT-II T cells that infiltrate the pancreas and cause 
insulitis can be detected by histological analyses. It remains to be tested 
whether these functional assay systems are applicable and informative in 
the GVHD settings.     
A caveat of the OT-II system is the unphysiological high frequency 
of OVA-specific precursors, which may alter the negative selection 
process.250 To overcome this limitation, OT-II TCD bone marrow was 
transplanted together with B6 wild type TCD bone marrow at a 1:3 ratio. 
This strategy ensures proper negative selection of OVA-specific T cells as 
would be expected in normal T-cell development. In both, B6 and RIP-
mOVA hosts without acute GVHD, B6 wild type T cells used the Vα2 and 
Vβ5 chain randomly at a frequency of 4% as would be expected from a 
normally selected diverse TCR repertoire. Interestingly, in RIP-mOVA 
hosts with acute GVHD, B6 wild type T cells did not use the Vβ5 chain. 
These data further evidenced that the loss in ectopic TRA expression is 
sufficient for the de novo generation and export of TRA-specific CD4+ T 
cells in mice.  
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Potential mechanism of autoreactive T-cell neogenesis following 
allogeneic HSCT 
In summary, I propose an etiologic link between the alloreactivity of 
acute GVHD and the autoimmunity typically seen in chronic GVHD. Such 
a link may be based on an impaired size of the mTEChigh compartment as a 
result of acute GVHD. A potential mechanism how new T cells are 
generated following allogeneic HSCT from donor HSC in a thymus-
dependent regenerative mechanism is shown in Figure 38. The top panel A 
shows normal thymus function, which is briefly summarised again. T-cell 
development requires the seeding of grafted HSCs and subsequent import of 
progenitor cells from the host bone marrow (blue symbols) via the blood 
circulation into the thymus cortex. In an intact host thymus the T-cell 
precursors mature and are positively selected in response to signals 
provided by cTEC. In parallel to their migration to the thymus medulla, T-
cell precursors differentiate into CD4+ or CD8+ T cells which are then 
subjected to thymic negative selection. In such a process developing T cells 
are exposed to self-antigens, including TRA. An essential prerequisite for 
the negative selection of self-reactive T cells is the ability of Aire+mTEChigh 
to build a reservoir of a large array of TRA. TRA are presented either by 
mTEC themselves, indirectly by thymic dendritic cells, or by both cell 
types in parallel. High-affinity TCR ligation of these TRA leads to clonal 
deletion (negative selection) of the responding T cells. Aire+mTEChigh do 
not homogeneously express a large pool of TRA, however. Rather, the 
expression of individual antigens is restricted to a subset of mTEChigh, 
indicating a high level of heterogeneity between mTEC subpopulations. 
Hence, Aire+mTEChigh compartment size contributes to TRA diversity. The 
stochastic process of ectopic TRA expression is symbolised in Figure 38 by 
the expression of a given TRA by only a limited number of mTEChigh (e.g. 
TRA1, 2, 3 in one mTEChigh, TRA3, 4, 6 in another, TRA1, 2, 4, 5 in a 
third and TRA7 in a fourth cell). It is believed on the basis of a very 
limited set of single cell analysis that a comprehensive mosaic of TRA is 
only achieved by the complete mTEChigh pool which is symbolised by 
expression of all TRA (1-7) by the total cell pool. This mechanism ensures 
an efficient deletion of a highly diverse self-reactive TCR repertoire (red 
symbols). The surviving mature T cells (blue symbols) are exported to 
peripheral lymphoid tissues where they constitute the pool of self-tolerant 
	
  	
  	
   93 
but pathogen-specific naive T cells. In panel B of Figure 38 thymus 
function in recipients with acute GVHD is shown. In preclinical allogeneic 
HSCT models the activation of alloreactive donor T cells (black symbols) is 
linked to death of cells residing in the TEC compartment,36 including those 
mTEC that express Aire. A decrease in the size of the Aire+mTEChigh 
compartment results in the transcription of a smaller array of TRA. This 
mechanism is symbolised by the loss of TRA4, 5 and 6 in result from death 
of two mTEChigh cells. It is postulated that such reduction in TRA diversity 
leads to an enhanced emergence of new T-cell clones that are reactive to 
TRA4, 5 and 6 in the periphery. My studies then also demonstrated that 
many of those thymic TRA whose expression levels were reduced as a 
consequence of acute GVHD represented proteins that are specifically 
expressed in known target tissues of chronic GVHD, including salivary and 
lacrimal glands (e.g. salivary protein), liver (e.g. urinary protein) and lung 
(e.g. secretoglobin) (Figure 18). This proposed mechanism agrees with a 
recently published study by Wu et al.224 who showed that the mTEC 
compartment is disrupted by acute GVHD resulting in the emergence of 
host reactive T cells.  
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Figure 38. Hypothesised mechanism of autoreactive T-cell neogenesis following 
allogeneic HSCT. (A) Normal thymus function (B) Thymus function in recipients with 
acute GVHD (as described in the text) 
 
 
 
While my data make the mechanism shown in Figure 38 highly 
plausible, it should be noted that the emergence of autoreactive T cells may 
not be sufficient to cause an autoimmune syndrome typical for chronic 
GVHD. This fact may be due to additional peripheral control mechanisms 
that regulate autoimmunity. For example, natural Treg are generated in the 
thymus and prevent activation of peripheral autoreactive T cells.92,265 Very 
recent data demonstrated that the medullary compartment provides a 
developmental niche for natural Treg.94-96 Since the mTEC compartment is 
affected by acute GVHD, it can be envisaged that there is not only a defect 
in T cell development and the essential selection processes, but also in the 
intrathymic generation of Treg cells. If such a mechanism proves to be true, 
a 2-hit model for chronic GVHD will apply.266 This model suggests the 
development of chronic GVHD being dependent on the emergence of 
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autoreactive T cells from the thymus to the periphery (Hit 1) in the 
context of peripheral deficiencies in thymic Treg cells (Hit 2). 
Nevertheless, chronic GVHD and its autoimmune manifestations can 
occur also without preceding acute GVHD.139,149 Either thymic GVHD is 
present but not detectable by routine clinical analyses or thymic GVHD is 
indeed absent. The first possibility would not rule out a role for impaired 
thymic negative selection in the development of an autoimmune syndrome. 
In contrast to the tools available for the diagnosis of skin, gut, or liver 
acute GVHD (physical examination, biomarkers of inflammation, biopsy, 
endoscopy), routine diagnosis of acute GVHD of the thymus is not readily 
available. The development of minimally invasive tools for diagnosis of 
thymic GVHD (e.g. imaging or biomarker based) may be a methodologic 
necessity to assess thymic GVHD.226 The second possibility implies that 
other mechanism than impaired thymic negative selection must exist that 
drive the development of an autoimmune syndrome. A recent study 
suggested that autoimmunity can occur in the absence of any defects in 
thymic negative selection and in the presence of a functional Treg 
repertoire.267 The authors showed in a novel transgenic mouse model that 
during an infection T cells responded to a neo-self-antigen that did not 
induce negative selection when promiscuously expressed in the thymus 
medulla. This study suggested that a mismatch between the threshold for 
negative selection and activation in the periphery during an infection allows 
low avidity T cells to emerge from the thymus to the periphery where they 
can cause autoimmunity upon restimulation. Other experimental systems 
suggested the thymus to be negligible for the generation of autoimmune-like 
chronic GVHD.146,183-185 Rather mature donor T cells transferred in the graft 
are activated and expanded by alloimmune response and contribute to the 
development of chronic GVHD and its autoimmune manifestations. 
Furthermore, inappropriately low numbers of Treg in acute GVHD have 
been defined as a major event that leads to the development of 
autoimmunity and consequently chronic GVHD.166      
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Fgf7 restores the thymic mTEChigh compartment and sustains the 
diversity of TRA expression  
To test if factors that foster epithelial cell proliferations and act 
directly on TEC are thus effective in restoring the mTEC compartment and 
consequently improving the diversity of TRA expression, I chose to study 
Fgf7. Fgf7 has before been reported to efficiently enhance the proliferation 
of the TEC compartment, and thus to increase intrathymic T cell 
development.239 Murine studies of allogeneic HSCT showed that treatment 
with Fgf7 protects the host thymus239,241 and one study was able to 
demonstrate a beneficial effect on central tolerance induction.180  
The peritransplant administration of Fgf7 to allogeneically 
transplanted recipients did not affect the initial drop in mTEChigh numbers 
(Figure 29). Nevertheless, stable cell numbers of mTEChigh and 
Aire+mTEChigh similar to mice without disease were reached later after 
GVHD induction and maintained over the whole observation period. This 
result was not consistent with a previous study that showed an increase in 
all TEC populations as early as 3 days after Fgf7 treatment.239 These 
experiments were done in wild type mice without acute GVHD. These data 
suggested that Fgf7 could only partially compensate the loss of cells caused 
by acute GVHD at early time points. Fgf7 mediated its action by 
enhancing TEC proliferation early after administration, as shown by BrdU 
analyses (Figure 31). In the absence of exogenous Fgf7, 5% of mTEC 
underwent cell division within 1 week in the b→bd and bd→bd transplant 
group. These data are consistent with reports showing that mTEC are 
continuously replaced in adulthood.57,66 In mice with acute GVHD but 
treated with Fgf7 the frequency of proliferating cells in the first week 
increased to 15%. High turnover of mTEC in response to Fgf7 was therefore 
responsible for the rescue of mTEChigh numbers. However, it remains 
unknown how the stable cell population is maintained at later time points 
post treatment, since snap shot analysis of BrdU incorporation 2 weeks 
after Fgf7 administration and GVHD induction did not show increased 
proliferation compared to HBSS-treated recipients. This raises the question 
if Fgf7 has more a protective than a proliferative effect, a point that will 
need to be addressed. One possibility to test this issue will be to 
administrate Fgf7 before inducing acute GVHD. This prophylactic 
intervention may allow Fgf7 to firstly induce a protective effect before 
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alloreactive T cells can attack TEC. Another approach will be the long 
term follow up of recipients treated with Fgf7. Fgf7 has been shown to act 
on TEC progenitors by stimulating their proliferation and differentiation 
and on residual mTEC.239 It remains, however, unclear what the 
contribution of these two populations to the recovery of mTEChigh is. 
Interestingly, alloreactive donor T cells remained present in the host 
thymus despite Fgf7 administration. Given the fact that Fgf7’s receptor 
FgfR2IIIb is not expressed on T cells, it is not surprising that Fgf7 did not 
have a direct trophic or proliferative effect on thymus-infiltrating donor T 
cells. An explanation might be that the effect of Fgf7 on the TEC 
compartment overcomes the injury caused by alloreactive donor T cells. 
Gene expression data from mTEChigh cells isolated from syngeneically 
transplanted mice treated with Fgf7 are available and will provide further 
information about the molecular mechanism how Fgf7 protects the thymic 
epithelium (microarray data generated during this thesis project). 
Preliminary analyses revealed that a number of genes, which were 
upregulated upon Fgf7 administration, are involved in cell cycle regulation 
and in the control of apoptosis. This work is in progress.    
The presence of mTEChigh and Aire+mTEChigh cell numbers close to 
normal numbers observed in recipients without acute GVHD, suggest the 
recovery of TRA expression in response to Fgf7. Indeed, gene expression 
analysis revealed that peritransplant administration of Fgf7 sustained a 
more diverse TRA transcriptome during acute GVHD (Figure 32). 
However, 2 weeks after acute GVHD induction, the TRA spectrum was not 
preserved by Fgf7, although Aire+mTEChigh had recovered to normal levels 
yet. At 7 weeks post-transplantation, a broader array of TRA was 
expressed, which resembled the situation in normal (i.e. syngeneically 
transplanted) mice. I interpret these data such that the amelioration of 
TRA expression is secondary to the recovery of the mTEC compartment. 
Individual TRA expression patterns were differentially affected by Fgf7 as 
some but not all Aire-dependent TRA returned to nearly normal expression 
in the observation period (Figure 33). The molecular mechanism for this 
biased profile remains to date unknown. I cannot exclude from my data 
that mTEChigh had also at the individual cell level a decrease in the number 
of TRA transcribed. This hypothesis may be testable by the analysis of 
single cell mTEChigh transcriptomics.  
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To test if different signal intensities and Aire-dependency influenced 
the restoration of the TRA pool, multidensity histogram analysis was 
performed. Since signal intensities were similar between Ub, TRA, and 
Aire-dependent TRA, these data clearly suggested that Fgf7 restored gene 
expression independently of signal intensities (Figure 35). Such bias in gene 
regulation is indeed not a common observation in gene expression analysis 
(personal communication R. Ivanek, bioinformatician). These data also 
revealed that there was no significant preferential restoration of Aire-
dependent TRA compared to Aire-independent TRA. I interpret these data 
such that Fgf7 restored the whole mTEChigh pool, and did not favour the 
Aire+mTEChigh. In consequence, both, Aire-dependent and –independent 
TRA, are efficiently restored by Fgf7. Confirming the data that TRA 
restoration is an arbitrary process, there was no preferential effect of Fgf7 
on genes that are expressed mainly in chronic GVHD target tissues 
observed (Figure 36).  
In summary, these data suggest that normal numbers of 
Aire+mTEChigh and TRA diversity after engraftment of donor HSC possibly 
result in effective negative thymic selection and support of thymic Treg 
development. Such a mechanism would prevent the emergence of 
autoreactive T cells in the periphery and consequently result in the absence 
of chronic GVHD with its autoimmune manifestations. Nevertheless, there 
are open questions, which have not been addressed in this study. I did not 
investigate the effect of Fgf7 on already established acute or chronic 
GVHD. The question arises whether there are enough residual mTEC or 
progenitor cells in a recipient with already established thymic acute GVHD 
to respond to Fgf7. Does Fgf7 have any positive or negative effects on other 
epithelial cells than TEC? Since the Fgf7 administration was not locally 
directed at the thymus, Fgf7 might act in addition to TEC also on other 
cell types in the periphery.       
Whether peritransplant administration of Fgf7 results in a decreased 
occurrence of chronic GVHD and autoimmune syndrome in allogeneic 
HSCT patients, remains unknown so far. Clinical studies about Fgf7 
(Palifermin) are contradictory in this respect. One retrospective study 
concluded that Fgf7 decreases the incidence of acute GVHD268 but another 
one did not find any ameliorating effect of Fgf7 on GVHD in allogeneic 
HSCT.269 Moreover, prospective trials could not show differences in acute 
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GVHD incidence, severity, survival, and incidence of chronic GVHD 
between Fgf7 and placebo cohort in humans.270,271  
The rationale of my study was to provide mechanistic explanations 
and cell biological principles that ascribe how autoimmunity may develop in 
the context of antecedent alloimmunity. Fgf7 was used to test the 
hypothesis that interventions directed at epithelial cytoprotection maintain 
the integrity of the mTEC compartment after transplantation and reverse 
the loss of TRA diversity. Since promiscuous gene expression for the 
deletion of self-reactive T cells is not the only way how the self-reactive 
potential of the immune system is regulated (see above), such 
cytoprotection may not necessarily equate to an outright protection from 
autoimmunity. While Fgf7 effects the peripheral immune system,272 it may 
be incorrect to assume that its administration can prevent autoimmunity 
arising from a central in lieu of a peripheral defect in tolerance. However, 
interventions focused on mTEC cytoprotection, such as Fgf7, may 
contribute to prevent the emergence of thymus-dependent autoreactive T 
cells and thus alter autoimmune outcome. Although the successful results of 
Fgf7 from animal models have not yet been confirmed in human 
transplantation,273 the present data suggest to focus on new therapies that 
treat or prevent chronic GVHD by targeting the thymic microenvironment, 
rather than lymphohaematopoietic cells.  
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6. CONCLUSIONS 
Although, acute GVHD has been implicated as a risk factor for 
chronic GVHD, it remains unknown whether and how autoimmunity is 
linked to antecedent alloimmunity. My data provide a mechanism for how 
autoimmunity may develop in the context of acute GVHD (Figure 38). 
This mechanism is based on a contracted mTEC cellularity and 
consequently impaired TRA representation due to altered gene expression. 
In conclusion, the weakened platform for negative selection might provide 
the explanation for the emergence of autoreactive T cells seen in the murine 
transplantation models. Because thymic negative selection is sensitive to 
small changes in TRA expression, approaches for mTEC cytoprotection, as 
shown here with the administration of Fgf7, may prevent the emergence of 
thymus-dependent autoreactive T cells. In consequence, this might alter 
autoimmune outcome. The identification in chronic GVHD of the yet 
undefined specificities of autoreactive effector T cells will allow to test this 
argument directly in experimental systems and ultimately in clinical 
allogeneic HSCT.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
  	
  	
   101 
7. REFERENCES 
1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J 
Med. 2007;357:1472-1475. 
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 
2006;354:1813-1826. 
3. Gratwohl A, Baldomero H. Trends of hematopoietic stem cell 
transplantation in the third millennium. Curr Opin Hematol. 
2009;16:420-426. 
4. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, et al. 
The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 
2012;47:906-923. 
5. Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, et al. 
Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow 
Transplant. 2013;48:1161-1167. 
6. Passweg JR, Halter J, Bucher C, Gerull S, Heim D, et al. 
Hematopoietic stem cell transplantation: a review and 
recommendations for follow-up care for the general practitioner. Swiss 
Med Wkly. 2012;142:w13696. 
7. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, et al. Allogeneic 
stem cell transplantation for acute myeloid leukemia in first complete 
remission: systematic review and meta-analysis of prospective clinical 
trials. JAMA. 2009;301:2349-2361. 
8. Pasquini MC, Wang Z. Current use and outcome of hematopoietic 
stem cell transplantation: CIBMTR Summary Slides, 2012. Available 
at: http://www.cibmtr.org. . 
9. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic 
transplantation: current status and future perspectives. Blood. 
2011;118:6006-6017. 
10. Turner BE, Collin M, Rice AM. Reduced intensity conditioning for 
hematopoietic stem cell transplantation: has it achieved all it set out 
to? Cytotherapy. 2010;12:440-454. 
11. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, et al. 
Nonmyeloablative allogeneic hematopoietic cell transplantation in 
patients with acute myeloid leukemia. J Clin Oncol. 2010;28:2859-2867. 
	
  	
  	
   102 
12. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, et al. 
Reduced mortality after allogeneic hematopoietic-cell transplantation. 
N Engl J Med. 2010;363:2091-2101. 
13. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? 
Blood. 2010;116:4762-4770. 
14. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic 
hematopoietic cell transplantation. Blood. 2009;114:7-19. 
15. Baker KS, Bresters D, Sande JE. The burden of cure: long-term side 
effects following hematopoietic stem cell transplantation (HSCT) in 
children. Pediatr Clin North Am. 2010;57:323-342. 
16. Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, et 
al. Reducing transplant-related mortality after allogeneic 
hematopoietic stem cell transplantation. Haematologica. 2004;89:1238-
1247. 
17. Morris ES, Hill GR. Advances in the understanding of acute graft-
versus-host disease. Br J Haematol. 2007;137:3-19. 
18. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, 
et al. Comparison of immune reconstitution after unrelated and related 
T-cell-depleted bone marrow transplantation: effect of patient age and 
donor leukocyte infusions. Blood. 1999;93:467-480. 
19. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious 
morbidity in long-term survivors of allogeneic marrow transplantation 
is associated with low CD4 T cell counts. Am J Hematol. 1997;54:131-
138. 
20. Storek J, Joseph A, Espino G, Dawson MA, Douek DC, et al. 
Immunity of patients surviving 20 to 30 years after allogeneic or 
syngeneic bone marrow transplantation. Blood. 2001;98:3505. 
21. Barker JN, Hough RE, van Burik JA, DeFor TE, MacMillan ML, et 
al. Serious infections after unrelated donor transplantation in 136 
children: impact of stem cell source. Biol Blood Marrow Transplant. 
2005;11:362-370. 
22. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive 
aspergillosis in allogeneic stem cell transplant recipients: changes in 
epidemiology and risk factors. Blood. 2002;100:4358-4366. 
23. Ochs L, Shu XO, Miller J, Enright H, Wagner J, et al. Late infections 
after allogeneic bone marrow transplantations: comparison of incidence 
	
  	
  	
   103 
in related and unrelated donor transplant recipients. Blood. 
1995;86:3979. 
24. Cavazzana-Calvo M, André-Schmutz I, Dal Cortivo L, Neven B, 
Hacein-Bey-Abina S, Fischer A. Immune reconstitution after 
haematopoietic stem cell transplantation: obstacles and anticipated 
progress. Curr Opin Immunol. 2009;21:544-548. 
25. Seggewiss R, Einsele H. Immune reconstitution after allogeneic 
transplantation and expanding options for immunomodulation: an 
update. Blood. 2010;115:3861-3868. 
26. Storek J, Zhao Z, Lin E, Berger T, McSweeney PA, et al. Recovery 
from and consequences of severe iatrogenic lymphopenia (induced to 
treat autoimmune diseases). Clin Immunol. 2004;113:285-298. 
27. Muraro PA, Douek DC. Renewing the T cell repertoire to arrest 
autoimmune aggression. Trends Immunol. 2006;27:61-67. 
28. Crooks GM, Weinberg K, Mackall C. Immune reconstitution: from 
stem cells to lymphocytes. Biol Blood Marrow Transplant. 2006;12:42-
46. 
29. Storek J. Immunological reconstitution after hematopoietic cell 
transplantation - its relation to the contents of the graft. Expert Opin 
Biol Ther. 2008;8:583-597. 
30. Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, et al. 
Successful immune reconstitution decreases leukemic relapse and 
improves survival in recipients of unrelated cord blood transplantation. 
Biol Blood Marrow Transplant. 2006;12:919-927. 
31. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, 
et al. Long-term immune reconstitution and outcome after HLA-
nonidentical T-cell-depleted bone marrow transplantation for severe 
combined immunodeficiency: a European retrospective study of 116 
patients. Blood. 1998;91:3646-3653. 
32. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, et al. Early 
lymphocyte recovery is a predictive factor for prolonged survival after 
autologous hematopoietic stem cell transplantation for acute 
myelogenous leukemia. Leukemia. 2002;16:1311-1318. 
33. Clave E, Rocha V, Talvensaari K, Busson M, Douay C, et al. 
Prognostic value of pretransplantation host thymic function in HLA-
identical sibling hematopoietic stem cell transplantation. Blood. 
2005;105:2608-2613. 
	
  	
  	
   104 
34. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, et al. 
Prediction of survival using absolute lymphocyte count for newly 
diagnosed patients with multiple myeloma: a retrospective study. Br J 
Haematol. 2008;141:792-798. 
35. van Den Brink M, Leen AM, Baird K, Merchant M, Mackall C, 
Bollard CM. Enhancing immune reconstitution: from bench to bedside. 
Biol Blood Marrow Transplant. 2013;19:S79-S83. 
36. Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in 
allogeneic stem cell transplantation. Blood. 2011;117:6768-6776. 
37. Hollander G, Gill J, Zuklys S, Iwanami N, Liu C, Takahama Y. 
Cellular and molecular events during early thymus development. 
Immunological reviews. 2006;209:28-46. 
38. Gill J, Malin M, Sutherland J, Gray D, Hollander G, Boyd R. Thymic 
generation and regeneration. Immunol Rev. 2003;195:28-50. 
39. Guidos C. Thymus and T-lymphocyte development: what is new in the 
21st century? Immunol Rev. 2006;209:5-9. 
40. Boehm T. Thymus development and function. Curr Opin Immunol. 
2008;20:178-184. 
41. Rothenberg EV, Moore JE, Yui MA. Launching the T-cell-lineage 
developmental programme. Nat Rev Immunol. 2008;8:9-21. 
42. Zlotoff DA, Schwarz BA, Bhandoola A. The long road to the thymus: 
the generation, mobilization, and circulation of T-cell progenitors in 
mouse and man. Seminars in Immunopathology. 2008;30:371-382. 
43. Petrie HT, Zúñiga-Pflücker JC. Zoned out: functional mapping of 
stromal signaling microenvironments in the thymus. Annu Rev 
Immunol. 2007;25:649-679. 
44. Anderson G, Jenkinson EJ. Lymphostromal interactions in thymic 
development and function. Nat Rev Immunol. 2001;1:31-40. 
45. van Ewijk W, Shores EW, Singer A. Crosstalk in the mouse thymus. 
Immunol Today. 1994;15:214-217. 
46. Ceredig R, Rolink T. A positive look at double-negative thymocytes. 
Nat Rev Immunol. 2002;2:888-897. 
47. Godfrey DI, Kennedy J, Suda T, Zlotnik A. A developmental pathway 
involving four phenotypically and functionally distinct subsets of CD3-
CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 
and CD25 expression. J Immunol. 1993;150:4244-4252. 
	
  	
  	
   105 
48. von Boehmer H, Aifantis I, Feinberg J, Lechner O, Saint-Ruf C, et al. 
Pleiotropic changes controlled by the pre-T-cell receptor. Curr Opin 
Immunol. 1999;11:135-142. 
49. Aliahmad P, Kaye J. Commitment issues: linking positive selection 
signals and lineage diversification in the thymus. Immunological 
reviews. 2006;209:253-273. 
50. Singer A, Bosselut R. CD4/CD8 coreceptors in thymocyte 
development, selection, and lineage commitment: analysis of the 
CD4/CD8 lineage decision. Adv Immunol. 2004;83:91-131. 
51. Takahama Y. Journey through the thymus: stromal guides for T-cell 
development and selection. Nat Rev Immunol. 2006;6:127-135. 
52. Witt CM, Raychaudhuri S, Schaefer B, Chakraborty AK, Robey EA. 
Directed migration of positively selected thymocytes visualized in real 
time. PLoS Biol. 2005;3:e160. 
53. Palmer E. Negative selection--clearing out the bad apples from the T-
cell repertoire. Nat Rev Immunol. 2003;3:383-391. 
54. Holländer GA, Peterson P. Learning to be tolerant: how T cells keep 
out of trouble. J Intern Med. 2009;265:541-561. 
55. van Ewijk W, Wang B, Hollander G, Kawamoto H, Spanopoulou E, et 
al. Thymic microenvironments, 3-D versus 2-D? Semin Immunol. 
1999;11:57-64. 
56. Gray D, Abramson J, Benoist C, Mathis D. Proliferative arrest and 
rapid turnover of thymic epithelial cells expressing Aire. J Exp Med. 
2007;204:2521-2528. 
57. Gray DH, Seach N, Ueno T, Milton MK, Liston A, et al. 
Developmental kinetics, turnover, and stimulatory capacity of thymic 
epithelial cells. Blood. 2006;108:3777-3785. 
58. Klug DB, Carter C, Gimenez-Conti IB, Richie ER. Cutting edge: 
thymocyte-independent and thymocyte-dependent phases of epithelial 
patterning in the fetal thymus. J Immunol. 2002;169:2842-2845. 
59. Zuklys S, Gill J, Keller MP, Hauri-Hohl M, Zhanybekova S, et al. 
Stabilized beta-catenin in thymic epithelial cells blocks thymus 
development and function. J Immunol. 2009;182:2997-3007. 
60. Lee EN, Park JK, Lee JR, Oh SO, Baek SY, et al. Characterization of 
the expression of cytokeratins 5, 8, and 14 in mouse thymic epithelial 
cells during thymus regeneration following acute thymic involution. 
Anat Cell Biol. 2011;44:14-24. 
	
  	
  	
   106 
61. Bowlus CL, Ahn J, Chu T, Gruen JR. Cloning of a novel MHC-
encoded serine peptidase highly expressed by cortical epithelial cells of 
the thymus. Cell Immunol. 1999;196:80-86. 
62. Farr A, Nelson A, Truex J, Hosier S. Epithelial heterogeneity in the 
murine thymus: a cell surface glycoprotein expressed by subcapsular 
and medullary epithelium. Journal of Histochemistry & Cytochemistry. 
1991;39:645-653. 
63. Gray DH, Fletcher AL, Hammett M, Seach N, Ueno T, et al. Unbiased 
analysis, enrichment and purification of thymic stromal cells. J 
Immunol Methods. 2008;329:56-66. 
64. Derbinski J, Gäbler J, Brors B, Tierling S, Jonnakuty S, et al. 
Promiscuous gene expression in thymic epithelial cells is regulated at 
multiple levels. J Exp Med. 2005;202:33-45. 
65. Dooley J, Erickson M, Farr AG. An organized medullary epithelial 
structure in the normal thymus expresses molecules of respiratory 
epithelium and resembles the epithelial thymic rudiment of nude mice. 
J Immunol. 2005;175:4331-4337. 
66. Gillard GO, Farr AG. Features of medullary thymic epithelium 
implicate postnatal development in maintaining epithelial 
heterogeneity and tissue-restricted antigen expression. J Immunol. 
2006;176:5815-5824. 
67. Zuklys S, Mayer CE, Zhanybekova S, Stefanski HE, Nusspaumer G, et 
al. MicroRNAs control the maintenance of thymic epithelia and their 
competence for T lineage commitment and thymocyte selection. J 
Immunol. 2012;189:3894-3904. 
68. Farr AG, Dooley JL, Erickson M. Organization of thymic medullary 
epithelial heterogeneity: implications for mechanisms of epithelial 
differentiation. Immunol Rev. 2002;189:20-27. 
69. Koble C, Kyewski B. The thymic medulla: a unique microenvironment 
for intercellular self-antigen transfer. J Exp Med. 2009;206:1505-1513. 
70. Kyewski B, Klein L. A central role for central tolerance. Annu Rev 
Immunol. 2006;24:571-606. 
71. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene 
expression in medullary thymic epithelial cells mirrors the peripheral 
self. Nat Immunol. 2001;2:1032-1039. 
	
  	
  	
   107 
72. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, et al. 
Projection of an immunological self shadow within the thymus by the 
aire protein. Science. 2002;298:1395-1401. 
73. Liston A, Gray DH, Lesage S, Fletcher AL, Wilson J, et al. Gene 
dosage--limiting role of Aire in thymic expression, clonal deletion, and 
organ-specific autoimmunity. J Exp Med. 2004;200:1015-1026. 
74. Johnnidis JB, Venanzi ES, Taxman DJ, Ting JP, Benoist CO, Mathis 
DJ. Chromosomal clustering of genes controlled by the aire 
transcription factor. Proc Natl Acad Sci U S A. 2005;102:7233-7238. 
75. Derbinski J, Pinto S, Rösch S, Hexel K, Kyewski B. Promiscuous gene 
expression patterns in single medullary thymic epithelial cells argue for 
a stochastic mechanism. Proc Natl Acad Sci U S A. 2008;105:657-662. 
76. Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. 
The cellular mechanism of Aire control of T cell tolerance. Immunity. 
2005;23:227-239. 
77. Hubert FX, Kinkel SA, Webster KE, Cannon P, Crewther PE, et al. A 
specific anti-Aire antibody reveals aire expression is restricted to 
medullary thymic epithelial cells and not expressed in periphery. J 
Immunol. 2008;180:3824-3832. 
78. Finnish-German APECED Consortium. An autoimmune disease, 
APECED, caused by mutations in a novel gene featuring two PHD-
type zinc-finger domains. Nat Genet. 1997;17:399-403. 
79. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, et al. 
Positional cloning of the APECED gene. Nature genetics. 1997;17:393-
398. 
80. Betterle C, Greggio NA, Volpato M. Clinical review 93: Autoimmune 
polyglandular syndrome type 1. J Clin Endocrinol Metab. 
1998;83:1049-1055. 
81. Vogel A, Strassburg CP, Obermayer-Straub P, Brabant G, Manns MP. 
The genetic background of autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy and its autoimmune disease 
components. J Mol Med (Berl). 2002;80:201-211. 
82. Hamazaki Y, Fujita H, Kobayashi T, Choi Y, Scott HS, et al. 
Medullary thymic epithelial cells expressing Aire represent a unique 
lineage derived from cells expressing claudin. Nat Immunol. 2007;8:304-
311. 
	
  	
  	
   108 
83. Ramsey C, Winqvist O, Puhakka L, Halonen M, Moro A, et al. Aire 
deficient mice develop multiple features of APECED phenotype and 
show altered immune response. Hum Mol Genet. 2002;11:397-409. 
84. Kuroda N, Mitani T, Takeda N, Ishimaru N, Arakaki R, et al. 
Development of autoimmunity against transcriptionally unrepressed 
target antigen in the thymus of Aire-deficient mice. J Immunol. 
2005;174:1862-1870. 
85. DeVoss J, Hou Y, Johannes K, Lu W, Liou GI, et al. Spontaneous 
autoimmunity prevented by thymic expression of a single self-antigen. 
J Exp Med. 2006;203:2727-2735. 
86. Gavanescu I, Kessler B, Ploegh H, Benoist C, Mathis D. Loss of Aire-
dependent thymic expression of a peripheral tissue antigen renders it a 
target of autoimmunity. Proc Natl Acad Sci U S A. 2007;104:4583-
4587. 
87. Mathis D, Benoist C. Aire. Annual review of immunology. 2009;27:287-
312. 
88. Derbinski J, Kyewski B. How thymic antigen presenting cells sample 
the body's self-antigens. Curr Opin Immunol. 2010;22:592-600. 
89. Danzl NM, Donlin LT, Alexandropoulos K. Regulation of medullary 
thymic epithelial cell differentiation and function by the signaling 
protein Sin. J Exp Med. 2010;207:999-1013. 
90. Boehm T, Scheu S, Pfeffer K, Bleul CC. Thymic medullary epithelial 
cell differentiation, thymocyte emigration, and the control of 
autoimmunity require lympho-epithelial cross talk via LTbetaR. J Exp 
Med. 2003;198:757-769. 
91. Engel M, Sidwell T, Vasanthakumar A, Grigoriadis G, Banerjee A. 
Thymic Regulatory T Cell Development: Role of Signalling Pathways 
and Transcription Factors. Clin Dev Immunol. 2013;2013:617595. 
92. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: 
regulatory T cell development and the forkhead family transcription 
factor Foxp3. Nat Immunol. 2005;6:331-337. 
93. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of 
suppression. Trends Mol Med. 2007;13:108-116. 
94. Cowan JE, Parnell SM, Nakamura K, Caamano JH, Lane PJ, et al. 
The thymic medulla is required for Foxp3+ regulatory but not 
conventional CD4+ thymocyte development. J Exp Med. 
2013;210:675-681. 
	
  	
  	
   109 
95. Coquet JM, Ribot JC, Bąbała N, Middendorp S, van der Horst G, et 
al. Epithelial and dendritic cells in the thymic medulla promote 
CD4+Foxp3+ regulatory T cell development via the CD27-CD70 
pathway. J Exp Med. 2013;210:715-728. 
96. Leavy O. Regulatory T cells: the thymic medulla - a cradle for TReg 
cell development. Nat Rev Immunol. 2013;13:304. 
97. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. 
Constitutive class I-restricted exogenous presentation of self antigens 
in vivo. J Exp Med. 1996;184:923-930. 
98. Gallegos AM, Bevan MJ. Central tolerance to tissue-specific antigens 
mediated by direct and indirect antigen presentation. J Exp Med. 
2004;200:1039-1049. 
99. Barnden MJ, Heath WR, Rodda S, Carbone FR. Peptide antagonists 
that promote positive selection are inefficient at T cell activation and 
thymocyte deletion. Eur J Immunol. 1994;24:2452-2456. 
100. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR 
expression in transgenic mice constructed using cDNA-based alpha- 
and beta-chain genes under the control of heterologous regulatory 
elements. Immunol Cell Biol. 1998;76:34-40. 
101. Hakim FT, Gress RE. Reconstitution of the lymphocyte compartment 
after lymphocyte depletion: a key issue in clinical immunology. Eur J 
Immunol. 2005;35:3099-3102. 
102. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution 
following lymphodepletion. Semin Immunol. 2007;19:318-330. 
103. Bahceci E, Epperson D, Douek DC, Melenhorst JJ, Childs RC, Barrett 
AJ. Early reconstitution of the T-cell repertoire after non-
myeloablative peripheral blood stem cell transplantation is from post-
thymic T-cell expansion and is unaffected by graft-versus-host disease 
or mixed chimaerism. Br J Haematol. 2003;122:934-943. 
104. Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE. T-cell 
regeneration after bone marrow transplantation: differential CD45 
isoform expression on thymic-derived versus thymic-independent 
progeny. Blood. 1993;82:2585-2594. 
105. Fallen PR, McGreavey L, Madrigal JA, Potter M, Ethell M, et al. 
Factors affecting reconstitution of the T cell compartment in allogeneic 
haematopoietic cell transplant recipients. Bone Marrow Transplant. 
2003;32:1001-1014. 
	
  	
  	
   110 
106. Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, et al. Age-
dependent incidence, time course, and consequences of thymic renewal 
in adults. Journal of Clinical Investigation. 2005;115:930-939. 
107. Storek J, Geddes M, Khan F, Huard B, Helg C, et al. Reconstitution 
of the immune system after hematopoietic stem cell transplantation in 
humans. Semin Immunopathol. 2008;30:425-437. 
108. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, et al. 
Restoration of immunity in lymphopenic individuals with cancer by 
vaccination and adoptive T-cell transfer. Nat Med. 2005;11:1230-1237. 
109. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic 
hematopoietic cell transplantation following nonmyeloablative 
conditioning. Leukemia. 2006;20:1690-1700. 
110. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, et al. 
Kinetics of engraftment in patients with hematologic malignancies 
given allogeneic hematopoietic cell transplantation after 
nonmyeloablative conditioning. Blood. 2004;104:2254-2262. 
111. Bourgeois C, Stockinger B. T cell homeostasis in steady state and 
lymphopenic conditions. Immunol Lett. 2006;107:89-92. 
112. Jameson SC. T cell homeostasis: keeping useful T cells alive and live T 
cells useful. Semin Immunol. 2005;17:231-237. 
113. Roux E, Dumont-Girard F, Starobinski M, Siegrist CA, Helg C, et al. 
Recovery of immune reactivity after T-cell-depleted bone marrow 
transplantation depends on thymic activity. Blood. 2000;96:2299-2303. 
114. Almeida AR, Borghans JA, Freitas AA. T cell homeostasis: thymus 
regeneration and peripheral T cell restoration in mice with a reduced 
fraction of competent precursors. J Exp Med. 2001;194:591-599. 
115. Brugnoni D, Airò P, Pennacchio M, Carella G, Malagoli A, et al. 
Immune reconstitution after bone marrow transplantation for 
combined immunodeficiencies: down-modulation of Bcl-2 and high 
expression of CD95/Fas account for increased susceptibility to 
spontaneous and activation-induced lymphocyte cell death. Bone 
Marrow Transplant. 1999;23:451-457. 
116. Lin MT, Tseng LH, Frangoul H, Gooley T, Pei J, et al. Increased 
apoptosis of peripheral blood T cells following allogeneic hematopoietic 
cell transplantation. Blood. 2000;95:3832-3839. 
	
  	
  	
   111 
117. Warren EH, Deeg HJ. Dissecting graft-versus-leukemia from graft-
versus-host-disease using novel strategies. Tissue Antigens. 
2013;81:183-193. 
118. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell 
transplantation: individualized stem cell and immune therapy of 
cancer. Nat Rev Cancer. 2010;10:213-221. 
119. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic 
graft-versus-cancer effect. Br J Haematol. 2009;147:614-633. 
120. Vincent K, Roy DC, Perreault C. Next-generation leukemia 
immunotherapy. Blood. 2011;118:2951-2959. 
121. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. 
Feasibility of immunotherapy of relapsed leukemia with ex vivo-
generated cytotoxic T lymphocytes specific for hematopoietic system-
restricted minor histocompatibility antigens. Blood. 1999;93:2336-2341. 
122. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-
leukaemia effect. Nat Rev Cancer. 2004;4:371-380. 
123. Mommaas B, Kamp J, Drijfhout JW, Beekman N, Ossendorp F, et al. 
Identification of a novel HLA-B60-restricted T cell epitope of the 
minor histocompatibility antigen HA-1 locus. J Immunol. 
2002;169:3131-3136. 
124. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, 
Hirano N, et al. The shared tumor-associated antigen cytochrome P450 
1B1 is recognized by specific cytotoxic T cells. Blood. 2003;102:3287-
3294. 
125. Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J, et al. Induction 
of cytotoxic T-cell responses against the oncofetal antigen-immature 
laminin receptor for the treatment of hematologic malignancies. Blood. 
2003;102:4416-4423. 
126. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. 
The Lancet. 2009;373:1550-1561. 
127. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, 
et al. Evaluation of NIH consensus criteria for classification of late 
acute and chronic GVHD. Blood. 2009;114:702-708. 
128. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell 
transplantation. Cancer Control. 2011;18:268-276. 
129. Bacigalupo A, Palandri F. Management of acute graft versus host 
disease (GvHD). Hematol J. 2004;5:189-196. 
	
  	
  	
   112 
130. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, et al. Prospective 
evaluation of 2 acute graft-versus-host (GVHD) grading systems: a 
joint Société Française de Greffe de Moëlle et Thérapie Cellulaire 
(SFGM-TC), Dana Farber Cancer Institute (DFCI), and International 
Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 
2005;106:1495-1500. 
131. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, et al. Risk 
factors for acute GVHD and survival after hematopoietic cell 
transplantation. Blood. 2012;119:296-307. 
132. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, et al. 
Comparative analysis of risk factors for acute graft-versus-host disease 
and for chronic graft-versus-host disease according to National 
Institutes of Health consensus criteria. Blood. 2011;117:3214-3219. 
133. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von 
Bergwelt-Baildon M, et al. Novel treatment concepts for graft-versus-
host disease. Blood. 2012;119:16-25. 
134. Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, et al. HLA 
Association with hematopoietic stem cell transplantation outcome: the 
number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is 
strongly associated with overall survival. Biol Blood Marrow 
Transplant. 2007;13:965-974. 
135. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, 
Filipovich A, et al. Impact of HLA class I and class II high-resolution 
matching on outcomes of unrelated donor bone marrow 
transplantation: HLA-C mismatching is associated with a strong 
adverse effect on transplantation outcome. Blood. 2004;104:1923-1930. 
136. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, et al. Severity of 
chronic graft-versus-host disease: association with treatment-related 
mortality and relapse. Blood. 2002;100:406. 
137. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, et al. Duration of 
immunosuppressive treatment for chronic graft-versus-host disease. 
Blood. 2004;104:3501-3506. 
138. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, et al. Impact of 
chronic graft-versus-host disease on the health status of hematopoietic 
cell transplantation survivors: a report from the Bone Marrow 
Transplant Survivor Study. Blood. 2006;108:2867-2873. 
	
  	
  	
   113 
139. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, et al. 
National Institutes of Health consensus development project on criteria 
for clinical trials in chronic graft-versus-host disease: I. Diagnosis and 
staging working group report. Biol Blood Marrow Transplant. 
2005;11:945-956. 
140. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, et al. Patient-
reported quality of life is associated with severity of chronic graft-
versus-host disease as measured by NIH criteria: report on baseline 
data from the Chronic GVHD Consortium. Blood. 2011;117:4651-4657. 
141. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, et al. 
Chronic GVHD risk score: a Center for International Blood and 
Marrow Transplant Research analysis. Blood. 2011;117:6714-6720. 
142. Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal 
AM, et al. Influence of T-cell depletion on chronic graft-versus-host 
disease: results of a multicenter randomized trial in unrelated marrow 
donor transplantation. Blood. 2005;106:3308-3313. 
143. Linhares YP, Pavletic S, Gale RP. Chronic GVHD: Where are we? 
Where do we want to be? Will immunomodulatory drugs help? Bone 
Marrow Transplant. 2013;48:203-209. 
144. Filipovich AH. Diagnosis and manifestations of chronic graft-versus-
host disease. Best Pract Res Clin Haematol. 2008;21:251-257. 
145. Arai S, Jagasia M, Storer B, Chai X, Pidala J, et al. Global and organ-
specific chronic graft-versus-host disease severity according to the 2005 
NIH Consensus Criteria. Blood. 2011;118:4242-4249. 
146. Hess AD. Equal opportunity targeting in chronic GVHD. Blood. 
2012;119:6183-6184. 
147. Martin PJ. Biology of Chronic Graft-versus-Host Disease: Implications 
for a Future Therapeutic Approach. Keio J Med. 2008;57:177-183. 
148. Pavletic SZ, Lee SJ, Socie G, Vogelsang G. Chronic graft-versus-host 
disease: implications of the National Institutes of Health consensus 
development project on criteria for clinical trials. Bone Marrow 
Transplant. 2006;38:645-651. 
149. Pavletic SZ, Fowler DH. Are we making progress in GVHD 
prophylaxis and treatment? Hematology Am Soc Hematol Educ 
Program. 2012;2012:251-264. 
150. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: 
advances and limitations. Dis Model Mech. 2011;4:318-333. 
	
  	
  	
   114 
151. Matzinger P. The danger model: a renewed sense of self. Science. 
2002;296:301-305. 
152. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a 
target organ of acute graft-versus-host disease: rationale for the use of 
cytokine shields in allogeneic bone marrow transplantation. Blood. 
2000;95:2754-2759. 
153. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating 
innate immunity in graft-versus-host disease. J Mol Med (Berl). 
2011;89:833-845. 
154. Wilhelm K, Ganesan J, Müller T, Dürr C, Grimm M, et al. Graft-
versus-host disease is enhanced by extracellular ATP activating 
P2X7R. Nat Med. 2010;16:1434-1438. 
155. Chakraverty R, Sykes M. The role of antigen-presenting cells in 
triggering graft-versus-host disease and graft-versus-leukemia. Blood. 
2007;110:9-17. 
156. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, et al. Acute graft-
versus-host disease does not require alloantigen expression on host 
epithelium. Nature medicine. 2002;8:575-581. 
157. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. 
Semin Hematol. 2006;43:3-10. 
158. Goulmy E. Minor histocompatibility antigens: from transplantation 
problems to therapy of cancer. Hum Immunol. 2006;67:433-438. 
159. Hambach L, Spierings E, Goulmy E. Risk assessment in 
haematopoietic stem cell transplantation: minor histocompatibility 
antigens. Best Pract Res Clin Haematol. 2007;20:171-187. 
160. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor 
CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-
host disease without impairing allogeneic engraftment in sublethally 
irradiated mice. Blood. 1994;84:3540-3549. 
161. Yang Y-G, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived 
interferon gamma is required for inhibition of acute graft-versus-host 
disease by interleukin 12. Journal of Clinical Investigation. 
1998;102:2126. 
162. Hauri-Hohl MM, Keller MP, Gill J, Hafen K, Pachlatko E, et al. 
Donor T-cell alloreactivity against host thymic epithelium limits T-cell 
development after bone marrow transplantation. Blood. 2007;109:4080-
4088. 
	
  	
  	
   115 
163. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta 
treatment prevents skin and lung fibrosis in murine sclerodermatous 
graft-versus-host disease: a model for human scleroderma. J Immunol. 
1999;163:5693-5699. 
164. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, et al. Donor CD4+ 
T and B cells in transplants induce chronic graft-versus-host disease 
with autoimmune manifestations. Blood. 2006;107:2993-3001. 
165. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, et al. Rituximab 
for steroid-refractory chronic graft-versus-host disease. Blood. 
2006;108:756-762. 
166. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, 
Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 
cells is responsible for the autoimmune-mediated pathology in chronic 
graft-versus-host disease. Blood. 2007;110:3804-3813. 
167. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, 
Shlomchik MJ. Recipient CD4+ T cells that survive irradiation 
regulate chronic graft-versus-host disease. Blood. 2004;104:1565-1573. 
168. Fujita S, Sato Y, Sato K, Eizumi K, Fukaya T, et al. Regulatory 
dendritic cells protect against cutaneous chronic graft-versus-host 
disease mediated through CD4+CD25+Foxp3+ regulatory T cells. 
Blood. 2007;110:3793-3803. 
169. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, et al. 
Association of Foxp3 regulatory gene expression with graft-versus-host 
disease. Blood. 2004;104:2187-2193. 
170. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, et al. Reduced frequency 
of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic 
graft-versus-host disease. Blood. 2005;106:2903-2911. 
171. Meignin V, Peffault de Latour R, Zuber J, Régnault A, Mounier N, et 
al. Numbers of Foxp3-expressing CD4+CD25high T cells do not 
correlate with the establishment of long-term tolerance after allogeneic 
stem cell transplantation. Exp Hematol. 2005;33:894-900. 
172. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. 
FOXP3 expression in peripheral blood rapidly recovers and lacks 
correlation with the occurrence of graft-versus-host disease after 
allogeneic stem cell transplantation. International journal of 
hematology. 2007;85:154-162. 
	
  	
  	
   116 
173. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, et al. Mucosal 
FOXP3+ regulatory T cells are numerically deficient in acute and 
chronic GvHD. Blood. 2006;107:1717-1723. 
174. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, et al. 
Altered regulatory T cell homeostasis in patients with CD4+ 
lymphopenia following allogeneic hematopoietic stem cell 
transplantation. J Clin Invest. 2010;120:1479-1493. 
175. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, et al. 
Interleukin-2 and regulatory T cells in graft-versus-host disease. N 
Engl J Med. 2011;365:2055-2066. 
176. Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoé K. 
Abrogation of negative selection by GVHR induced by minor 
histocompatibility antigens or H-2D antigen alone. Immunobiology. 
2000;202:268-279. 
177. Holländer GA, Widmer B, Burakoff SJ. Loss of normal thymic 
repertoire selection and persistence of autoreactive T cells in graft vs 
host disease. J Immunol. 1994;152:1609-1617. 
178. van den Brink MR, Moore E, Ferrara JL, Burakoff SJ. Graft-versus-
host-disease-associated thymic damage results in the appearance of T 
cell clones with anti-host reactivity. Transplantation. 2000;69:446-449. 
179. Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL. 
Impaired thymic negative selection causes autoimmune graft-versus-
host disease. Blood. 2003;102:429-435. 
180. Zhang Y, Hexner E, Frank D, Emerson SG. CD4+ T cells generated 
de novo from donor hemopoietic stem cells mediate the evolution from 
acute to chronic graft-versus-host disease. J Immunol. 2007;179:3305-
3314. 
181. Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, et al. 
Donor-derived thymic-dependent T cells cause chronic graft-versus-
host disease. Blood. 2007;109:1756-1764. 
182. Hakim FT, Payne S, Shearer GM. Recovery of T cell populations after 
acute graft-vs-host reaction. The Journal of Immunology. 1994;152:58-
64. 
183. Zhao D, Young JS, Chen YH, Shen E, Yi T, et al. Alloimmune 
response results in expansion of autoreactive donor CD4+ T cells in 
transplants that can mediate chronic graft-versus-host disease. J 
Immunol. 2011;186:856-868. 
	
  	
  	
   117 
184. Rangarajan H, Yassai M, Subramanian H, Komorowski R, Whitaker 
M, et al. Emergence of T cells that recognize nonpolymorphic antigens 
during graft-versus- host disease. Blood. 2012;119:6354-6364. 
185. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in 
graft-versus-host disease. Blood. 2005;105:4885-4891. 
186. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: 
immunobiology, prevention, and treatment. Stem Cells Transl Med. 
2013;2:25-32. 
187. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-
versus-host disease prophylaxis for allogeneic hematopoietic stem cell 
transplantation. Blood. 2001;98:3192-3204. 
188. Platzbecker U, Ehninger G, Bornhäuser M. Allogeneic transplantation 
of CD34+ selected hematopoietic cells--clinical problems and current 
challenges. Leuk Lymphoma. 2004;45:447-453. 
189. Wagner JE, Thompson JS, Carter SL, Kernan NA, Unrelated Donor 
Marrow Transplantation Trial. Effect of graft-versus-host disease 
prophylaxis on 3-year disease-free survival in recipients of unrelated 
donor bone marrow (T-cell Depletion Trial): a multi-centre, 
randomised phase II-III trial. Lancet. 2005;366:733-741. 
190. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, et al. Acute 
and chronic graft-versus-host disease after ablative and 
nonmyeloablative conditioning for allogeneic hematopoietic 
transplantation. Biology of Blood and Marrow Transplantation. 
2004;10:178-185. 
191. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, et al. 
Comparing morbidity and mortality of HLA-matched unrelated donor 
hematopoietic cell transplantation after nonmyeloablative and 
myeloablative conditioning: influence of pretransplantation 
comorbidities. Blood. 2004;104:961-968. 
192. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, et 
al. Graft-versus-host disease after nonmyeloablative versus 
conventional hematopoietic stem cell transplantation. Blood. 
2003;102:756-762. 
193. Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, 
et al. Nonmyeloablative transplantation with or without alemtuzumab: 
comparison between 2 prospective studies in patients with 
lymphoproliferative disorders. Blood. 2002;100:3121-3127. 
	
  	
  	
   118 
194. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, et al. 
Chronic graft-versus-host disease: long-term results from a randomized 
trial on graft-versus-host disease prophylaxis with or without anti-T-
cell globulin ATG-Fresenius. Blood. 2011;117:6375-6382. 
195. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, et al. Impact of 
immune modulation with anti-T-cell antibodies on the outcome of 
reduced-intensity allogeneic hematopoietic stem cell transplantation for 
hematologic malignancies. Blood. 2011;117:6963-6970. 
196. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host 
disease in 2011. Current Opinion in Hematology. 2011;18:414-420. 
197. Clave E, Busson M, Douay C, Peffault de Latour R, Berrou J, et al. 
Acute graft versus host disease transiently impairs thymic output in 
young patients after allogeneic hematopoietic stem cell transplantation. 
Blood. 2009;113:6477-6484. 
198. Olkinuora H, von Willebrand E, Kantele JM, Vainio O, Talvensaari K, 
et al. The impact of early viral infections and graft-versus-host disease 
on immune reconstitution following paediatric stem cell 
transplantation. Scand J Immunol. 2011;73:586-593. 
199. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos 
EB, et al. Long-term follow-up of patients treated with daclizumab for 
steroid-refractory acute graft-vs-host disease. Bone Marrow 
Transplant. 2007;40:481-486. 
200. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. 
Treatment of steroid refractory acute and chronic graft-versus-host 
disease with daclizumab. Br J Haematol. 2001;112:820-823. 
201. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor 
outcome in steroid-refractory graft-versus-host disease with 
antithymocyte globulin treatment. Biology of Blood and Marrow 
Transplantation. 2002;8:155-160. 
202. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, et al. 
Treatment of steroid-resistant acute graft-versus-host disease with 
rabbit antithymocyte globulin. J Hematother Stem Cell Res. 
2000;9:367-374. 
203. Remberger M, Ringden O, Aschan J, Ljungman P, Lönnqvist B, 
Markling L. Long-term follow-up of a randomized trial comparing T-
cell depletion with a combination of methotrexate and cyclosporine in 
	
  	
  	
   119 
adult leukemic marrow transplant recipients. Transplant Proc. 
1994;26:1829-1830. 
204. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, et al. 
Treatment of steroid-resistant acute graft-versus-host disease with 
anti-thymocyte globulin. Bone Marrow Transplant. 2001;27:1059-1064. 
205. Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, et al. Factors 
affecting thymic function after allogeneic hematopoietic stem cell 
transplantation. Blood. 2001;97:1458-1466. 
206. Hakim FT, Gress RE. Reconstitution of thymic function after stem cell 
transplantation in humans. Curr Opin Hematol. 2002;9:490-496. 
207. Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, et al. A 
broad T-cell repertoire diversity and an efficient thymic function 
indicate a favorable long-term immune reconstitution after cord blood 
stem cell transplantation. Blood. 2002;99:1458. 
208. Seddik M, Seemayer TA, Lapp WS. T cell functional defect associated 
with thymid epithelial cell injury induced by a graft-versus-host 
reaction. Transplantation. 1980;29:61-66. 
209. Seemayer TA, Lapp WS, Bolande RP. Thymic epithelial injury in 
graft-versus-host reactions following adrenalectomy. Am J Pathol. 
1978;93:325-338. 
210. Lapp WS, Ghayur T, Mendes M, Seddik M, Seemayer TA. The 
functional and histological basis for graft-versus-host-induced 
immunosuppression. Immunol Rev. 1985;88:107-133. 
211. Seemayer TA, Bolande RP. Thymic involution mimicking thymic 
dysplasia: a consequence of transfusion-induced graft versus host 
disease in a premature infant. Arch Pathol Lab Med. 1980;104:141-144. 
212. Krenger W, Holländer GA. The immunopathology of thymic GVHD. 
Semin Immunopathol. 2008;30:439-456. 
213. Krenger W, Schmidlin H, Cavadini G, Holländer GA. On the relevance 
of TCR rearrangement circles as molecular markers for thymic output 
during experimental graft-versus-host disease. J Immunol. 
2004;172:7359-7367. 
214. Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, et al. Direct 
evidence for new T-cell generation by patients after either T-cell-
depleted or unmodified allogeneic hematopoietic stem cell 
transplantations. Blood. 2002;100:2235-2242. 
	
  	
  	
   120 
215. Storek J, Joseph A, Dawson MA, Douek DC, Storer B, Maloney DG. 
Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell 
transplantation. Transplantation. 2002;73:1154-1158. 
216. Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL, et al. 
Keratinocyte growth factor preserves normal thymopoiesis and thymic 
microenvironment during experimental graft-versus-host disease. 
Blood. 2002;100:682-691. 
217. Krenger W, Rossi S, Holländer GA. Apoptosis of thymocytes during 
acute graft-versus-host disease is independent of glucocorticoids. 
Transplantation. 2000;69:2190-2193. 
218. Kumamoto T, Inaba M, Toki J, Adachi Y, Imamura H, Ikehara S. 
Cytotoxic effects of irradiation and deoxyguanosine on fetal thymus. 
Immunobiology. 1995;192:365-381. 
219. Pénit C, Lucas B, Vasseur F. Cell expansion and growth arrest phases 
during the transition from precursor (CD4-8-) to immature (CD4+8+) 
thymocytes in normal and genetically modified mice. J Immunol. 
1995;154:5103-5113. 
220. Rodewald HR, Fehling HJ. Molecular and cellular events in early 
thymocyte development. Adv Immunol. 1998;69:1-112. 
221. Krenger W, Rossi S, Piali L, Holländer GA. Thymic atrophy in murine 
acute graft-versus-host disease is effected by impaired cell cycle 
progression of host pro-T and pre-T cells. Blood. 2000;96:347-354. 
222. Krenger W, Holländer GA. The thymus in GVHD pathophysiology. 
Best Pract Res Clin Haematol. 2008;21:119-128. 
223. Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, et al. The cytolytic 
molecules Fas ligand and TRAIL are required for murine thymic graft-
versus-host disease. J Clin Invest. 2010;120:343-356. 
224. Wu T, Young JS, Johnston H, Ni X, Deng R, et al. Thymic damage, 
impaired negative selection, and development of chronic graft-versus-
host disease caused by donor CD4+ and CD8+ T cells. J Immunol. 
2013;191:488-499. 
225. Dertschnig S, Nusspaumer G, Ivanek R, Hauri-Hohl MM, Holländer 
GA, Krenger W. Epithelial cytoprotection sustains ectopic expression 
of tissue-restricted antigens in the thymus during murine acute GVHD. 
Blood. 2013;122:837-841. 
226. Weinberg KI. ProTECtion from posttransplantation immune 
deficiency? Blood. 2007;109:3617-2618. 
	
  	
  	
   121 
227. Holländer GA, Krenger W, Blazar BR. Emerging strategies to boost 
thymic function. Curr Opin Pharmacol. 2010. 
228. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth 
factor 7, a homeostatic factor with therapeutic potential for epithelial 
protection and repair. Adv Cancer Res. 2004;91:69-136. 
229. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, et al. 
Palifermin for oral mucositis after intensive therapy for hematologic 
cancers. N Engl J Med. 2004;351:2590-2598. 
230. Radtke ML, Kolesar JM. Palifermin (Kepivance) for the treatment of 
oral mucositis in patients with hematologic malignancies requiring 
hematopoietic stem cell support. J Oncol Pharm Pract. 2005;11:121-
125. 
231. Siddiqui MA, Wellington K. Palifermin: in myelotoxic therapy-induced 
oral mucositis. Drugs. 2005;65:2139-46; discussion 2147-9. 
232. Turner N, Grose R. Fibroblast growth factor signalling: from 
development to cancer. Nature Reviews Cancer. 2010;10:116-129. 
233. Werner S. Keratinocyte growth factor: a unique player in epithelial 
repair processes. Cytokine & growth factor reviews. 1998;9:153-165. 
234. Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors 
and their receptors in hematopoiesis and hematological tumors. J 
Hematother Stem Cell Res. 2002;11:19-32. 
235. Erickson M, Morkowski S, Lehar S, Gillard G, Beers C, et al. 
Regulation of thymic epithelium by keratinocyte growth factor. Blood. 
2002;100:3269-3278. 
236. Revest JM, Suniara RK, Kerr K, Owen JJ, Dickson C. Development of 
the thymus requires signaling through the fibroblast growth factor 
receptor R2-IIIb. J Immunol. 2001;167:1954-1961. 
237. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, 
Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of 
Shh and Fgf4 and is required for limb bud maintenance but not for the 
induction of Fgf8, Fgf10, Msx1, or Bmp4. Dev Biol. 2001;231:47-62. 
238. Suniara RK, Jenkinson EJ, Owen JJ. An essential role for thymic 
mesenchyme in early T cell development. J Exp Med. 2000;191:1051-
1056. 
239. Rossi SW, Jeker LT, Ueno T, Kuse S, Keller MP, et al. Keratinocyte 
growth factor (KGF) enhances postnatal T-cell development via 
	
  	
  	
   122 
enhancements in proliferation and function of thymic epithelial cells. 
Blood. 2007;109:3803-3811. 
240. Alpdogan O, Hubbard VM, Smith OM, Patel N, Lu S, et al. 
Keratinocyte growth factor (KGF) is required for postnatal thymic 
regeneration. Blood. 2006;107:2453-2460. 
241. Min D, Panoskaltsis-Mortari A, Kuro-O M, Holländer GA, Blazar BR, 
Weinberg KI. Sustained thymopoiesis and improvement in functional 
immunity induced by exogenous KGF administration in murine models 
of aging. Blood. 2007;109:2529-2537. 
242. Chu -W, Hakim  T. KGF boosts thymic archiTECture. Blood. 
2007;109:3613-3614. 
243. Wang Y, Chen G, Qiao S, Ma X, Tang X, et al. Keratinocyte growth 
factor enhanced immune reconstitution in murine allogeneic umbilical 
cord blood cell transplant. Leukemia & Lymphoma. 2011;52:1556-1566. 
244. Ben-Sasson SZ, Gerstel R, Hu-Li J, Paul WE. Cell division is not a 
"clock" measuring acquisition of competence to produce IFN-gamma or 
IL-4. J Immunol. 2001;166:112-120. 
245. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et 
al. Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics. 2003;4:249-264. 
246. Grunkemeier GL, Wu Y. What are the odds? Ann Thorac Surg. 
2007;83:1240-1244. 
247. Gotter J. Medullary epithelial cells of the human thymus express a 
highly diverse selection of tissue-specific genes colocalized in 
chromosomal clusters. J Exp Med. 2004;199:155-166. 
248. Anderson MS, Su MA. Aire and T cell development. Curr Opin 
Immunol. 2011;23:198-206. 
249. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen 
presentation in the thymus for positive selection and central tolerance 
induction. Nat Rev Immunol. 2009;9:833-844. 
250. Hu Q, Nicol SA, Suen AY, Baldwin TA. Examination of thymic 
positive and negative selection by flow cytometry. J Vis Exp. 2012. 
251. Suen AY, Baldwin TA. Proapoptotic protein Bim is differentially 
required during thymic clonal deletion to ubiquitous versus tissue-
restricted antigens. Proc Natl Acad Sci U S A. 2012;109:893-898. 
	
  	
  	
   123 
252. Hubert FX, Kinkel SA, Davey GM, Phipson B, Mueller SN, et al. Aire 
regulates the transfer of antigen from mTECs to dendritic cells for 
induction of thymic tolerance. Blood. 2011;118:2462-2472. 
253. Metzger TC, Khan IS, Gardner JM, Mouchess ML, Johannes KP, et 
al. Lineage tracing and cell ablation identify a post-aire-expressing 
thymic epithelial cell population. Cell Rep. 2013;5:166-179. 
254. Martinez RJ, Zhang N, Thomas SR, Nandiwada SL, Jenkins MK, et 
al. Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi 
anergic state in the presence of Foxp3+ regulatory T cells. J Immunol. 
2012;188:170-181. 
255. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. 
T regulatory and primed uncommitted CD4 T cells express CD73, 
which suppresses effector CD4 T cells by converting 5'-adenosine 
monophosphate to adenosine. J Immunol. 2006;177:6780-6786. 
256. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, et al. 
Control of immune responses by antigen-specific regulatory T cells 
expressing the folate receptor. Immunity. 2007;27:145-159. 
257. Balzar M, Winter J, de Boer J, Not Available SL. The biology of the 
17-1A antigen (Ep-CAM). Journal of Molecular Medicine. 1999;77:699-
712. 
258. Blackburn CC, Augustine CL, Li R, Harvey RP, Malin MA, et al. The 
nu gene acts cell-autonomously and is required for differentiation of 
thymic epithelial progenitors. Proc Natl Acad Sci U S A. 1996;93:5742-
5746. 
259. Dudakov JA, Hanash AM, Jenq RR, Young LF, Ghosh A, et al. 
Interleukin-22 drives endogenous thymic regeneration in mice. Science. 
2012;336:91-95. 
260. Fletcher AL, Lowen TE, Sakkal S, Reiseger JJ, Hammett MV, et al. 
Ablation and regeneration of tolerance-inducing medullary thymic 
epithelial cells after cyclosporine, cyclophosphamide, and 
dexamethasone treatment. J Immunol. 2009;183:823-831. 
261. Su MA, Giang K, Zumer K, Jiang H, Oven I, et al. Mechanisms of an 
autoimmunity syndrome in mice caused by a dominant mutation in 
Aire. J Clin Invest. 2008;118:1712-1726. 
262. Ukena SN, Grosse J, Mischak-Weissinger E, Buchholz S, Stadler M, et 
al. Acute but not chronic graft-versus-host disease is associated with a 
	
  	
  	
   124 
reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory 
T cells. Ann Hematol. 2011;90:213-218. 
263. Hänninen A, Nurmela R, Maksimow M, Heino J, Jalkanen S, Kurts C. 
Islet beta-cell-specific T cells can use different homing mechanisms to 
infiltrate and destroy pancreatic islets. Am J Pathol. 2007;170:240-250. 
264. 264. Gagnerault -C, Luan  J, Lotton C, Lepault F. Pancreatic Lymph 
Nodes Are Required for Priming of   Cell Reactive T Cells in NOD 
Mice. Journal of Experimental Medicine. 2002;196:369-377. 
265. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated 
suppression. Immunity. 2009;30:636-645. 
266. Parkman R. A 2-hit model for chronic GVHD. Blood. 2013;122:623-
624. 
267. Enouz S, Carrié L, Merkler D, Bevan MJ, Zehn D. Autoreactive T 
cells bypass negative selection and respond to self-antigen stimulation 
during infection. J Exp Med. 2012;209:1769-1779. 
268. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, 
et al. The influence of palifermin (Kepivance) on oral mucositis and 
acute graft versus host disease in patients with hematological diseases 
undergoing hematopoietic stem cell transplant. Bone Marrow 
Transplant. 2007;40:983-988. 
269. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, et al. 
Palifermin reduces incidence and severity of oral mucositis in allogeneic 
stem-cell transplant recipients. Bone Marrow Transplant. 2008;42:275-
279. 
270. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, et al. Phase 
1/2 randomized, placebo-control trial of palifermin to prevent graft-
versus-host disease (GVHD) after allogeneic hematopoietic stem cell 
transplantation (HSCT). Blood. 2006;108:3216-3222. 
271. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term 
follow-up of a phase I/II randomized, placebo-controlled trial of 
palifermin to prevent graft-versus-host disease (GVHD) after related 
donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood 
Marrow Transplant. 2008;14:1017-1021. 
272. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, et al. 
Keratinocyte growth factor separates graft-versus-leukemia effects from 
graft-versus-host disease. Blood. 1999;94:825-831. 
	
  	
  	
   125 
273. Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, et al. 
Palifermin for the reduction of acute GVHD: a randomized, double-
blind, placebo-controlled trial. Bone Marrow Transplant. 2012;47:1350-
1355. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
  	
  	
   126 
8. ACKNOWLEDGEMENTS  
First and foremost a big thank you to Werner Krenger who 
supported and advised me throughout my PhD years. It was a big pleasure 
to have you as a supervisor, you taught me a lot, and I think we had a 
good time, not only science related but also auf den Brettern, die die Welt 
bedeuten. The second, but not less important, thank you goes to Georg A. 
Holländer for letting me work in his lab, independently and free, and giving 
me the right support when it was needed. I always appreciate your 
feedback. There are many people in and around the lab without whom I 
would not have been able to finish this work and I would like to mention 
them here in no specific order. A big thanks to Robert Ivanek for helping 
me tremendously with the microarray analysis and introducing me into R, 
Katrin Hafen for teaching me everything about the mouse, Gretel 
Nusspaumer for supporting me in experiment planning, Mathias M. Hauri 
for scientific support and shipping boneys from Seattle, to all the other girls 
and boys from the lab for cheerful moments, for lunch times, for solving my 
computer problems, for i.p. injections when I was too busy, for watching 
the royal wedding, for gossip chitchats, and for many other things, thank 
you Angela, Noriko, Elisa, Chiara, Caroline, Saule, Martha, Elli, Tatjana, 
Annick, Hong Ying, Sanjay, Carlos, Gabor, Thomas and Saulius. I would 
also like to acknowledge Prof. Christoph Hess and Prof. Jean Pieters as 
members of my PhD committee.  
Beside the science world, there are many people who are here when 
I need them and contribute substantially to me being smiley and happy. 
Daniel, thank you for everything you give me, be it in easy or rather 
difficult moments. I know, I can be quite “pesante”, especially when I’m 
about to finish my PhD…thanks for being here for me, supporting me and 
for your love. Danke Papi! Ich möchte keine grossen Worte verlieren, 
sondern einfach Danke sagen. Last but not least, I would like to remember 
my mum. I know that she is with me and knowing her support gave me 
power and strength to reach this and many other targets in my life. She 
would be happy now.  	
  	
  	
  	
  
	
  	
  	
   127 
9. APPENDIX 	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
  	
  	
   128 
doi:10.1182/blood-2012-12-474759
Prepublished online May 29, 2013;
2013 122: 837-841
 
 
 
 
and Werner Krenger
Simone Dertschnig, Gretel Nusspaumer, Robert Ivanek, Mathias M. Hauri-Hohl, Georg A. Holländer
 
tissue-restricted antigens in the thymus during murine acute GVHD
Epithelial cytoprotection sustains ectopic expression of
 http://bloodjournal.hematologylibrary.org/content/122/5/837.full.html
Updated information and services can be found at:
 (1890 articles)Transplantation    
 (1664 articles)Brief Reports    
Articles on similar topics can be found in the following Blood collections
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
 http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
 Copyright 2011 by The American Society of Hematology; all rights reserved.
Washington DC 20036.
by the American Society of Hematology, 2021 L St, NW, Suite 900, 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly
 
 
 
 
 For personal use only. at MEDIZINBIBLIOTEK on August 2, 2013. bloodjournal.hematologylibrary.orgFrom 
	
  	
  	
   129 
Brief Report
TRANSPLANTATION
Epithelial cytoprotection sustains ectopic expression of tissue-restricted
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Key Points
• Acute GVHD predisposes to
autoimmune chronic GVHD,
but it is currently unclear how
autoimmunity is linked to
antecedent alloimmunity.
• Loss of central tolerance
induction that occurs via
functional compromise of
thymic epithelial cells may
provide such a pathogenic link.
Development of acute graft-versus-host disease (aGVHD) predisposes to chronic GVHD
with autoimmune manifestations. A characteristic of experimental aGVHD is the de novo
generation of autoreactive T cells. Central tolerance is dependent on the intrathymic ex-
pression of tissue-restricted peripheral self-antigens (TRA), which is in mature medullary
thymic epithelial cells (mTEChigh) partly controlled by the autoimmune regulator (Aire).
Because TECs are targets of donor T-cell alloimmunity, we tested whether murine aGVHD
interferedwith the capacity of recipient Aire1mTEChigh to sustain TRA diversity. We report
that aGVHDweakens the platform for central tolerance induction because individual TRAs
are purged from the total repertoire secondary to a decline in the Aire1mTEChigh cell
pool. Peritransplant administration of an epithelial cytoprotective agent, fibroblast growth
factor-7, maintained a stable pool of Aire1mTEChigh, with an improved TRA transcriptome
despite aGVHD. Taken together, our data provide a mechanism for how autoimmunity may
develop in the context of antecedent alloimmunity. (Blood. 2013;122(5):837-841)
Introduction
Self-tolerance of the nascent T-cell receptor repertoire is attained
through negative selection in the thymus.1 Essential for clonal
deletion is the exposure of thymocytes to self-antigens, including
those with highly restricted tissue expression. Within the thymus,
the ectopic expression of many tissue-restricted peripheral self-
antigens (TRAs) is a distinct property of mature medullary thymic
epithelial cells (mTEChigh).2,3 TRA expression is controlled partly
by the transcription factor autoimmune regulator (Aire).3 Deficits
in Aire and/or TRA expression (independent of their causes)
impair negative selection and can consequently cause autoimmune
disease.2-5
Acute and chronic graft-versus-host disease (aGVHDand cGVHD,
respectively) remain the primary complications of allogeneic hema-
topoietic stem cell transplantation (allo-HSCT).6 aGVHD is initiated
by alloreactive donor T cells and targets a restricted set of tissues,
including the thymus.7,8 The development of human aGVHD pre-
disposes to cGVHD, whose autoimmune manifestations are integral
components of disease.9 It remains uncertain, however, whether and
how autoimmunity is linked to antecedent alloimmunity. A hallmark
of murine aGVHD is the de novo generation of autoreactive T cells
from donor HSC10,11 which can mediate the evolution from acute to
chronic GVHD.12,13 Because the thymic epithelium is a target of
donor T-cell alloimmunity,7,8,14 we hypothesized that thymic
aGVHD interferes with the mTEChigh capacity to sustain TRA
diversity, thus decreasing the platform for central tolerance. In this
context, interventions directed at epithelial cytoprotection are
expected to maintain posttransplantation mTEChigh integrity and
function. To test these 2 interrelated hypotheses, we used murine
allo-HSCT models and investigated the effects of fibroblast growth
factor-7 (Fgf7), which boosts thymopoiesis through its mitogenic
action on TEC.15,16
Study design
Female C57BL/6 (B6;H-2b), (C57BL/6xDBA/2)F1 (BDF1;H-2
bd), Balb/c
(H-2d), CBy.PL(B6)-Thy1a/ScrJ (Balb/c-Thy1.1;H-2d), 129/Sv (H-2b), and
B6.SJL-PtprcaPep3b/BoyJ (B6.CD45.1;H-2b) mice were kept in accordance
with federal regulations. Thymic aGVHD was induced in unirradiated or total
body–irradiated recipients14 (supplemental Figure 1). Recombinant human
Fgf7 (palifermin, Kepivance, Biovitrum, Sweden) was injected intraper-
itoneally from day 23 to day 13 after allo-HSCT at a dose of 5 mg/kg
per day.15,16
Confocal microscopy of thymic sections was performed using a Zeiss
LSM510 (Carl-Zeiss AG, Switzerland).17 The TEC compartment was
analyzed by flow cytometry (FACSAria, Becton Dickinson, Mountain
View, CA). mTEChigh were identified as cells with a CD45-EpCam1Ly51-
UEA11MHCIIhigh phenotype17-19 (supplemental Figure 2). Global gene ex-
pression profiling was used to establish TRA diversity in transplant recipients.
Microarray data of triplicate samples of pure mTEChigh preparations (Mouse
Gene 1.0 ST Array, Affymetrix, Santa Clara, CA; data available under
Submitted December 19, 2012; accepted May 17, 2013. Prepublished online
as Blood First Edition paper, May 29, 2013; DOI 10.1182/blood-2012-12-
474759.
G.A.H. and W.K. contributed equally to this study.
The online version of this article contains a data supplement.
There is an Inside Blood commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2013 by The American Society of Hematology
BLOOD, 1 AUGUST 2013 x VOLUME 122, NUMBER 5 837
 For personal use only. at MEDIZINBIBLIOTEK on August 2, 2013. bloodjournal.hematologylibrary.orgFrom 
	
  	
  	
   130   
accession number E-MEXP-3745 at http://www.ebi.ac.uk/arrayexpress) were
verified by quantitative polymerase chaine reaction. Gene expression data from
multiple published sources20,21 and from MOE430 and GNF1M gene atlases
(http://biogps.org) were combined for identification of Aire-dependent and
Aire-independent TRA (supplemental Methods). Bioinformatics was imple-
mented using software from “The R Project for Statistical Computing” (http://
www.r-project.org).
Results and discussion
Total numbers of mTEChigh declined over time in untransplanted
adult BDF1 and B6 mice, confirming age-dependent changes of the
thymic stroma22 (Figure 1A-B).We then investigated 4mousemodels
of age-matched allo-HSCT. In unconditioned recipients of hap-
loidentical HSCT (H-2b→H-2bd; b→bd), the induction of thymic
aGVHD14,15 (supplemental Figures 1 and 2) progressively reduced
total mTEChigh numbers to <103 cells/mouse in animals surviving
aGVHD (Figure 1A). This observation was mirrored in allo-HSCT that
included total body–irradiated before MHC-identical, MHC-
disparate, or haploidentical transplantation (Figure 1B). In these
models, the conditioning initially reduced mTEChigh numbers
independently of aGVHD, but cell loss was either more pronounced
(b→bd) or more protracted (d→b; b→b) in the presence of disease.
Hence, reduction in mTEChigh compartment size is a universal
manifestation of thymic aGVHD,7 and radiation injury is not
mandatory. Contraction of the total mTEChigh pool in unconditioned
b→bd recipients corresponded to progressive decreases in the subset
that expresses Aire5,23 (Figure 1C-E). In 12-week-old recipients,
residual Aire1mTEChigh were low in numbers (,300 cells/thymus)
and later became virtually undetectable, owing to the smaller than
normal frequencies of Aire-expressing cells among declining
mTEChigh numbers.
Given the intimate associations among Aire-deficiency, TRA re-
pression, and autoimmunity,3 we determined whether aGVHD inter-
fered with TRA transcription. Development of thymic GVHD (b→bd)
altered global gene expression profiles in total residual mTEChigh
cell pools isolated at 2 to 4 weeks after transplantation (Figure 2A,
supplemental Table 1). Using a special algorithm (supplemental
Figure 1. Acute GVHD impairs mTEChigh compartment size. The mTEChigh compartment was analyzed as a function of recipient age in 4 different murine models of allo-
HSCT, as detailed in supplemental Figures 1 and 2. (A) Acute GVHD was induced in 8-week-old unconditioned BDF1 recipients (b→bd, black circles). Untransplanted BDF1
mice (gray squares) or syngeneically transplanted mice (bd→bd, open circles) served as controls. In 1 group, Fgf7 was administered (b→bd 1 Fgf7, triangles) as described.15
A total of 6 experiments were performed, with 3 to 5 mice per group and experiment. (B) Acute GVHD (TCD1T group, black circles) was induced in irradiated 8-week-old
BDF1 recipients (b→bd, left panel), 9-week-old B6 recipients (d→b, middle panel) or 8-week-old B6 recipients (b→b, right panel) as described in supplemental Figures 1 and 2.
Untransplanted BDF1 or B6 mice (gray squares) and recipients of TCD bone marrow (TCD group, open circles) were used as controls without disease in all models. A total of 3
experiments were performed. The line graphs show total numbers (mean 6 SD) of mTEChigh cells in thymi from individual mice. *P , .05, analysis of variance (ANOVA), aGVHD
versus transplanted mice without aGVHD. TCD, T-cell–depleted; n.d., not done. (C-E) Qualitative and quantitative analysis of thymic Aire expression, as described in supplemental
Methods. Immunohistochemistry and confocal microscope analysis (C) was performed on thymic frozen sections taken from unconditioned transplant recipients at ages 10, 12, and
15 weeks (ie, 2, 4, and 7 weeks after transplantation; [i-iii] bd→bd, [iv-vi] b→bd, [vii-ix] b→bd 1 Fgf7). Cytokeratin-18 (CK18, blue) and CK14-positive cells (red) denote cTEC and
mTEC, respectively.14,17 Aire1 cells are yellow in color and localize to the thymus medulla. Syngeneically transplanted mice (bd→bd: 186 4 Aire1mTEC/0.04 mm2 medulla) were not
different from age-matched untransplanted control mice (data not shown5). The flow cytometry plots in (D) depict Aire and MHC class II expression of DAPI–CD45–EpCam1
Ly51–UEA11mTECs. Numbers represent frequencies (%) of cells (mean6 SD). Total numbers of Aire1mTEChigh in thymi from individual recipient mice (E) was calculated from flow
cytometry data (mean6 SD). Groups are the same as in panel (A). A total of 5 experiments were performed, with 3 to 5 mice per group. *P , .05, ANOVA, aGVHD vs transplanted
mice without aGVHD.
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Methods: “Bioinformatics”), we discriminated between TRA and
ubiquitously expressed transcripts (Ub) in mTEChigh. Several hundred
transcripts were expressed at reduced levels (.3-fold change) in
mice with aGVHD (Figure 2A). Notably, the TRA/Ub ratios for
repressed transcripts were significantly higher than would have been
expected to be observed by chance (O/E ratio.1.0 TRA;,1.0 Ub;
P , .001; Figure 2A, right panel)). A low correlation coefficient
between TRA expression in b→bd vs bd→bdmice (Pearson’s r5 0.700
and r 5 0.625 in 10- and 12-week-old recipients, respectively)
indicated a sizable number of TRAs being reduced during lethal
Figure 2. Peritransplant administration of Fgf7 sustains a more diverse TRA transcriptome in mTEChigh during aGVHD. Acute GVHD (b→bd) was induced in
8-week-old unconditioned recipient BDF1 mice as in Figure 1A. Global gene expression was analyzed in entire residual mTEC
high cell pools isolated from individual
recipients at 10, 12, and 15 weeks of age (ie, 2, 4, and 7 weeks after transplantation). The figure reflects data from 5 independent experiments, with 2 to 4 mice per group
and experiment. (A) Left panel: gene expression profiling of mTEChigh in transplant recipients using Mouse Gene 1.0 ST arrays (Affymetrix). The x- and y-axes represent
relative expression of individual genes (given as log2 values of signal intensity ratios, S.I.) in mice with aGVHD (b→bd) vs syngeneically transplanted recipients without
disease (bd→bd). Data were plotted as a function of recipient age (10 vs 12 weeks). Genes whose expression levels were enhanced or decreased more than threefold
relative to the control group (corresponding to relative expression values given by the S.I. ratios of ,0.33 and .3.0, respectively, or ,21.6 and .11.6 on the log2 scale)
were considered to be significantly altered in consequence of aGVHD (threshold is indicated by dashed lines). Q2 is the lower left quadrant, denoting genes whose
expression levels were depressed at both 2 and 4 weeks after allo-HSCT (10- and 12-week-old recipients). The inserted numbers denote the absolute numbers of genes
in the respective quadrants. Transcripts from a total of 21 759 genes were analyzed. An annotated list of the genes most affected by aGVHD is given in supplemental
Table 1. Ub (ubiquitously expressed genes, gray squares) and TRA (dark blue squares). (Right panel) O/E performance analysis (O, observed number of events; E,
expected number of events) of the presence of TRA vs Ub among the genes with relative expression ,0.33 and .0.3. O/E ratio .1.0 for TRA and ,1.0 for Ub; *P , .001
using hypergeometric statistical analysis. A value of O/E 5 1.0 represents a distribution among TRA and Ub according to expectations (that is sequestration according to
the relative frequencies of TRA and Ub in adult mice without disease). (B) The linear relationship between 2 experimental groups was tested for Ub and TRA using
a correlation matrix, as detailed in supplemental Figure 3. The variation of each gene was calculated using the interquartile range, a measure of statistical dispersion.
Pearson’s correlation coefficient r is shown as a function of age and time after transplantation. The asterisk (*) symbol indicates a statistical P value for the quality of each
measured r at any given time point for TRA and Ub, respectively; *P , .001 of Pearson’s r. (C) Tissue representation of TRA repressed during aGVHD (,0.1 and ,0.33
relative expression, respectively, vs mice without GVHD at 10 and 12 weeks of age). As control, a random set of 200 TRAs was used that remained unchanged in the
course of GVHD (relative expression ;1). Many repressed TRAs were specific for tissues of the gastrointestinal tract, skin, and eye. Changes in expression of these
genes in response to Fgf7 are given in supplemental Figure 4. (D) Aire dependency of TRA repressed in mTEChigh during aGVHD in 10- and 12-week-old recipients
(quadrant Q2; the axes are the same as in panel A). Examples shown are the following: Scgb1a1, secretoglobin; Csn1s2a, casein g, Mup1, major urinary protein 1; Spt1,
salivary protein 1 (see supplemental Table 1). Aire-dependent TRA (yellow circles), Aire-independent TRA (dark blue circles), and Ub (gray circles). (E) Analysis of TEC
proliferation in response to Fgf7. Eight-week-old BDF1 mice were left untreated or were treated with Fgf7 from days 23 to 13 after allo-HSCT. All mice simultaneously
received 0.8 mg/mL BrdU in their drinking water. mTECs were analyzed for BrdU incorporation at the indicated ages after transplantation. BrdU1 cells (%) 6 SD, *P , .001,
ANOVA, aGVHD vs mice without aGVHD. (F) Expression levels of individual genes expressed in mTEChigh is given in a heatmap as color-coded log2 value of signal intensities.
(Left panel) The map was sorted according to relative expression of genes in mTEChigh (b→bd vs bd→bd mice; 12 weeks old) and contains all TRA with a relative expression of
,0.3 during aGVHD in age-matched mice. Enhancement of TRA expression in response to Fgf7 was detectable by higher signal intensities of individual genes. (Right panel) Aire-
dependent TRAs were sorted as listed before.
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aGVHD (Figure 2B, supplemental Figure 3). We interpreted these
data such that a contraction in TRA diversity during aGVHD was
caused by cellular loss of mTEChigh, in particular Aire-positive
mTEC. This explanation was based on the fact that ectopic TRA
expression is a stochastic process in which only a limited number of
mTEChigh express a given TRA.2,18 A comprehensive coverage of
TRA expression is therefore only achieved by a sufficiently large
mTEChigh pool, which is, however, missing under conditions of
aGVHD. The most substantially reduced TRAs were found to be
enriched for genes that are characteristically expressed in tissues
known to be targets of cGVHD9 (Figure 2C). Many of these genes
belonged to the subset of Aire-dependent TRAs20 (Figure 2D,F,
supplemental Figure 3).
Because efficient central tolerance requires the full scope of
TRA, we next asked whether mTEChigh compartment size and
heterogeneity is sustained by using strategies for epithelial cyto-
protection. Peritransplant administration of the TEC mitogen
Fgf715,16 failed to prevent initial mTEChigh cell loss in b→bd
recipients (Figure 1A). However, Fgf7maintained stable numbers of
mTEChigh, including the subset expressing Aire (;3000 cells/mouse
during aGVHD; Figure 1C-E). Consistent with reports that mTEC
are continuously replaced in adulthood,18,22;5% of mTECs underwent
cell division within 1 week in the b→bd and bd→bd transplant
groups (Figure 2E). This frequency increased to;15% in mice with
aGVHD but that treated with Fgf7. Label retention analyses
indicated high turnover of mTEC in response to Fgf7 in b→bd
recipients (Figure 2E). Rescue of mTEChigh numbers was therefore
the consequence of enhanced proliferation within the entire mTEC
compartment. During early aGVHD, the TRA spectrum was not
preserved by Fgf7 (Pearson’s r5 0.635 vs bd→bdmice; Figure 2B,
supplemental Figure 3). However, a broader array of TRA was
expressed by 7 weeks after allo-HSCT as indicated by an expression
profile that was closer to that of age-matched bd→bd controls
(r 5 0.807). Hence, peritransplant administration of Fgf7 sustained
a more diverse TRA transcriptome during aGVHD. Individual TRA
expression patterns were differentially affected by aGVHD and Fgf7
as some but not all Aire-dependent TRA returned to nearly normal
expression in the observation period (Figure 2F, supplemental
Figures 3 and 4). However, the molecular mechanism for this biased
profile remains to date unknown.
Taken together, our data provide a mechanism for how auto-
immunity may develop in the context of aGVHD (supplemental
Figure 5). Because thymic-negative selection is sensitive to small
changes in TRA expression,4,5 approaches for mTEC cytoprotection
may prevent the emergence of thymus-dependent autoreactive
T cells12 and thus alter autoimmune outcome. The identification in
cGVHD of the yet undefined specificities of autoreactive effector
T cells24 will allow to test this argument directly in experimental
systems and ultimately in clinical allo-HSCT.
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Comment on Dertschnig et al, page 837
A 2-hit model for chronic GVHD
-----------------------------------------------------------------------------------------------------
Robertson Parkman1,2 1CHILDREN’S HOSPITAL LOS ANGELES; 2UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL
OF MEDICINE
In this issue of Blood, Dertschnig and colleagues1 demonstrate in mice that acute
graft-versus-host disease (GHVD) results in a marked reduction of autoimmune
receptor–expressing medullary thymic epithelial cells (Aire1 mTEC) and
a decrease in the diversity of Aire-dependent tissue-restricted peripheral self-
antigens (TRAs) required for effective negative thymic selection. Both of these
abnormalities are reversed by the peritransplant administration of the epithelial
protectant drug, fibroblast growth factor 7(Fgf7).
Chronic GVHD continues to be a majorcause of both morbidity and mortality
after allogeneic hematopoietic stem cell
transplantation (HSCT).2 Chronic GVHD
has been assumed to be caused by the
continuation of the pathogeneic mechanisms
that cause acute GVHD, primarily donor-
derived T lymphocytes specific for
histocompatibility antigens uniquely expressed
by recipient cells.3 As a consequence, therapy
for chronic GVHD has traditionally been
directed at suppressing the donor antirecipient
immune response. However, during the last
25 years, a series of murine experiments have
indicated that donor-derived, autoreactive
T lymphocytes (ie, T lymphocytes specific for
antigens expressed by both donor and recipient
cells) are present in murine HSCT recipients
with chronic GVHD and that the chronic
GVHD could be transferred by the donor-
derived T lymphocytes into both donor and
recipient mice.4-6
More recently, a clinical trial of low-dose
subcutaneous IL-2 in human HSCT recipients
with established chronic GVHD demonstrated
that an increase in circulating regulatory
T lymphocytes (Treg) resulted in clinical
improvement, suggesting that deficiencies
in Treg lymphocytes play a role in the
pathogenesis of human chronic GVHD.7
Dertschnig et al report that mice with
acute GVHD have a profound decrease in the
frequency of Aire1 mTEC, which are
necessary for the thymic production of
naturally occurring Treg lymphocytes. Other
investigators have previously demonstrated
that the diverse expression of TRA by Aire1
mTEC is required for the effective thymic
elimination of autoreactive T lymphocytes by
negative selection.8 Using microarray analyses
of isolated Aire1 mTEC, the present
investigators report the decreased expression
and diversity of TRA with a selective decrease
in the TRA associated with the tissues that are
the target organs of human chronic GVHD
(skin, liver, salivary glands, lung, eye, and
gastrointestinal tract). The result of the
restricted diversity of TRA expression would
be the extrathymic presence of autoreactive
T lymphocytes. Their present results suggest
a 2-hit model for chronic GVHD, in which
the presence of extrathymic autoreactive
T lymphocytes (Hit 1) in the context of
immune dysregulation (deficiencies in
Treg lymphocytes, Hit 2) can result in the
development of chronic GVHD.
The peri-HSCT administration of the
epithelial protectant drug, Fgf7, does not
affect the initial post-HSCT decrease in
mTEC but does hasten the recovery of Aire1
mTEC and improves the diversity of TRA
expression. Fgf7 acts by stimulating the
proliferation and differentiation of TEC
progenitors and the proliferation of residual
mTEC.9 The relative contribution of the 2
populations to the recovery of Aire1 mTEC is
unclear. The presence of normal numbers of
Aire1 mTEC with normal TRA diversity
during the recapitulation of immunologic
ontogeny, which occurs after the engraftment
of donor hematopoietic stem cells, may result
in the presence of adequate numbers of
circulating Treg lymphocytes and effective
negative thymic selection, which would
eliminate the peripheral presence of
autoreactive T lymphocytes, and an absence
of chronic GVHD. As such, clinical trials
to determine whether the peritransplant
administration of Fgf7 results in a decreased
incidence of chronic GVHD in human HSCT
recipients are indicated.
The present murine experiments,
however, do not address several potentially
important clinical questions: (1) What would
be the impact of the administration of Fgf7
to patients with established chronic GVHD?;
(2) Do HSCT recipients with established
chronic GVHD have an adequate number of
TEC progenitors and residual mTEC for
the Fgf7 to be effective?; (3) Do the TEC
progenitors and mTEC in chronic GVHD
patients become refractory to the action of
Fgf7?; and (4) Is the loss of Aire1 mTEC
during acute GVHD paralleled by a decrease
in TRA diversity, or are they separable
biological processes? If they differ, then some
HSCT recipients may have a deficiency of
Treg lymphocytes without the concomitant
presence of peripheral autoreactive
T lymphocytes, whereas other recipients
may have adequate numbers of
Treg lymphocytes with the presence of
peripheral autoreactive T lymphocytes. Only
HSCT recipients with both the presence of
peripheral autoreactive T lymphocytes (Hit 1)
and deficiencies in Treg lymphocytes
(Hit 2) would be at risk of developing
chronic GVHD. The immunophenotypic
identification of functional human Treg
lymphocytes will aid in the evaluation of
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human chronic GVHD; however, the inability
to identify immunophenotypic human
autoreactive T lymphocytes is still a major
limitation to our better understanding.10
Finally, the present results suggest that
the focus of future research into new
therapies to prevent or treat chronic
GVHD should be directed at the thymic
microenvironment rather than at
lymphohematopoietic cells.
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The endothelial protein C receptor
and malaria
-----------------------------------------------------------------------------------------------------
Tom van der Poll1 1UNIVERSITY OF AMSTERDAM
In this issue of Blood, Moxon et al provide novel insight into the pathogenesis of
cerebral malaria, linking loss of the endothelial protein C receptor (EPCR) on
brain vessels, caused by cytoadherent infected erythrocytes, with localized
coagulation, inflammation, and disruption of endothelial barrier function.1
Malaria is caused by parasites of the genusPlasmodium, of which P falciparum is
the most virulent.2 One of the most fatal
manifestations of P falciparum infection is
cerebral malaria, which especially affects
children,6 years of age and is responsible for
an annual death toll of nearly a million infants
in Africa alone. In recent years, the cycle of
coagulation and inflammation has emerged as a
pivotal component of malaria pathogenesis.3
In normal homeostasis, activation of coag-
ulation is compensated by concurrent
induction of anticoagulant mechanisms.4
In areas of excessive activation of the clotting
cascade, thrombin acts as a feedback in-
hibitor of coagulation by binding to the
endothelial receptor thrombomodulin (see
figure). The thrombomodulin-thrombin
complex converts the zymogen protein C into
activated protein C (APC), a reaction that is
greatly accelerated by EPCR.5,6 APC acts as an
anticoagulant by virtue of its capacity to
proteolytically inactivate clotting factors Va
and VIIIa. When attached to EPCR, APC
in addition can exert anti-inflammatory,
antiapoptotic, and vasculoprotective signals
via protease activated receptor (PAR)1. In case
of impaired function of the protein C system,
high thrombin levels can activate PAR1,
resulting in effects that are opposite to those
transduced by APC, disrupting endothelial
barrier function.
A hallmark feature of severe malaria is
sequestration of infected erythrocytes in
blood vessels.2 The elegant investigations by
Moxon et al provide a long-sought explanation
of why red blood cell sequestration especially
leads to damage in the brain.1 In postmortem
studies in children that had died of cerebral
malaria, endothelial sites of adherent
erythrocytes were shown to colocalize with loss
of EPCR. Moreover, the authors developed
a novel approach that enabled examination of
blood vessels with relevance for the brain
vasculature in children with cerebral malaria
directly after admission to the hospital. For this,
they used subcutaneous tissue microvessels as
an ex vivo surrogate for brain endothelium and
demonstrated reduced expression of both
EPCR and thrombomodulin in cerebral malaria
patients compared with healthy controls.
Children with cerebral malaria had higher levels
of soluble EPCR and thrombomodulin in their
cerebrospinal fluid than febrile control patients,
suggesting that the loss of these receptors
at least in part was caused by shedding.
Importantly, in plasma, the balance between
the production of thrombin (measured by the
levels of the prothrombin F112 fragment)
and APC was not altered in cerebral malaria
compared with healthy children and children
with mild febrile disease or uncomplicated
malaria, indicating that at the systemic level,
coagulation activation was compensated.
Together, these data strongly suggest that
cerebral malaria is associated with a localized
disturbance of coagulation and inflammation
caused by a local loss of EPCR and
thrombomodulin initiated by sequestration of
infected erythrocytes, changes that damage
the brain due to the already low constitutive
expression of EPCR and thrombomodulin in
healthy brain vessels.1,7
Another recent study has implicated EPCR
in the pathogenesis of malaria by a completely
different mechanism.8 In malaria, adherence
of red blood cells to endothelium is caused
by an interaction between P falciparum
erythrocyte membrane protein-1 (PfEMP1)
family members, transported to the erythrocyte
membrane as a consequence of parasite
infection, and receptors on the vascular
endothelium.2 In this respect, PfEMP1
subtypes containing domain cassettes 8 and
13 are important for sequestration of infected
erythrocytes in severe childhood malaria.9
Turner et al very recently revealed EPCR as
the endothelial receptor for PfEMP1 domain
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